#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Relationships between abnormal neural activities and cognitive impairments in patients with drug-naive first-episode schizophrenia
#Text=Background
#Text=Prior resting state functional Magnetic Resonance Imaging studies (rs-fMRI) via the regional homogeneity (ReHo) method have demonstrated inconsistent and conflicting results because of several confounding factors, such as small sample size, medicinal influence, and illness duration.
1-1	0-13	Relationships	_	
1-2	14-21	between	_	
1-3	22-30	abnormal	_	
1-4	31-37	neural	_	
1-5	38-48	activities	_	
1-6	49-52	and	_	
1-7	53-62	cognitive	_	
1-8	63-74	impairments	_	
1-9	75-77	in	_	
1-10	78-86	patients	_	
1-11	87-91	with	_	
1-12	92-102	drug-naive	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[1]	
1-13	103-116	first-episode	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[1]	
1-14	117-130	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[1]	
1-15	131-141	Background	_	
1-16	142-147	Prior	_	
1-17	148-155	resting	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[2]	
1-18	156-161	state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[2]	
1-19	162-172	functional	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[2]	
1-20	173-181	Magnetic	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[2]	
1-21	182-191	Resonance	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[2]	
1-22	192-199	Imaging	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[2]	
1-23	200-207	studies	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[2]	
1-24	208-209	(	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[2]	
1-25	209-216	rs-fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[2]	
1-26	216-217	)	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[2]	
1-27	218-221	via	_	
1-28	222-225	the	_	
1-29	226-234	regional	_	
1-30	235-246	homogeneity	_	
1-31	247-248	(	_	
1-32	248-252	ReHo	_	
1-33	252-253	)	_	
1-34	254-260	method	_	
1-35	261-265	have	_	
1-36	266-278	demonstrated	_	
1-37	279-291	inconsistent	_	
1-38	292-295	and	_	
1-39	296-307	conflicting	_	
1-40	308-315	results	_	
1-41	316-323	because	_	
1-42	324-326	of	_	
1-43	327-334	several	_	
1-44	335-346	confounding	_	
1-45	347-354	factors	_	
1-46	354-355	,	_	
1-47	356-360	such	_	
1-48	361-363	as	_	
1-49	364-369	small	_	
1-50	370-376	sample	_	
1-51	377-381	size	_	
1-52	381-382	,	_	
1-53	383-392	medicinal	_	
1-54	393-402	influence	_	
1-55	402-403	,	_	
1-56	404-407	and	_	
1-57	408-415	illness	_	
1-58	416-424	duration	_	
1-59	424-425	.	_	

#Text=Relationships between ReHo measures and cognitive impairments in patients with drug-naive First-Episode Schizophrenia (dn-FES) are rarely reported.
2-1	426-439	Relationships	_	
2-2	440-447	between	_	
2-3	448-452	ReHo	_	
2-4	453-461	measures	_	
2-5	462-465	and	_	
2-6	466-475	cognitive	_	
2-7	476-487	impairments	_	
2-8	488-490	in	_	
2-9	491-499	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[3]|http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[4]|http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated[5]	
2-10	500-504	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[3]|http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[4]|http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated[5]	
2-11	505-515	drug-naive	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[3]|http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[4]|http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated[5]	
2-12	516-529	First-Episode	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[3]|http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[4]|http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated[5]	
2-13	530-543	Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[3]|http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[4]|http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated[5]	
2-14	544-545	(	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[3]|http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[4]|http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated[5]	
2-15	545-551	dn-FES	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[3]|http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[4]|http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated[5]	
2-16	551-552	)	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[3]	
2-17	553-556	are	_	
2-18	557-563	rarely	_	
2-19	564-572	reported	_	
2-20	572-573	.	_	

#Text=This study was conducted to explore the correlations between ReHo measures and cognitive deficits and clinical symptoms in patients with dn-FES.
3-1	574-578	This	_	
3-2	579-584	study	_	
3-3	585-588	was	_	
3-4	589-598	conducted	_	
3-5	599-601	to	_	
3-6	602-609	explore	_	
3-7	610-613	the	_	
3-8	614-626	correlations	_	
3-9	627-634	between	_	
3-10	635-639	ReHo	_	
3-11	640-648	measures	_	
3-12	649-652	and	_	
3-13	653-662	cognitive	_	
3-14	663-671	deficits	_	
3-15	672-675	and	_	
3-16	676-684	clinical	_	
3-17	685-693	symptoms	_	
3-18	694-696	in	_	
3-19	697-705	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[6]	
3-20	706-710	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[6]	
3-21	711-717	dn-FES	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[6]	
3-22	717-718	.	_	

#Text=Methods
#Text=A total of 69 patients with dn-FES and 74 healthy controls were recruited.
4-1	719-726	Methods	_	
4-2	727-728	A	_	
4-3	729-734	total	_	
4-4	735-737	of	_	
4-5	738-740	69	_	
4-6	741-749	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[7]|http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated[8]|http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[9]	
4-7	750-754	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[7]|http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated[8]|http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[9]	
4-8	755-761	dn-FES	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[7]|http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated[8]|http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[9]	
4-9	762-765	and	_	
4-10	766-768	74	_	
4-11	769-776	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[10]	
4-12	777-785	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[10]	
4-13	786-790	were	_	
4-14	791-800	recruited	_	
4-15	800-801	.	_	

#Text=MATRICS Consensus Cognitive Battery (MCCB), Wechsler Adult Intelligence Scale (WAIS), and Positive And Negative Syndrome Scale (PANSS) were used to assess cognitive function, Intelligence Quotient (IQ), and clinical symptoms, respectively.
5-1	802-809	MATRICS	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[11]	
5-2	810-819	Consensus	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[11]	
5-3	820-829	Cognitive	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[11]	
5-4	830-837	Battery	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[11]	
5-5	838-839	(	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[11]	
5-6	839-843	MCCB	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[11]	
5-7	843-844	)	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[11]	
5-8	844-845	,	_	
5-9	846-854	Wechsler	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[12]	
5-10	855-860	Adult	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[12]	
5-11	861-873	Intelligence	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[12]	
5-12	874-879	Scale	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[12]	
5-13	880-881	(	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[12]	
5-14	881-885	WAIS	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[12]	
5-15	885-886	)	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[12]	
5-16	886-887	,	_	
5-17	888-891	and	_	
5-18	892-900	Positive	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[13]	
5-19	901-904	And	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[13]	
5-20	905-913	Negative	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[13]	
5-21	914-922	Syndrome	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[13]	
5-22	923-928	Scale	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[13]	
5-23	929-930	(	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[13]	
5-24	930-935	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[13]	
5-25	935-936	)	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[13]	
5-26	937-941	were	_	
5-27	942-946	used	_	
5-28	947-949	to	_	
5-29	950-956	assess	_	
5-30	957-966	cognitive	_	
5-31	967-975	function	_	
5-32	975-976	,	_	
5-33	977-989	Intelligence	_	
5-34	990-998	Quotient	_	
5-35	999-1000	(	_	
5-36	1000-1002	IQ	_	
5-37	1002-1003	)	_	
5-38	1003-1004	,	_	
5-39	1005-1008	and	_	
5-40	1009-1017	clinical	_	
5-41	1018-1026	symptoms	_	
5-42	1026-1027	,	_	
5-43	1028-1040	respectively	_	
5-44	1040-1041	.	_	

#Text=The correlations between ReHo maps and cognitive deficits and the severity of symptoms were examined using strict correlation analysis.
6-1	1042-1045	The	_	
6-2	1046-1058	correlations	_	
6-3	1059-1066	between	_	
6-4	1067-1071	ReHo	_	
6-5	1072-1076	maps	_	
6-6	1077-1080	and	_	
6-7	1081-1090	cognitive	_	
6-8	1091-1099	deficits	_	
6-9	1100-1103	and	_	
6-10	1104-1107	the	_	
6-11	1108-1116	severity	_	
6-12	1117-1119	of	_	
6-13	1120-1128	symptoms	_	
6-14	1129-1133	were	_	
6-15	1134-1142	examined	_	
6-16	1143-1148	using	_	
6-17	1149-1155	strict	_	
6-18	1156-1167	correlation	_	
6-19	1168-1176	analysis	_	
6-20	1176-1177	.	_	

#Text=Results
#Text=ReHo values in right Middle Frontal Gyrus (MFG) and Superior Frontal Gyrus (SFG) increased in dn-FES group, whereas ReHo values in right cuneus decreased.
7-1	1178-1185	Results	_	
7-2	1186-1190	ReHo	_	
7-3	1191-1197	values	_	
7-4	1198-1200	in	_	
7-5	1201-1206	right	_	
7-6	1207-1213	Middle	_	
7-7	1214-1221	Frontal	_	
7-8	1222-1227	Gyrus	_	
7-9	1228-1229	(	_	
7-10	1229-1232	MFG	_	
7-11	1232-1233	)	_	
7-12	1234-1237	and	_	
7-13	1238-1246	Superior	_	
7-14	1247-1254	Frontal	_	
7-15	1255-1260	Gyrus	_	
7-16	1261-1262	(	_	
7-17	1262-1265	SFG	_	
7-18	1265-1266	)	_	
7-19	1267-1276	increased	_	
7-20	1277-1279	in	_	
7-21	1280-1286	dn-FES	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[14]|http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[15]|http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated[16]	
7-22	1287-1292	group	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[14]|http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[15]	
7-23	1292-1293	,	_	
7-24	1294-1301	whereas	_	
7-25	1302-1306	ReHo	_	
7-26	1307-1313	values	_	
7-27	1314-1316	in	_	
7-28	1317-1322	right	_	
7-29	1323-1329	cuneus	_	
7-30	1330-1339	decreased	_	
7-31	1339-1340	.	_	

#Text=Correlation analysis showed that the ReHo values in right MFG positively correlated with attention/vigilance impairments, social cognition deficits, and the severity of clinical manifestations.
8-1	1341-1352	Correlation	_	
8-2	1353-1361	analysis	_	
8-3	1362-1368	showed	_	
8-4	1369-1373	that	_	
8-5	1374-1377	the	_	
8-6	1378-1382	ReHo	_	
8-7	1383-1389	values	_	
8-8	1390-1392	in	_	
8-9	1393-1398	right	_	
8-10	1399-1402	MFG	_	
8-11	1403-1413	positively	_	
8-12	1414-1424	correlated	_	
8-13	1425-1429	with	_	
8-14	1430-1439	attention	_	
8-15	1439-1440	/	_	
8-16	1440-1449	vigilance	_	
8-17	1450-1461	impairments	_	
8-18	1461-1462	,	_	
8-19	1463-1469	social	_	
8-20	1470-1479	cognition	_	
8-21	1480-1488	deficits	_	
8-22	1488-1489	,	_	
8-23	1490-1493	and	_	
8-24	1494-1497	the	_	
8-25	1498-1506	severity	_	
8-26	1507-1509	of	_	
8-27	1510-1518	clinical	_	
8-28	1519-1533	manifestations	_	
8-29	1533-1534	.	_	

#Text=Conclusions
#Text=These findings suggested that abnormal spontaneous activities in right MFG reflect illness severity and cognitive deficits, which also serve as a basis for establishing objective diagnostic markers and might be a clinical intervention target for treating patients with schizophrenia.
9-1	1535-1546	Conclusions	_	
9-2	1547-1552	These	_	
9-3	1553-1561	findings	_	
9-4	1562-1571	suggested	_	
9-5	1572-1576	that	_	
9-6	1577-1585	abnormal	_	
9-7	1586-1597	spontaneous	_	
9-8	1598-1608	activities	_	
9-9	1609-1611	in	_	
9-10	1612-1617	right	_	
9-11	1618-1621	MFG	_	
9-12	1622-1629	reflect	_	
9-13	1630-1637	illness	_	
9-14	1638-1646	severity	_	
9-15	1647-1650	and	_	
9-16	1651-1660	cognitive	_	
9-17	1661-1669	deficits	_	
9-18	1669-1670	,	_	
9-19	1671-1676	which	_	
9-20	1677-1681	also	_	
9-21	1682-1687	serve	_	
9-22	1688-1690	as	_	
9-23	1691-1692	a	_	
9-24	1693-1698	basis	_	
9-25	1699-1702	for	_	
9-26	1703-1715	establishing	_	
9-27	1716-1725	objective	_	
9-28	1726-1736	diagnostic	_	
9-29	1737-1744	markers	_	
9-30	1745-1748	and	_	
9-31	1749-1754	might	_	
9-32	1755-1757	be	_	
9-33	1758-1759	a	_	
9-34	1760-1768	clinical	_	
9-35	1769-1781	intervention	_	
9-36	1782-1788	target	_	
9-37	1789-1792	for	_	
9-38	1793-1801	treating	_	
9-39	1802-1810	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[17]	
9-40	1811-1815	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[17]	
9-41	1816-1829	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[17]	
9-42	1829-1830	.	_	

#Text=Background
#Text=Schizophrenia (SZ) is a disabled mental illness that affects 0.5% of the China’s population.
10-1	1831-1841	Background	_	
10-2	1842-1855	Schizophrenia	_	
10-3	1856-1857	(	_	
10-4	1857-1859	SZ	_	
10-5	1859-1860	)	_	
10-6	1861-1863	is	_	
10-7	1864-1865	a	_	
10-8	1866-1874	disabled	_	
10-9	1875-1881	mental	_	
10-10	1882-1889	illness	_	
10-11	1890-1894	that	_	
10-12	1895-1902	affects	_	
10-13	1903-1907	0.5%	_	
10-14	1908-1910	of	_	
10-15	1911-1914	the	_	
10-16	1915-1920	China	_	
10-17	1920-1921	’	_	
10-18	1921-1922	s	_	
10-19	1923-1933	population	_	
10-20	1933-1934	.	_	

#Text=SZ patients show deficits in a broad array of domains, including perception, attention, memory, processing speed, reasoning, problem solving, and social cognition.
11-1	1935-1937	SZ	_	
11-2	1938-1946	patients	_	
11-3	1947-1951	show	_	
11-4	1952-1960	deficits	_	
11-5	1961-1963	in	_	
11-6	1964-1965	a	_	
11-7	1966-1971	broad	_	
11-8	1972-1977	array	_	
11-9	1978-1980	of	_	
11-10	1981-1988	domains	_	
11-11	1988-1989	,	_	
11-12	1990-1999	including	_	
11-13	2000-2010	perception	_	
11-14	2010-2011	,	_	
11-15	2012-2021	attention	_	
11-16	2021-2022	,	_	
11-17	2023-2029	memory	_	
11-18	2029-2030	,	_	
11-19	2031-2041	processing	_	
11-20	2042-2047	speed	_	
11-21	2047-2048	,	_	
11-22	2049-2058	reasoning	_	
11-23	2058-2059	,	_	
11-24	2060-2067	problem	_	
11-25	2068-2075	solving	_	
11-26	2075-2076	,	_	
11-27	2077-2080	and	_	
11-28	2081-2087	social	_	
11-29	2088-2097	cognition	_	
11-30	2097-2098	.	_	

#Text=Cognitive impairments are core features of SZ and have a substantial influence on patients’ psychosocial life.
12-1	2099-2108	Cognitive	_	
12-2	2109-2120	impairments	_	
12-3	2121-2124	are	_	
12-4	2125-2129	core	_	
12-5	2130-2138	features	_	
12-6	2139-2141	of	_	
12-7	2142-2144	SZ	_	
12-8	2145-2148	and	_	
12-9	2149-2153	have	_	
12-10	2154-2155	a	_	
12-11	2156-2167	substantial	_	
12-12	2168-2177	influence	_	
12-13	2178-2180	on	_	
12-14	2181-2189	patients	_	
12-15	2189-2190	’	_	
12-16	2191-2203	psychosocial	_	
12-17	2204-2208	life	_	
12-18	2208-2209	.	_	

#Text=Cognitive impairments have also emerged as important targets of treatment-oriented research.
13-1	2210-2219	Cognitive	_	
13-2	2220-2231	impairments	_	
13-3	2232-2236	have	_	
13-4	2237-2241	also	_	
13-5	2242-2249	emerged	_	
13-6	2250-2252	as	_	
13-7	2253-2262	important	_	
13-8	2263-2270	targets	_	
13-9	2271-2273	of	_	
13-10	2274-2292	treatment-oriented	_	
13-11	2293-2301	research	_	
13-12	2301-2302	.	_	

#Text=The Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) is a standard cognitive battery and contains ten tests that measure seven cognitive domains: speed of processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition.
14-1	2303-2306	The	_	
14-2	2307-2318	Measurement	_	
14-3	2319-2322	and	_	
14-4	2323-2332	Treatment	_	
14-5	2333-2341	Research	_	
14-6	2342-2344	to	_	
14-7	2345-2352	Improve	_	
14-8	2353-2362	Cognition	_	
14-9	2363-2365	in	_	
14-10	2366-2379	Schizophrenia	_	
14-11	2380-2381	(	_	
14-12	2381-2388	MATRICS	_	
14-13	2388-2389	)	_	
14-14	2390-2399	Consensus	_	
14-15	2400-2409	Cognitive	_	
14-16	2410-2417	Battery	_	
14-17	2418-2419	(	_	
14-18	2419-2423	MCCB	_	
14-19	2423-2424	)	_	
14-20	2425-2427	is	_	
14-21	2428-2429	a	_	
14-22	2430-2438	standard	_	
14-23	2439-2448	cognitive	_	
14-24	2449-2456	battery	_	
14-25	2457-2460	and	_	
14-26	2461-2469	contains	_	
14-27	2470-2473	ten	_	
14-28	2474-2479	tests	_	
14-29	2480-2484	that	_	
14-30	2485-2492	measure	_	
14-31	2493-2498	seven	_	
14-32	2499-2508	cognitive	_	
14-33	2509-2516	domains	_	
14-34	2516-2517	:	_	
14-35	2518-2523	speed	_	
14-36	2524-2526	of	_	
14-37	2527-2537	processing	_	
14-38	2537-2538	,	_	
14-39	2539-2548	attention	_	
14-40	2548-2549	/	_	
14-41	2549-2558	vigilance	_	
14-42	2558-2559	,	_	
14-43	2560-2567	working	_	
14-44	2568-2574	memory	_	
14-45	2574-2575	,	_	
14-46	2576-2582	verbal	_	
14-47	2583-2591	learning	_	
14-48	2591-2592	,	_	
14-49	2593-2599	visual	_	
14-50	2600-2608	learning	_	
14-51	2608-2609	,	_	
14-52	2610-2619	reasoning	_	
14-53	2620-2623	and	_	
14-54	2624-2631	problem	_	
14-55	2632-2639	solving	_	
14-56	2639-2640	,	_	
14-57	2641-2644	and	_	
14-58	2645-2651	social	_	
14-59	2652-2661	cognition	_	
14-60	2661-2662	.	_	

#Text=Patients with SZ show significant cognitive deficits across multiple cognitive domains assessed with the MCCB.
15-1	2663-2671	Patients	_	
15-2	2672-2676	with	_	
15-3	2677-2679	SZ	_	
15-4	2680-2684	show	_	
15-5	2685-2696	significant	_	
15-6	2697-2706	cognitive	_	
15-7	2707-2715	deficits	_	
15-8	2716-2722	across	_	
15-9	2723-2731	multiple	_	
15-10	2732-2741	cognitive	_	
15-11	2742-2749	domains	_	
15-12	2750-2758	assessed	_	
15-13	2759-2763	with	_	
15-14	2764-2767	the	_	
15-15	2768-2772	MCCB	_	
15-16	2772-2773	.	_	

#Text=Resting state functional Magnetic Resonance Imaging (rs-fMRI) is a useful non-invasive neuroimaging technique for exploring local spontaneous neural activities and studying cognitive impairments.
16-1	2774-2781	Resting	_	
16-2	2782-2787	state	_	
16-3	2788-2798	functional	_	
16-4	2799-2807	Magnetic	_	
16-5	2808-2817	Resonance	_	
16-6	2818-2825	Imaging	_	
16-7	2826-2827	(	_	
16-8	2827-2834	rs-fMRI	_	
16-9	2834-2835	)	_	
16-10	2836-2838	is	_	
16-11	2839-2840	a	_	
16-12	2841-2847	useful	_	
16-13	2848-2860	non-invasive	_	
16-14	2861-2873	neuroimaging	_	
16-15	2874-2883	technique	_	
16-16	2884-2887	for	_	
16-17	2888-2897	exploring	_	
16-18	2898-2903	local	_	
16-19	2904-2915	spontaneous	_	
16-20	2916-2922	neural	_	
16-21	2923-2933	activities	_	
16-22	2934-2937	and	_	
16-23	2938-2946	studying	_	
16-24	2947-2956	cognitive	_	
16-25	2957-2968	impairments	_	
16-26	2968-2969	.	_	

#Text=Regional homogeneity (ReHo) is a method employed in rs-fMRI and based on Kendall’s coefficient of concordance to measure the temporal synchronization of the time series of each voxel and compare it with that of its adjacent neighbors.
17-1	2970-2978	Regional	_	
17-2	2979-2990	homogeneity	_	
17-3	2991-2992	(	_	
17-4	2992-2996	ReHo	_	
17-5	2996-2997	)	_	
17-6	2998-3000	is	_	
17-7	3001-3002	a	_	
17-8	3003-3009	method	_	
17-9	3010-3018	employed	_	
17-10	3019-3021	in	_	
17-11	3022-3029	rs-fMRI	_	
17-12	3030-3033	and	_	
17-13	3034-3039	based	_	
17-14	3040-3042	on	_	
17-15	3043-3050	Kendall	_	
17-16	3050-3051	’	_	
17-17	3051-3052	s	_	
17-18	3053-3064	coefficient	_	
17-19	3065-3067	of	_	
17-20	3068-3079	concordance	_	
17-21	3080-3082	to	_	
17-22	3083-3090	measure	_	
17-23	3091-3094	the	_	
17-24	3095-3103	temporal	_	
17-25	3104-3119	synchronization	_	
17-26	3120-3122	of	_	
17-27	3123-3126	the	_	
17-28	3127-3131	time	_	
17-29	3132-3138	series	_	
17-30	3139-3141	of	_	
17-31	3142-3146	each	_	
17-32	3147-3152	voxel	_	
17-33	3153-3156	and	_	
17-34	3157-3164	compare	_	
17-35	3165-3167	it	_	
17-36	3168-3172	with	_	
17-37	3173-3177	that	_	
17-38	3178-3180	of	_	
17-39	3181-3184	its	_	
17-40	3185-3193	adjacent	_	
17-41	3194-3203	neighbors	_	
17-42	3203-3204	.	_	

#Text=Patients with SZ exhibit increased ReHo values in Dorsolateral Prefrontal Cortex (DLPFC), medial prefrontal cortex, angular gyrus, precentral gyrus, and superior temporal gyrus and decreased ReHo values in the superior temporal gyrus, occipital lobes, parietal lobule, precentral lobule, and postcentral gyrus.
18-1	3205-3213	Patients	_	
18-2	3214-3218	with	_	
18-3	3219-3221	SZ	_	
18-4	3222-3229	exhibit	_	
18-5	3230-3239	increased	_	
18-6	3240-3244	ReHo	_	
18-7	3245-3251	values	_	
18-8	3252-3254	in	_	
18-9	3255-3267	Dorsolateral	_	
18-10	3268-3278	Prefrontal	_	
18-11	3279-3285	Cortex	_	
18-12	3286-3287	(	_	
18-13	3287-3292	DLPFC	_	
18-14	3292-3293	)	_	
18-15	3293-3294	,	_	
18-16	3295-3301	medial	_	
18-17	3302-3312	prefrontal	_	
18-18	3313-3319	cortex	_	
18-19	3319-3320	,	_	
18-20	3321-3328	angular	_	
18-21	3329-3334	gyrus	_	
18-22	3334-3335	,	_	
18-23	3336-3346	precentral	_	
18-24	3347-3352	gyrus	_	
18-25	3352-3353	,	_	
18-26	3354-3357	and	_	
18-27	3358-3366	superior	_	
18-28	3367-3375	temporal	_	
18-29	3376-3381	gyrus	_	
18-30	3382-3385	and	_	
18-31	3386-3395	decreased	_	
18-32	3396-3400	ReHo	_	
18-33	3401-3407	values	_	
18-34	3408-3410	in	_	
18-35	3411-3414	the	_	
18-36	3415-3423	superior	_	
18-37	3424-3432	temporal	_	
18-38	3433-3438	gyrus	_	
18-39	3438-3439	,	_	
18-40	3440-3449	occipital	_	
18-41	3450-3455	lobes	_	
18-42	3455-3456	,	_	
18-43	3457-3465	parietal	_	
18-44	3466-3472	lobule	_	
18-45	3472-3473	,	_	
18-46	3474-3484	precentral	_	
18-47	3485-3491	lobule	_	
18-48	3491-3492	,	_	
18-49	3493-3496	and	_	
18-50	3497-3508	postcentral	_	
18-51	3509-3514	gyrus	_	
18-52	3514-3515	.	_	

#Text=A recent study showed positive correlations between attention function and mean ReHo values in the left middle frontal gyrus, right inferior/ middle temporal gyrus, angular gyrus, and inferior/superior parietal lobe in healthy control group, but no significant correlations were found in SZ group.
19-1	3516-3517	A	_	
19-2	3518-3524	recent	_	
19-3	3525-3530	study	_	
19-4	3531-3537	showed	_	
19-5	3538-3546	positive	_	
19-6	3547-3559	correlations	_	
19-7	3560-3567	between	_	
19-8	3568-3577	attention	_	
19-9	3578-3586	function	_	
19-10	3587-3590	and	_	
19-11	3591-3595	mean	_	
19-12	3596-3600	ReHo	_	
19-13	3601-3607	values	_	
19-14	3608-3610	in	_	
19-15	3611-3614	the	_	
19-16	3615-3619	left	_	
19-17	3620-3626	middle	_	
19-18	3627-3634	frontal	_	
19-19	3635-3640	gyrus	_	
19-20	3640-3641	,	_	
19-21	3642-3647	right	_	
19-22	3648-3656	inferior	_	
19-23	3656-3657	/	_	
19-24	3658-3664	middle	_	
19-25	3665-3673	temporal	_	
19-26	3674-3679	gyrus	_	
19-27	3679-3680	,	_	
19-28	3681-3688	angular	_	
19-29	3689-3694	gyrus	_	
19-30	3694-3695	,	_	
19-31	3696-3699	and	_	
19-32	3700-3708	inferior	_	
19-33	3708-3709	/	_	
19-34	3709-3717	superior	_	
19-35	3718-3726	parietal	_	
19-36	3727-3731	lobe	_	
19-37	3732-3734	in	_	
19-38	3735-3742	healthy	_	
19-39	3743-3750	control	_	
19-40	3751-3756	group	_	
19-41	3756-3757	,	_	
19-42	3758-3761	but	_	
19-43	3762-3764	no	_	
19-44	3765-3776	significant	_	
19-45	3777-3789	correlations	_	
19-46	3790-3794	were	_	
19-47	3795-3800	found	_	
19-48	3801-3803	in	_	
19-49	3804-3806	SZ	_	
19-50	3807-3812	group	_	
19-51	3812-3813	.	_	

#Text=ReHo studies on SZ have shown several promising findings, but such findings are inconsistent and conflicting.
20-1	3814-3818	ReHo	_	
20-2	3819-3826	studies	_	
20-3	3827-3829	on	_	
20-4	3830-3832	SZ	_	
20-5	3833-3837	have	_	
20-6	3838-3843	shown	_	
20-7	3844-3851	several	_	
20-8	3852-3861	promising	_	
20-9	3862-3870	findings	_	
20-10	3870-3871	,	_	
20-11	3872-3875	but	_	
20-12	3876-3880	such	_	
20-13	3881-3889	findings	_	
20-14	3890-3893	are	_	
20-15	3894-3906	inconsistent	_	
20-16	3907-3910	and	_	
20-17	3911-3922	conflicting	_	
20-18	3922-3923	.	_	

#Text=The reduced function of DLPFC plays a major role in pathophysiology of SZ and is associated with executive function deficits, response inhibition, and working memory errors.
21-1	3924-3927	The	_	
21-2	3928-3935	reduced	_	
21-3	3936-3944	function	_	
21-4	3945-3947	of	_	
21-5	3948-3953	DLPFC	_	
21-6	3954-3959	plays	_	
21-7	3960-3961	a	_	
21-8	3962-3967	major	_	
21-9	3968-3972	role	_	
21-10	3973-3975	in	_	
21-11	3976-3991	pathophysiology	_	
21-12	3992-3994	of	_	
21-13	3995-3997	SZ	_	
21-14	3998-4001	and	_	
21-15	4002-4004	is	_	
21-16	4005-4015	associated	_	
21-17	4016-4020	with	_	
21-18	4021-4030	executive	_	
21-19	4031-4039	function	_	
21-20	4040-4048	deficits	_	
21-21	4048-4049	,	_	
21-22	4050-4058	response	_	
21-23	4059-4069	inhibition	_	
21-24	4069-4070	,	_	
21-25	4071-4074	and	_	
21-26	4075-4082	working	_	
21-27	4083-4089	memory	_	
21-28	4090-4096	errors	_	
21-29	4096-4097	.	_	

#Text=However, other brain areas, such as the superior temporal gyrus and precentral lobule, have yielded inconsistent and controversial results, and the relationships between abnormal brain activities and cognitive impairments have not been well investigated.
22-1	4098-4105	However	_	
22-2	4105-4106	,	_	
22-3	4107-4112	other	_	
22-4	4113-4118	brain	_	
22-5	4119-4124	areas	_	
22-6	4124-4125	,	_	
22-7	4126-4130	such	_	
22-8	4131-4133	as	_	
22-9	4134-4137	the	_	
22-10	4138-4146	superior	_	
22-11	4147-4155	temporal	_	
22-12	4156-4161	gyrus	_	
22-13	4162-4165	and	_	
22-14	4166-4176	precentral	_	
22-15	4177-4183	lobule	_	
22-16	4183-4184	,	_	
22-17	4185-4189	have	_	
22-18	4190-4197	yielded	_	
22-19	4198-4210	inconsistent	_	
22-20	4211-4214	and	_	
22-21	4215-4228	controversial	_	
22-22	4229-4236	results	_	
22-23	4236-4237	,	_	
22-24	4238-4241	and	_	
22-25	4242-4245	the	_	
22-26	4246-4259	relationships	_	
22-27	4260-4267	between	_	
22-28	4268-4276	abnormal	_	
22-29	4277-4282	brain	_	
22-30	4283-4293	activities	_	
22-31	4294-4297	and	_	
22-32	4298-4307	cognitive	_	
22-33	4308-4319	impairments	_	
22-34	4320-4324	have	_	
22-35	4325-4328	not	_	
22-36	4329-4333	been	_	
22-37	4334-4338	well	_	
22-38	4339-4351	investigated	_	
22-39	4351-4352	.	_	

#Text=Numerous researchers attempted to map the neuronal pathophysiology in schizophrenia, but the results were often contradictory.
23-1	4353-4361	Numerous	_	
23-2	4362-4373	researchers	_	
23-3	4374-4383	attempted	_	
23-4	4384-4386	to	_	
23-5	4387-4390	map	_	
23-6	4391-4394	the	_	
23-7	4395-4403	neuronal	_	
23-8	4404-4419	pathophysiology	_	
23-9	4420-4422	in	_	
23-10	4423-4436	schizophrenia	_	
23-11	4436-4437	,	_	
23-12	4438-4441	but	_	
23-13	4442-4445	the	_	
23-14	4446-4453	results	_	
23-15	4454-4458	were	_	
23-16	4459-4464	often	_	
23-17	4465-4478	contradictory	_	
23-18	4478-4479	.	_	

#Text=The underlying etiology and pathophysiology of SZ remain unknown, and the following reasons should be considered: (1) existing studies have no adequate statistical power because of a small sample size; (2) in previous studies, the main threshold setting at a low or even incorrect level for multiple tests produced hundreds or even thousands of false positives to reflect true effects; this setting should be replicated in future studies, but strict correction should be performed to prevent type I errors; (3) the heterogeneity of patients related to multiple episode courses, illness duration, and medical effect causes inconsistent and contradictory findings.
24-1	4480-4483	The	_	
24-2	4484-4494	underlying	_	
24-3	4495-4503	etiology	_	
24-4	4504-4507	and	_	
24-5	4508-4523	pathophysiology	_	
24-6	4524-4526	of	_	
24-7	4527-4529	SZ	_	
24-8	4530-4536	remain	_	
24-9	4537-4544	unknown	_	
24-10	4544-4545	,	_	
24-11	4546-4549	and	_	
24-12	4550-4553	the	_	
24-13	4554-4563	following	_	
24-14	4564-4571	reasons	_	
24-15	4572-4578	should	_	
24-16	4579-4581	be	_	
24-17	4582-4592	considered	_	
24-18	4592-4593	:	_	
24-19	4594-4595	(	_	
24-20	4595-4596	1	_	
24-21	4596-4597	)	_	
24-22	4598-4606	existing	_	
24-23	4607-4614	studies	_	
24-24	4615-4619	have	_	
24-25	4620-4622	no	_	
24-26	4623-4631	adequate	_	
24-27	4632-4643	statistical	_	
24-28	4644-4649	power	_	
24-29	4650-4657	because	_	
24-30	4658-4660	of	_	
24-31	4661-4662	a	_	
24-32	4663-4668	small	_	
24-33	4669-4675	sample	_	
24-34	4676-4680	size	_	
24-35	4680-4681	;	_	
24-36	4682-4683	(	_	
24-37	4683-4684	2	_	
24-38	4684-4685	)	_	
24-39	4686-4688	in	_	
24-40	4689-4697	previous	_	
24-41	4698-4705	studies	_	
24-42	4705-4706	,	_	
24-43	4707-4710	the	_	
24-44	4711-4715	main	_	
24-45	4716-4725	threshold	_	
24-46	4726-4733	setting	_	
24-47	4734-4736	at	_	
24-48	4737-4738	a	_	
24-49	4739-4742	low	_	
24-50	4743-4745	or	_	
24-51	4746-4750	even	_	
24-52	4751-4760	incorrect	_	
24-53	4761-4766	level	_	
24-54	4767-4770	for	_	
24-55	4771-4779	multiple	_	
24-56	4780-4785	tests	_	
24-57	4786-4794	produced	_	
24-58	4795-4803	hundreds	_	
24-59	4804-4806	or	_	
24-60	4807-4811	even	_	
24-61	4812-4821	thousands	_	
24-62	4822-4824	of	_	
24-63	4825-4830	false	_	
24-64	4831-4840	positives	_	
24-65	4841-4843	to	_	
24-66	4844-4851	reflect	_	
24-67	4852-4856	true	_	
24-68	4857-4864	effects	_	
24-69	4864-4865	;	_	
24-70	4866-4870	this	_	
24-71	4871-4878	setting	_	
24-72	4879-4885	should	_	
24-73	4886-4888	be	_	
24-74	4889-4899	replicated	_	
24-75	4900-4902	in	_	
24-76	4903-4909	future	_	
24-77	4910-4917	studies	_	
24-78	4917-4918	,	_	
24-79	4919-4922	but	_	
24-80	4923-4929	strict	_	
24-81	4930-4940	correction	_	
24-82	4941-4947	should	_	
24-83	4948-4950	be	_	
24-84	4951-4960	performed	_	
24-85	4961-4963	to	_	
24-86	4964-4971	prevent	_	
24-87	4972-4976	type	_	
24-88	4977-4978	I	_	
24-89	4979-4985	errors	_	
24-90	4985-4986	;	_	
24-91	4987-4988	(	_	
24-92	4988-4989	3	_	
24-93	4989-4990	)	_	
24-94	4991-4994	the	_	
24-95	4995-5008	heterogeneity	_	
24-96	5009-5011	of	_	
24-97	5012-5020	patients	_	
24-98	5021-5028	related	_	
24-99	5029-5031	to	_	
24-100	5032-5040	multiple	_	
24-101	5041-5048	episode	_	
24-102	5049-5056	courses	_	
24-103	5056-5057	,	_	
24-104	5058-5065	illness	_	
24-105	5066-5074	duration	_	
24-106	5074-5075	,	_	
24-107	5076-5079	and	_	
24-108	5080-5087	medical	_	
24-109	5088-5094	effect	_	
24-110	5095-5101	causes	_	
24-111	5102-5114	inconsistent	_	
24-112	5115-5118	and	_	
24-113	5119-5132	contradictory	_	
24-114	5133-5141	findings	_	
24-115	5141-5142	.	_	

#Text=In the current study, we hypothesized that patients with SZ exhibiting common or distinct brain activities would reflect the severity of psychotic symptoms and cognitive deficits.
25-1	5143-5145	In	_	
25-2	5146-5149	the	_	
25-3	5150-5157	current	_	
25-4	5158-5163	study	_	
25-5	5163-5164	,	_	
25-6	5165-5167	we	_	
25-7	5168-5180	hypothesized	_	
25-8	5181-5185	that	_	
25-9	5186-5194	patients	_	
25-10	5195-5199	with	_	
25-11	5200-5202	SZ	_	
25-12	5203-5213	exhibiting	_	
25-13	5214-5220	common	_	
25-14	5221-5223	or	_	
25-15	5224-5232	distinct	_	
25-16	5233-5238	brain	_	
25-17	5239-5249	activities	_	
25-18	5250-5255	would	_	
25-19	5256-5263	reflect	_	
25-20	5264-5267	the	_	
25-21	5268-5276	severity	_	
25-22	5277-5279	of	_	
25-23	5280-5289	psychotic	_	
25-24	5290-5298	symptoms	_	
25-25	5299-5302	and	_	
25-26	5303-5312	cognitive	_	
25-27	5313-5321	deficits	_	
25-28	5321-5322	.	_	

#Text=This study intended to investigate the ReHo and its association with the systematic cognitive dysfunction between patients with drug-naive First-Episode Schizophrenia (dn-FES) and matching healthy controls (HCs).
26-1	5323-5327	This	_	
26-2	5328-5333	study	_	
26-3	5334-5342	intended	_	
26-4	5343-5345	to	_	
26-5	5346-5357	investigate	_	
26-6	5358-5361	the	_	
26-7	5362-5366	ReHo	_	
26-8	5367-5370	and	_	
26-9	5371-5374	its	_	
26-10	5375-5386	association	_	
26-11	5387-5391	with	_	
26-12	5392-5395	the	_	
26-13	5396-5406	systematic	_	
26-14	5407-5416	cognitive	_	
26-15	5417-5428	dysfunction	_	
26-16	5429-5436	between	_	
26-17	5437-5445	patients	_	
26-18	5446-5450	with	_	
26-19	5451-5461	drug-naive	_	
26-20	5462-5475	First-Episode	_	
26-21	5476-5489	Schizophrenia	_	
26-22	5490-5491	(	_	
26-23	5491-5497	dn-FES	_	
26-24	5497-5498	)	_	
26-25	5499-5502	and	_	
26-26	5503-5511	matching	_	
26-27	5512-5519	healthy	_	
26-28	5520-5528	controls	_	
26-29	5529-5530	(	_	
26-30	5530-5533	HCs	_	
26-31	5533-5534	)	_	
26-32	5534-5535	.	_	

#Text=It also aimed to explore the associations between signal changes and clinical symptoms and to provide more revealing and consistent findings.
27-1	5536-5538	It	_	
27-2	5539-5543	also	_	
27-3	5544-5549	aimed	_	
27-4	5550-5552	to	_	
27-5	5553-5560	explore	_	
27-6	5561-5564	the	_	
27-7	5565-5577	associations	_	
27-8	5578-5585	between	_	
27-9	5586-5592	signal	_	
27-10	5593-5600	changes	_	
27-11	5601-5604	and	_	
27-12	5605-5613	clinical	_	
27-13	5614-5622	symptoms	_	
27-14	5623-5626	and	_	
27-15	5627-5629	to	_	
27-16	5630-5637	provide	_	
27-17	5638-5642	more	_	
27-18	5643-5652	revealing	_	
27-19	5653-5656	and	_	
27-20	5657-5667	consistent	_	
27-21	5668-5676	findings	_	
27-22	5676-5677	.	_	

#Text=In addition, it is another purpose of the study to ascertain which functional brain aberrations would reflect the clinical moderators including illness severity and cognitive deficits.
28-1	5678-5680	In	_	
28-2	5681-5689	addition	_	
28-3	5689-5690	,	_	
28-4	5691-5693	it	_	
28-5	5694-5696	is	_	
28-6	5697-5704	another	_	
28-7	5705-5712	purpose	_	
28-8	5713-5715	of	_	
28-9	5716-5719	the	_	
28-10	5720-5725	study	_	
28-11	5726-5728	to	_	
28-12	5729-5738	ascertain	_	
28-13	5739-5744	which	_	
28-14	5745-5755	functional	_	
28-15	5756-5761	brain	_	
28-16	5762-5773	aberrations	_	
28-17	5774-5779	would	_	
28-18	5780-5787	reflect	_	
28-19	5788-5791	the	_	
28-20	5792-5800	clinical	_	
28-21	5801-5811	moderators	_	
28-22	5812-5821	including	_	
28-23	5822-5829	illness	_	
28-24	5830-5838	severity	_	
28-25	5839-5842	and	_	
28-26	5843-5852	cognitive	_	
28-27	5853-5861	deficits	_	
28-28	5861-5862	.	_	

#Text=Methods
#Text=Participants
#Text=Eighty-seven patients who had first-episode schizophrenia in the past three years and were never medicated were recruited from Nanjing Brain Hospital from January 2017 to December 2018.
29-1	5863-5870	Methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod	
29-2	5871-5883	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
29-3	5884-5896	Eighty-seven	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
29-4	5897-5905	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[19]	
29-5	5906-5909	who	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[19]	
29-6	5910-5913	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[19]	
29-7	5914-5927	first-episode	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[19]|http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[20]	
29-8	5928-5941	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[19]|http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[20]	
29-9	5942-5944	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[19]	
29-10	5945-5948	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[19]	
29-11	5949-5953	past	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[19]	
29-12	5954-5959	three	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[19]	
29-13	5960-5965	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[19]	
29-14	5966-5969	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[19]	
29-15	5970-5974	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[19]	
29-16	5975-5980	never	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[19]|http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated[21]	
29-17	5981-5990	medicated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[19]|http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated[21]	
29-18	5991-5995	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
29-19	5996-6005	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
29-20	6006-6010	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
29-21	6011-6018	Nanjing	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
29-22	6019-6024	Brain	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
29-23	6025-6033	Hospital	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
29-24	6034-6038	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
29-25	6039-6046	January	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
29-26	6047-6051	2017	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
29-27	6052-6054	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
29-28	6055-6063	December	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
29-29	6064-6068	2018	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
29-30	6068-6069	.	_	

#Text=Eighty-two healthy controls matched in terms of age, gender and ethnicity were recruited from the same area through advertising.
30-1	6070-6080	Eighty-two	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
30-2	6081-6088	healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[23]	
30-3	6089-6097	controls	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[23]	
30-4	6098-6105	matched	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
30-5	6106-6108	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
30-6	6109-6114	terms	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
30-7	6115-6117	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
30-8	6118-6121	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
30-9	6121-6122	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
30-10	6123-6129	gender	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
30-11	6130-6133	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
30-12	6134-6143	ethnicity	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
30-13	6144-6148	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
30-14	6149-6158	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
30-15	6159-6163	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
30-16	6164-6167	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
30-17	6168-6172	same	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
30-18	6173-6177	area	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
30-19	6178-6185	through	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
30-20	6186-6197	advertising	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
30-21	6197-6198	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	

#Text=The general inclusion criteria for two groups were right handed, aged 16–45, and able to understand survey instructions and execute cognitive tests.
31-1	6199-6202	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
31-2	6203-6210	general	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
31-3	6211-6220	inclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
31-4	6221-6229	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
31-5	6230-6233	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
31-6	6234-6237	two	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
31-7	6238-6244	groups	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
31-8	6245-6249	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
31-9	6250-6255	right	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
31-10	6256-6262	handed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
31-11	6262-6263	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
31-12	6264-6268	aged	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
31-13	6269-6271	16	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
31-14	6271-6272	–	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
31-15	6272-6274	45	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
31-16	6274-6275	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
31-17	6276-6279	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
31-18	6280-6284	able	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
31-19	6285-6287	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
31-20	6288-6298	understand	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
31-21	6299-6305	survey	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
31-22	6306-6318	instructions	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
31-23	6319-6322	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
31-24	6323-6330	execute	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
31-25	6331-6340	cognitive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
31-26	6341-6346	tests	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
31-27	6346-6347	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	

#Text=Two qualified clinical psychologists conducted the Mini-International Neuropsychiatric Interview (M.I.N.I.) to confirm diagnosis with the DSM-IV diagnostic criteria for schizophrenia and to exclude participants with a history of affective disorders, head trauma, and substance abuse.
32-1	6348-6351	Two	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
32-2	6352-6361	qualified	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
32-3	6362-6370	clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
32-4	6371-6384	psychologists	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
32-5	6385-6394	conducted	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
32-6	6395-6398	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
32-7	6399-6417	Mini-International	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[26]	
32-8	6418-6434	Neuropsychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[26]	
32-9	6435-6444	Interview	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[26]	
32-10	6445-6446	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[26]	
32-11	6446-6453	M.I.N.I	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[26]	
32-12	6453-6454	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[26]	
32-13	6454-6455	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[26]	
32-14	6456-6458	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
32-15	6459-6466	confirm	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
32-16	6467-6476	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
32-17	6477-6481	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
32-18	6482-6485	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
32-19	6486-6492	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
32-20	6493-6503	diagnostic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
32-21	6504-6512	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
32-22	6513-6516	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
32-23	6517-6530	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
32-24	6531-6534	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
32-25	6535-6537	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
32-26	6538-6545	exclude	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
32-27	6546-6558	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
32-28	6559-6563	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
32-29	6564-6565	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
32-30	6566-6573	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
32-31	6574-6576	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
32-32	6577-6586	affective	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
32-33	6587-6596	disorders	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
32-34	6596-6597	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
32-35	6598-6602	head	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
32-36	6603-6609	trauma	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
32-37	6609-6610	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
32-38	6611-6614	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
32-39	6615-6624	substance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
32-40	6625-6630	abuse	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
32-41	6630-6631	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	

#Text=Healthy controls were also interviewed using the M.I.N.I. and excluded according to the same criteria adopted in screening patients as well as a major psychiatric disorder and family history of psychotic disorder.
33-1	6632-6639	Healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[28]	
33-2	6640-6648	controls	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[28]	
33-3	6649-6653	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
33-4	6654-6658	also	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
33-5	6659-6670	interviewed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
33-6	6671-6676	using	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
33-7	6677-6680	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
33-8	6681-6688	M.I.N.I	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[29]	
33-9	6688-6689	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[29]	
33-10	6690-6693	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
33-11	6694-6702	excluded	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
33-12	6703-6712	according	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
33-13	6713-6715	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
33-14	6716-6719	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
33-15	6720-6724	same	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
33-16	6725-6733	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
33-17	6734-6741	adopted	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
33-18	6742-6744	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
33-19	6745-6754	screening	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
33-20	6755-6763	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
33-21	6764-6766	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
33-22	6767-6771	well	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
33-23	6772-6774	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
33-24	6775-6776	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
33-25	6777-6782	major	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
33-26	6783-6794	psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
33-27	6795-6803	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
33-28	6804-6807	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
33-29	6808-6814	family	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
33-30	6815-6822	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
33-31	6823-6825	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
33-32	6826-6835	psychotic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
33-33	6836-6844	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
33-34	6844-6845	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	

#Text=The study was approved by Nanjing Brain Hospital Ethics Committee.
34-1	6846-6849	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
34-2	6850-6855	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
34-3	6856-6859	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
34-4	6860-6868	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
34-5	6869-6871	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
34-6	6872-6879	Nanjing	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
34-7	6880-6885	Brain	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
34-8	6886-6894	Hospital	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
34-9	6895-6901	Ethics	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
34-10	6902-6911	Committee	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
34-11	6911-6912	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	

#Text=After comprehensively describing and explaining the study, a written informed consent was obtained from each participant.
35-1	6913-6918	After	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]	
35-2	6919-6934	comprehensively	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]	
35-3	6935-6945	describing	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]	
35-4	6946-6949	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]	
35-5	6950-6960	explaining	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]	
35-6	6961-6964	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]	
35-7	6965-6970	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]	
35-8	6970-6971	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]	
35-9	6972-6973	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]	
35-10	6974-6981	written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]	
35-11	6982-6990	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]	
35-12	6991-6998	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]	
35-13	6999-7002	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]	
35-14	7003-7011	obtained	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]	
35-15	7012-7016	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]	
35-16	7017-7021	each	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]	
35-17	7022-7033	participant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]	
35-18	7033-7034	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]	

#Text=Neuropsychological and clinical assessments
#Text=The MCCB was used to assess cognitive function.
36-1	7035-7053	Neuropsychological	_	
36-2	7054-7057	and	_	
36-3	7058-7066	clinical	_	
36-4	7067-7078	assessments	_	
36-5	7079-7082	The	_	
36-6	7083-7087	MCCB	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest	
36-7	7088-7091	was	_	
36-8	7092-7096	used	_	
36-9	7097-7099	to	_	
36-10	7100-7106	assess	_	
36-11	7107-7116	cognitive	_	
36-12	7117-7125	function	_	
36-13	7125-7126	.	_	

#Text=The present study included nine tasks across seven cognitive domains, including speed of processing (Category Fluency, Trails A, Brief Assessment of Cognition in Schizophrenia Symbol Coding), attention/vigilance (Continuous Performance Test), working memory (Wechsler Memory Scale-III Spatial Span), verbal learning (Hopkins Verbal Learning Test–Revised), visual learning (Brief Visuospatial Memory Test–Revised), reasoning and problem solving (The Mazes test), and social cognition (Mayer–Salovey–Caruso Emotional Intelligence Test).
37-1	7127-7130	The	_	
37-2	7131-7138	present	_	
37-3	7139-7144	study	_	
37-4	7145-7153	included	_	
37-5	7154-7158	nine	_	
37-6	7159-7164	tasks	_	
37-7	7165-7171	across	_	
37-8	7172-7177	seven	_	
37-9	7178-7187	cognitive	_	
37-10	7188-7195	domains	_	
37-11	7195-7196	,	_	
37-12	7197-7206	including	_	
37-13	7207-7212	speed	_	
37-14	7213-7215	of	_	
37-15	7216-7226	processing	_	
37-16	7227-7228	(	_	
37-17	7228-7236	Category	_	
37-18	7237-7244	Fluency	_	
37-19	7244-7245	,	_	
37-20	7246-7252	Trails	_	
37-21	7253-7254	A	_	
37-22	7254-7255	,	_	
37-23	7256-7261	Brief	_	
37-24	7262-7272	Assessment	_	
37-25	7273-7275	of	_	
37-26	7276-7285	Cognition	_	
37-27	7286-7288	in	_	
37-28	7289-7302	Schizophrenia	_	
37-29	7303-7309	Symbol	_	
37-30	7310-7316	Coding	_	
37-31	7316-7317	)	_	
37-32	7317-7318	,	_	
37-33	7319-7328	attention	_	
37-34	7328-7329	/	_	
37-35	7329-7338	vigilance	_	
37-36	7339-7340	(	_	
37-37	7340-7350	Continuous	_	
37-38	7351-7362	Performance	_	
37-39	7363-7367	Test	_	
37-40	7367-7368	)	_	
37-41	7368-7369	,	_	
37-42	7370-7377	working	_	
37-43	7378-7384	memory	_	
37-44	7385-7386	(	_	
37-45	7386-7394	Wechsler	_	
37-46	7395-7401	Memory	_	
37-47	7402-7411	Scale-III	_	
37-48	7412-7419	Spatial	_	
37-49	7420-7424	Span	_	
37-50	7424-7425	)	_	
37-51	7425-7426	,	_	
37-52	7427-7433	verbal	_	
37-53	7434-7442	learning	_	
37-54	7443-7444	(	_	
37-55	7444-7451	Hopkins	_	
37-56	7452-7458	Verbal	_	
37-57	7459-7467	Learning	_	
37-58	7468-7480	Test–Revised	_	
37-59	7480-7481	)	_	
37-60	7481-7482	,	_	
37-61	7483-7489	visual	_	
37-62	7490-7498	learning	_	
37-63	7499-7500	(	_	
37-64	7500-7505	Brief	_	
37-65	7506-7518	Visuospatial	_	
37-66	7519-7525	Memory	_	
37-67	7526-7538	Test–Revised	_	
37-68	7538-7539	)	_	
37-69	7539-7540	,	_	
37-70	7541-7550	reasoning	_	
37-71	7551-7554	and	_	
37-72	7555-7562	problem	_	
37-73	7563-7570	solving	_	
37-74	7571-7572	(	_	
37-75	7572-7575	The	_	
37-76	7576-7581	Mazes	_	
37-77	7582-7586	test	_	
37-78	7586-7587	)	_	
37-79	7587-7588	,	_	
37-80	7589-7592	and	_	
37-81	7593-7599	social	_	
37-82	7600-7609	cognition	_	
37-83	7610-7611	(	_	
37-84	7611-7631	Mayer–Salovey–Caruso	_	
37-85	7632-7641	Emotional	_	
37-86	7642-7654	Intelligence	_	
37-87	7655-7659	Test	_	
37-88	7659-7660	)	_	
37-89	7660-7661	.	_	

#Text=We corrected the original score for age, gender, and education to obtain a T score to evaluate cognitive function, and high score showed a good performance.
38-1	7662-7664	We	_	
38-2	7665-7674	corrected	_	
38-3	7675-7678	the	_	
38-4	7679-7687	original	_	
38-5	7688-7693	score	_	
38-6	7694-7697	for	_	
38-7	7698-7701	age	_	
38-8	7701-7702	,	_	
38-9	7703-7709	gender	_	
38-10	7709-7710	,	_	
38-11	7711-7714	and	_	
38-12	7715-7724	education	_	
38-13	7725-7727	to	_	
38-14	7728-7734	obtain	_	
38-15	7735-7736	a	_	
38-16	7737-7738	T	_	
38-17	7739-7744	score	_	
38-18	7745-7747	to	_	
38-19	7748-7756	evaluate	_	
38-20	7757-7766	cognitive	_	
38-21	7767-7775	function	_	
38-22	7775-7776	,	_	
38-23	7777-7780	and	_	
38-24	7781-7785	high	_	
38-25	7786-7791	score	_	
38-26	7792-7798	showed	_	
38-27	7799-7800	a	_	
38-28	7801-7805	good	_	
38-29	7806-7817	performance	_	
38-30	7817-7818	.	_	

#Text=We adopted the Wechsler Adult Scale of Intelligence (WAIS) to test the Intelligence Quotient (IQ).
39-1	7819-7821	We	_	
39-2	7822-7829	adopted	_	
39-3	7830-7833	the	_	
39-4	7834-7842	Wechsler	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[32]	
39-5	7843-7848	Adult	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[32]	
39-6	7849-7854	Scale	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[32]	
39-7	7855-7857	of	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[32]	
39-8	7858-7870	Intelligence	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[32]	
39-9	7871-7872	(	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[32]	
39-10	7872-7876	WAIS	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[32]	
39-11	7876-7877	)	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[32]	
39-12	7878-7880	to	_	
39-13	7881-7885	test	_	
39-14	7886-7889	the	_	
39-15	7890-7902	Intelligence	_	
39-16	7903-7911	Quotient	_	
39-17	7912-7913	(	_	
39-18	7913-7915	IQ	_	
39-19	7915-7916	)	_	
39-20	7916-7917	.	_	

#Text=Positive And Negative Syndrome Scale (PANSS) was used to assess symptoms of the patients, and the process was carried out by two experienced psychiatrists.
40-1	7918-7926	Positive	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[33]	
40-2	7927-7930	And	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[33]	
40-3	7931-7939	Negative	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[33]	
40-4	7940-7948	Syndrome	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[33]	
40-5	7949-7954	Scale	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[33]	
40-6	7955-7956	(	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[33]	
40-7	7956-7961	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[33]	
40-8	7961-7962	)	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[33]	
40-9	7963-7966	was	_	
40-10	7967-7971	used	_	
40-11	7972-7974	to	_	
40-12	7975-7981	assess	_	
40-13	7982-7990	symptoms	_	
40-14	7991-7993	of	_	
40-15	7994-7997	the	_	
40-16	7998-8006	patients	_	
40-17	8006-8007	,	_	
40-18	8008-8011	and	_	
40-19	8012-8015	the	_	
40-20	8016-8023	process	_	
40-21	8024-8027	was	_	
40-22	8028-8035	carried	_	
40-23	8036-8039	out	_	
40-24	8040-8042	by	_	
40-25	8043-8046	two	_	
40-26	8047-8058	experienced	_	
40-27	8059-8072	psychiatrists	_	
40-28	8072-8073	.	_	

#Text=Image data acquisition
#Text=MRI scanning was performed with a Siemens 3.0-T signal scanner, and a standard head coil padded with foam was used to reduce head motion and scanner noise.
41-1	8074-8079	Image	_	
41-2	8080-8084	data	_	
41-3	8085-8096	acquisition	_	
41-4	8097-8100	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging	
41-5	8101-8109	scanning	_	
41-6	8110-8113	was	_	
41-7	8114-8123	performed	_	
41-8	8124-8128	with	_	
41-9	8129-8130	a	_	
41-10	8131-8138	Siemens	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[34]	
41-11	8139-8142	3.0	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[34]	
41-12	8142-8143	-	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[34]	
41-13	8143-8144	T	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[34]	
41-14	8145-8151	signal	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[34]	
41-15	8152-8159	scanner	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[34]	
41-16	8159-8160	,	_	
41-17	8161-8164	and	_	
41-18	8165-8166	a	_	
41-19	8167-8175	standard	_	
41-20	8176-8180	head	_	
41-21	8181-8185	coil	_	
41-22	8186-8192	padded	_	
41-23	8193-8197	with	_	
41-24	8198-8202	foam	_	
41-25	8203-8206	was	_	
41-26	8207-8211	used	_	
41-27	8212-8214	to	_	
41-28	8215-8221	reduce	_	
41-29	8222-8226	head	_	
41-30	8227-8233	motion	_	
41-31	8234-8237	and	_	
41-32	8238-8245	scanner	_	
41-33	8246-8251	noise	_	
41-34	8251-8252	.	_	

#Text=All of the participants lay in a supine position and were instructed to stay still, close their eyes, keep awake, and let their mind go blank.
42-1	8253-8256	All	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[35]	
42-2	8257-8259	of	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[35]	
42-3	8260-8263	the	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[35]	
42-4	8264-8276	participants	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[35]	
42-5	8277-8280	lay	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[35]	
42-6	8281-8283	in	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[35]	
42-7	8284-8285	a	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[35]	
42-8	8286-8292	supine	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[35]	
42-9	8293-8301	position	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[35]	
42-10	8302-8305	and	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[35]	
42-11	8306-8310	were	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[35]	
42-12	8311-8321	instructed	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[35]	
42-13	8322-8324	to	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[35]	
42-14	8325-8329	stay	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[35]	
42-15	8330-8335	still	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[35]	
42-16	8335-8336	,	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[35]	
42-17	8337-8342	close	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[35]	
42-18	8343-8348	their	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[35]	
42-19	8349-8353	eyes	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[35]	
42-20	8353-8354	,	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[35]	
42-21	8355-8359	keep	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[35]	
42-22	8360-8365	awake	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[35]	
42-23	8365-8366	,	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[35]	
42-24	8367-8370	and	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[35]	
42-25	8371-8374	let	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[35]	
42-26	8375-8380	their	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[35]	
42-27	8381-8385	mind	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[35]	
42-28	8386-8388	go	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[35]	
42-29	8389-8394	blank	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[35]	
42-30	8394-8395	.	_	

#Text=Three-dimensional T1-weighted sagittal images were acquired using a brain volume sequence with following parameters: repetition time (TR) = 2300 ms, echo time (TE) = 2.96 ms, inversion time = 900 ms, flip angle (FA) = 9°, field of view (FOV) = 256 mm × 256 mm, matrix = 256 × 256, slice thickness = 1 mm, 192 sagittal slices, and acquisition time = 554 s.
43-1	8396-8413	Three-dimensional	_	
43-2	8414-8416	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[36]	
43-3	8416-8417	-	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[36]	
43-4	8417-8425	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[36]	
43-5	8426-8434	sagittal	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[36]	
43-6	8435-8441	images	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[36]	
43-7	8442-8446	were	_	
43-8	8447-8455	acquired	_	
43-9	8456-8461	using	_	
43-10	8462-8463	a	_	
43-11	8464-8469	brain	_	
43-12	8470-8476	volume	_	
43-13	8477-8485	sequence	_	
43-14	8486-8490	with	_	
43-15	8491-8500	following	_	
43-16	8501-8511	parameters	_	
43-17	8511-8512	:	_	
43-18	8513-8523	repetition	_	
43-19	8524-8528	time	_	
43-20	8529-8530	(	_	
43-21	8530-8532	TR	_	
43-22	8532-8533	)	_	
43-23	8534-8535	=	_	
43-24	8536-8540	2300	_	
43-25	8541-8543	ms	_	
43-26	8543-8544	,	_	
43-27	8545-8549	echo	_	
43-28	8550-8554	time	_	
43-29	8555-8556	(	_	
43-30	8556-8558	TE	_	
43-31	8558-8559	)	_	
43-32	8560-8561	=	_	
43-33	8562-8566	2.96	_	
43-34	8567-8569	ms	_	
43-35	8569-8570	,	_	
43-36	8571-8580	inversion	_	
43-37	8581-8585	time	_	
43-38	8586-8587	=	_	
43-39	8588-8591	900	_	
43-40	8592-8594	ms	_	
43-41	8594-8595	,	_	
43-42	8596-8600	flip	_	
43-43	8601-8606	angle	_	
43-44	8607-8608	(	_	
43-45	8608-8610	FA	_	
43-46	8610-8611	)	_	
43-47	8612-8613	=	_	
43-48	8614-8615	9	_	
43-49	8615-8616	°	_	
43-50	8616-8617	,	_	
43-51	8618-8623	field	_	
43-52	8624-8626	of	_	
43-53	8627-8631	view	_	
43-54	8632-8633	(	_	
43-55	8633-8636	FOV	_	
43-56	8636-8637	)	_	
43-57	8638-8639	=	_	
43-58	8640-8643	256	_	
43-59	8644-8646	mm	_	
43-60	8647-8648	×	_	
43-61	8649-8652	256	_	
43-62	8653-8655	mm	_	
43-63	8655-8656	,	_	
43-64	8657-8663	matrix	_	
43-65	8664-8665	=	_	
43-66	8666-8669	256	_	
43-67	8670-8671	×	_	
43-68	8672-8675	256	_	
43-69	8675-8676	,	_	
43-70	8677-8682	slice	_	
43-71	8683-8692	thickness	_	
43-72	8693-8694	=	_	
43-73	8695-8696	1	_	
43-74	8697-8699	mm	_	
43-75	8699-8700	,	_	
43-76	8701-8704	192	_	
43-77	8705-8713	sagittal	_	
43-78	8714-8720	slices	_	
43-79	8720-8721	,	_	
43-80	8722-8725	and	_	
43-81	8726-8737	acquisition	_	
43-82	8738-8742	time	_	
43-83	8743-8744	=	_	
43-84	8745-8748	554	_	
43-85	8749-8750	s	_	
43-86	8750-8751	.	_	

#Text=The images were acquired using a gradient echo single-shot echo planar imaging sequence with the following parameters: TR/TE = 2500/30 ms, FOV = 224 mm × 224 mm, matrix = 64 × 64, FA = 90°, slice thickness = 3.5 mm, no gap, 37 interleaved transverse slices, 149 volumes, and acquisition time = 379 s.
44-1	8752-8755	The	_	
44-2	8756-8762	images	_	
44-3	8763-8767	were	_	
44-4	8768-8776	acquired	_	
44-5	8777-8782	using	_	
44-6	8783-8784	a	_	
44-7	8785-8793	gradient	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[37]	
44-8	8794-8798	echo	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[37]	
44-9	8799-8810	single-shot	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[37]	
44-10	8811-8815	echo	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[37]	
44-11	8816-8822	planar	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[37]	
44-12	8823-8830	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[37]	
44-13	8831-8839	sequence	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[37]	
44-14	8840-8844	with	_	
44-15	8845-8848	the	_	
44-16	8849-8858	following	_	
44-17	8859-8869	parameters	_	
44-18	8869-8870	:	_	
44-19	8871-8873	TR	_	
44-20	8873-8874	/	_	
44-21	8874-8876	TE	_	
44-22	8877-8878	=	_	
44-23	8879-8883	2500	_	
44-24	8883-8884	/	_	
44-25	8884-8886	30	_	
44-26	8887-8889	ms	_	
44-27	8889-8890	,	_	
44-28	8891-8894	FOV	_	
44-29	8895-8896	=	_	
44-30	8897-8900	224	_	
44-31	8901-8903	mm	_	
44-32	8904-8905	×	_	
44-33	8906-8909	224	_	
44-34	8910-8912	mm	_	
44-35	8912-8913	,	_	
44-36	8914-8920	matrix	_	
44-37	8921-8922	=	_	
44-38	8923-8925	64	_	
44-39	8926-8927	×	_	
44-40	8928-8930	64	_	
44-41	8930-8931	,	_	
44-42	8932-8934	FA	_	
44-43	8935-8936	=	_	
44-44	8937-8939	90	_	
44-45	8939-8940	°	_	
44-46	8940-8941	,	_	
44-47	8942-8947	slice	_	
44-48	8948-8957	thickness	_	
44-49	8958-8959	=	_	
44-50	8960-8963	3.5	_	
44-51	8964-8966	mm	_	
44-52	8966-8967	,	_	
44-53	8968-8970	no	_	
44-54	8971-8974	gap	_	
44-55	8974-8975	,	_	
44-56	8976-8978	37	_	
44-57	8979-8990	interleaved	_	
44-58	8991-9001	transverse	_	
44-59	9002-9008	slices	_	
44-60	9008-9009	,	_	
44-61	9010-9013	149	_	
44-62	9014-9021	volumes	_	
44-63	9021-9022	,	_	
44-64	9023-9026	and	_	
44-65	9027-9038	acquisition	_	
44-66	9039-9043	time	_	
44-67	9044-9045	=	_	
44-68	9046-9049	379	_	
44-69	9050-9051	s	_	
44-70	9051-9052	.	_	

#Text=Data preprocessing and processing
#Text=Functional images were preprocessed with the Matlab2013b platform and the Data Processing Assistant for rs-fMRI (DPARSF4.4, advanced edition).
45-1	9053-9057	Data	_	
45-2	9058-9071	preprocessing	_	
45-3	9072-9075	and	_	
45-4	9076-9086	processing	_	
45-5	9087-9097	Functional	_	
45-6	9098-9104	images	_	
45-7	9105-9109	were	_	
45-8	9110-9122	preprocessed	_	
45-9	9123-9127	with	_	
45-10	9128-9131	the	_	
45-11	9132-9143	Matlab2013b	_	
45-12	9144-9152	platform	_	
45-13	9153-9156	and	_	
45-14	9157-9160	the	_	
45-15	9161-9165	Data	_	
45-16	9166-9176	Processing	_	
45-17	9177-9186	Assistant	_	
45-18	9187-9190	for	_	
45-19	9191-9198	rs-fMRI	_	
45-20	9199-9200	(	_	
45-21	9200-9209	DPARSF4.4	_	
45-22	9209-9210	,	_	
45-23	9211-9219	advanced	_	
45-24	9220-9227	edition	_	
45-25	9227-9228	)	_	
45-26	9228-9229	.	_	

#Text=Data were calculated in an original space warped by diffeomorphic anatomical registration through exponentiated Lie algebra (DARTEL).
46-1	9230-9234	Data	_	
46-2	9235-9239	were	_	
46-3	9240-9250	calculated	_	
46-4	9251-9253	in	_	
46-5	9254-9256	an	_	
46-6	9257-9265	original	_	
46-7	9266-9271	space	_	
46-8	9272-9278	warped	_	
46-9	9279-9281	by	_	
46-10	9282-9295	diffeomorphic	_	
46-11	9296-9306	anatomical	_	
46-12	9307-9319	registration	_	
46-13	9320-9327	through	_	
46-14	9328-9341	exponentiated	_	
46-15	9342-9345	Lie	_	
46-16	9346-9353	algebra	_	
46-17	9354-9355	(	_	
46-18	9355-9361	DARTEL	_	
46-19	9361-9362	)	_	
46-20	9362-9363	.	_	

#Text=The first four volumes of the BOLD data were discarded for each subject to allow the signal to reach equilibrium.
47-1	9364-9367	The	_	
47-2	9368-9373	first	_	
47-3	9374-9378	four	_	
47-4	9379-9386	volumes	_	
47-5	9387-9389	of	_	
47-6	9390-9393	the	_	
47-7	9394-9398	BOLD	_	
47-8	9399-9403	data	_	
47-9	9404-9408	were	_	
47-10	9409-9418	discarded	_	
47-11	9419-9422	for	_	
47-12	9423-9427	each	_	
47-13	9428-9435	subject	_	
47-14	9436-9438	to	_	
47-15	9439-9444	allow	_	
47-16	9445-9448	the	_	
47-17	9449-9455	signal	_	
47-18	9456-9458	to	_	
47-19	9459-9464	reach	_	
47-20	9465-9476	equilibrium	_	
47-21	9476-9477	.	_	

#Text=The remaining images were corrected for the acquisition time delay between slices.
48-1	9478-9481	The	_	
48-2	9482-9491	remaining	_	
48-3	9492-9498	images	_	
48-4	9499-9503	were	_	
48-5	9504-9513	corrected	_	
48-6	9514-9517	for	_	
48-7	9518-9521	the	_	
48-8	9522-9533	acquisition	_	
48-9	9534-9538	time	_	
48-10	9539-9544	delay	_	
48-11	9545-9552	between	_	
48-12	9553-9559	slices	_	
48-13	9559-9560	.	_	

#Text=All of the subjects should have no > 2 mm maximum displacement in any plane, 2° of angular motion, and 0.2 mm mean frame-wise displacement.
49-1	9561-9564	All	_	
49-2	9565-9567	of	_	
49-3	9568-9571	the	_	
49-4	9572-9580	subjects	_	
49-5	9581-9587	should	_	
49-6	9588-9592	have	_	
49-7	9593-9595	no	_	
49-8	9596-9597	>	_	
49-9	9598-9599	2	_	
49-10	9600-9602	mm	_	
49-11	9603-9610	maximum	_	
49-12	9611-9623	displacement	_	
49-13	9624-9626	in	_	
49-14	9627-9630	any	_	
49-15	9631-9636	plane	_	
49-16	9636-9637	,	_	
49-17	9638-9639	2	_	
49-18	9639-9640	°	_	
49-19	9641-9643	of	_	
49-20	9644-9651	angular	_	
49-21	9652-9658	motion	_	
49-22	9658-9659	,	_	
49-23	9660-9663	and	_	
49-24	9664-9667	0.2	_	
49-25	9668-9670	mm	_	
49-26	9671-9675	mean	_	
49-27	9676-9686	frame-wise	_	
49-28	9687-9699	displacement	_	
49-29	9699-9700	.	_	

#Text=Then, the images were spatially realigned to the first image of each dataset, and movement parameters were assessed for each subject and corrected using the Friston 24 approach.
50-1	9701-9705	Then	_	
50-2	9705-9706	,	_	
50-3	9707-9710	the	_	
50-4	9711-9717	images	_	
50-5	9718-9722	were	_	
50-6	9723-9732	spatially	_	
50-7	9733-9742	realigned	_	
50-8	9743-9745	to	_	
50-9	9746-9749	the	_	
50-10	9750-9755	first	_	
50-11	9756-9761	image	_	
50-12	9762-9764	of	_	
50-13	9765-9769	each	_	
50-14	9770-9777	dataset	_	
50-15	9777-9778	,	_	
50-16	9779-9782	and	_	
50-17	9783-9791	movement	_	
50-18	9792-9802	parameters	_	
50-19	9803-9807	were	_	
50-20	9808-9816	assessed	_	
50-21	9817-9820	for	_	
50-22	9821-9825	each	_	
50-23	9826-9833	subject	_	
50-24	9834-9837	and	_	
50-25	9838-9847	corrected	_	
50-26	9848-9853	using	_	
50-27	9854-9857	the	_	
50-28	9858-9865	Friston	_	
50-29	9866-9868	24	_	
50-30	9869-9877	approach	_	
50-31	9877-9878	.	_	

#Text=Several nuisance covariates (global brain, white matter, and cerebrospinal fluid signals) were regressed.
51-1	9879-9886	Several	_	
51-2	9887-9895	nuisance	_	
51-3	9896-9906	covariates	_	
51-4	9907-9908	(	_	
51-5	9908-9914	global	_	
51-6	9915-9920	brain	_	
51-7	9920-9921	,	_	
51-8	9922-9927	white	_	
51-9	9928-9934	matter	_	
51-10	9934-9935	,	_	
51-11	9936-9939	and	_	
51-12	9940-9953	cerebrospinal	_	
51-13	9954-9959	fluid	_	
51-14	9960-9967	signals	_	
51-15	9967-9968	)	_	
51-16	9969-9973	were	_	
51-17	9974-9983	regressed	_	
51-18	9983-9984	.	_	

#Text=The datasets were band-pass filtered to reduce low-frequency drift and high-frequency physiological respiratory and cardiac noise (0.01 < f < 0.1 Hz).
52-1	9985-9988	The	_	
52-2	9989-9997	datasets	_	
52-3	9998-10002	were	_	
52-4	10003-10012	band-pass	_	
52-5	10013-10021	filtered	_	
52-6	10022-10024	to	_	
52-7	10025-10031	reduce	_	
52-8	10032-10045	low-frequency	_	
52-9	10046-10051	drift	_	
52-10	10052-10055	and	_	
52-11	10056-10070	high-frequency	_	
52-12	10071-10084	physiological	_	
52-13	10085-10096	respiratory	_	
52-14	10097-10100	and	_	
52-15	10101-10108	cardiac	_	
52-16	10109-10114	noise	_	
52-17	10115-10116	(	_	
52-18	10116-10120	0.01	_	
52-19	10121-10122	<	_	
52-20	10123-10124	f	_	
52-21	10125-10126	<	_	
52-22	10127-10130	0.1	_	
52-23	10131-10133	Hz	_	
52-24	10133-10134	)	_	
52-25	10134-10135	.	_	

#Text=ReHo was calculated on a voxel-by-voxel basis by calculating Kendall’s coefficient of concordance on the basis of regional homogeneity hypothesis, which estimates similarity in the time series of a given voxel to its nearest 26 voxels.
53-1	10136-10140	ReHo	_	
53-2	10141-10144	was	_	
53-3	10145-10155	calculated	_	
53-4	10156-10158	on	_	
53-5	10159-10160	a	_	
53-6	10161-10175	voxel-by-voxel	_	
53-7	10176-10181	basis	_	
53-8	10182-10184	by	_	
53-9	10185-10196	calculating	_	
53-10	10197-10204	Kendall	_	
53-11	10204-10205	’	_	
53-12	10205-10206	s	_	
53-13	10207-10218	coefficient	_	
53-14	10219-10221	of	_	
53-15	10222-10233	concordance	_	
53-16	10234-10236	on	_	
53-17	10237-10240	the	_	
53-18	10241-10246	basis	_	
53-19	10247-10249	of	_	
53-20	10250-10258	regional	_	
53-21	10259-10270	homogeneity	_	
53-22	10271-10281	hypothesis	_	
53-23	10281-10282	,	_	
53-24	10283-10288	which	_	
53-25	10289-10298	estimates	_	
53-26	10299-10309	similarity	_	
53-27	10310-10312	in	_	
53-28	10313-10316	the	_	
53-29	10317-10321	time	_	
53-30	10322-10328	series	_	
53-31	10329-10331	of	_	
53-32	10332-10333	a	_	
53-33	10334-10339	given	_	
53-34	10340-10345	voxel	_	
53-35	10346-10348	to	_	
53-36	10349-10352	its	_	
53-37	10353-10360	nearest	_	
53-38	10361-10363	26	_	
53-39	10364-10370	voxels	_	
53-40	10370-10371	.	_	

#Text=Each subject’s value was divided by the mean value of their whole-brain ReHo to eliminate the whole-brain effect to the utmost extent.
54-1	10372-10376	Each	_	
54-2	10377-10384	subject	_	
54-3	10384-10385	’	_	
54-4	10385-10386	s	_	
54-5	10387-10392	value	_	
54-6	10393-10396	was	_	
54-7	10397-10404	divided	_	
54-8	10405-10407	by	_	
54-9	10408-10411	the	_	
54-10	10412-10416	mean	_	
54-11	10417-10422	value	_	
54-12	10423-10425	of	_	
54-13	10426-10431	their	_	
54-14	10432-10443	whole-brain	_	
54-15	10444-10448	ReHo	_	
54-16	10449-10451	to	_	
54-17	10452-10461	eliminate	_	
54-18	10462-10465	the	_	
54-19	10466-10477	whole-brain	_	
54-20	10478-10484	effect	_	
54-21	10485-10487	to	_	
54-22	10488-10491	the	_	
54-23	10492-10498	utmost	_	
54-24	10499-10505	extent	_	
54-25	10505-10506	.	_	

#Text=The standardized ReHo images were spatially smoothed with a Gaussian filter with a full width at half maximum (FWHM) of 4 mm.
55-1	10507-10510	The	_	
55-2	10511-10523	standardized	_	
55-3	10524-10528	ReHo	_	
55-4	10529-10535	images	_	
55-5	10536-10540	were	_	
55-6	10541-10550	spatially	_	
55-7	10551-10559	smoothed	_	
55-8	10560-10564	with	_	
55-9	10565-10566	a	_	
55-10	10567-10575	Gaussian	_	
55-11	10576-10582	filter	_	
55-12	10583-10587	with	_	
55-13	10588-10589	a	_	
55-14	10590-10594	full	_	
55-15	10595-10600	width	_	
55-16	10601-10603	at	_	
55-17	10604-10608	half	_	
55-18	10609-10616	maximum	_	
55-19	10617-10618	(	_	
55-20	10618-10622	FWHM	_	
55-21	10622-10623	)	_	
55-22	10624-10626	of	_	
55-23	10627-10628	4	_	
55-24	10629-10631	mm	_	
55-25	10631-10632	.	_	

#Text=Finally, ReHo values were used for statistical analysis.
56-1	10633-10640	Finally	_	
56-2	10640-10641	,	_	
56-3	10642-10646	ReHo	_	
56-4	10647-10653	values	_	
56-5	10654-10658	were	_	
56-6	10659-10663	used	_	
56-7	10664-10667	for	_	
56-8	10668-10679	statistical	_	
56-9	10680-10688	analysis	_	
56-10	10688-10689	.	_	

#Text=Statistical analysis
#Text=Statistical analysis was conducted using SPSS software (version20.0).
57-1	10690-10701	Statistical	_	
57-2	10702-10710	analysis	_	
57-3	10711-10722	Statistical	_	
57-4	10723-10731	analysis	_	
57-5	10732-10735	was	_	
57-6	10736-10745	conducted	_	
57-7	10746-10751	using	_	
57-8	10752-10756	SPSS	_	
57-9	10757-10765	software	_	
57-10	10766-10767	(	_	
57-11	10767-10778	version20.0	_	
57-12	10778-10779	)	_	
57-13	10779-10780	.	_	

#Text=Demographic and clinical variables of dn-FES and healthy controls were compared using two-sample t-test for continuous variables and chi-squared for categorical variables.
58-1	10781-10792	Demographic	_	
58-2	10793-10796	and	_	
58-3	10797-10805	clinical	_	
58-4	10806-10815	variables	_	
58-5	10816-10818	of	_	
58-6	10819-10825	dn-FES	_	
58-7	10826-10829	and	_	
58-8	10830-10837	healthy	_	
58-9	10838-10846	controls	_	
58-10	10847-10851	were	_	
58-11	10852-10860	compared	_	
58-12	10861-10866	using	_	
58-13	10867-10877	two-sample	_	
58-14	10878-10884	t-test	_	
58-15	10885-10888	for	_	
58-16	10889-10899	continuous	_	
58-17	10900-10909	variables	_	
58-18	10910-10913	and	_	
58-19	10914-10925	chi-squared	_	
58-20	10926-10929	for	_	
58-21	10930-10941	categorical	_	
58-22	10942-10951	variables	_	
58-23	10951-10952	.	_	

#Text=F-test was used for data analysis of cognitive domains after taking smoking as a covariate controlling.
59-1	10953-10959	F-test	_	
59-2	10960-10963	was	_	
59-3	10964-10968	used	_	
59-4	10969-10972	for	_	
59-5	10973-10977	data	_	
59-6	10978-10986	analysis	_	
59-7	10987-10989	of	_	
59-8	10990-10999	cognitive	_	
59-9	11000-11007	domains	_	
59-10	11008-11013	after	_	
59-11	11014-11020	taking	_	
59-12	11021-11028	smoking	_	
59-13	11029-11031	as	_	
59-14	11032-11033	a	_	
59-15	11034-11043	covariate	_	
59-16	11044-11055	controlling	_	
59-17	11055-11056	.	_	

#Text=The ReHo maps were compared between the two groups by using the threshold-free cluster enhancement (TFCE) method with family wise-error (FWE) correction for multiple comparisons.
60-1	11057-11060	The	_	
60-2	11061-11065	ReHo	_	
60-3	11066-11070	maps	_	
60-4	11071-11075	were	_	
60-5	11076-11084	compared	_	
60-6	11085-11092	between	_	
60-7	11093-11096	the	_	
60-8	11097-11100	two	_	
60-9	11101-11107	groups	_	
60-10	11108-11110	by	_	
60-11	11111-11116	using	_	
60-12	11117-11120	the	_	
60-13	11121-11135	threshold-free	_	
60-14	11136-11143	cluster	_	
60-15	11144-11155	enhancement	_	
60-16	11156-11157	(	_	
60-17	11157-11161	TFCE	_	
60-18	11161-11162	)	_	
60-19	11163-11169	method	_	
60-20	11170-11174	with	_	
60-21	11175-11181	family	_	
60-22	11182-11192	wise-error	_	
60-23	11193-11194	(	_	
60-24	11194-11197	FWE	_	
60-25	11197-11198	)	_	
60-26	11199-11209	correction	_	
60-27	11210-11213	for	_	
60-28	11214-11222	multiple	_	
60-29	11223-11234	comparisons	_	
60-30	11234-11235	.	_	

#Text=Age, gender, education, and probability of gray matter were treated as covariates, and the threshold for significance was p < 0.05.
61-1	11236-11239	Age	_	
61-2	11239-11240	,	_	
61-3	11241-11247	gender	_	
61-4	11247-11248	,	_	
61-5	11249-11258	education	_	
61-6	11258-11259	,	_	
61-7	11260-11263	and	_	
61-8	11264-11275	probability	_	
61-9	11276-11278	of	_	
61-10	11279-11283	gray	_	
61-11	11284-11290	matter	_	
61-12	11291-11295	were	_	
61-13	11296-11303	treated	_	
61-14	11304-11306	as	_	
61-15	11307-11317	covariates	_	
61-16	11317-11318	,	_	
61-17	11319-11322	and	_	
61-18	11323-11326	the	_	
61-19	11327-11336	threshold	_	
61-20	11337-11340	for	_	
61-21	11341-11353	significance	_	
61-22	11354-11357	was	_	
61-23	11358-11359	p	_	
61-24	11360-11361	<	_	
61-25	11362-11366	0.05	_	
61-26	11366-11367	.	_	

#Text=In the following correlation analysis, the resultant significant ReHo map was used as inclusion mask.
62-1	11368-11370	In	_	
62-2	11371-11374	the	_	
62-3	11375-11384	following	_	
62-4	11385-11396	correlation	_	
62-5	11397-11405	analysis	_	
62-6	11405-11406	,	_	
62-7	11407-11410	the	_	
62-8	11411-11420	resultant	_	
62-9	11421-11432	significant	_	
62-10	11433-11437	ReHo	_	
62-11	11438-11441	map	_	
62-12	11442-11445	was	_	
62-13	11446-11450	used	_	
62-14	11451-11453	as	_	
62-15	11454-11463	inclusion	_	
62-16	11464-11468	mask	_	
62-17	11468-11469	.	_	

#Text=Patients with schizophrenia were under voxel-wise correlation analysis to explore the correlations between the ReHo maps and the PANSS (positive symptoms, negative symptoms, general, and all totals) and the correlations between the ReHo maps and the MCCB (speed of processing, verbal learning, working memory, reasoning/problem solving, visual learning, attention/vigilance, social cognition, and overall composite).
63-1	11470-11478	Patients	_	
63-2	11479-11483	with	_	
63-3	11484-11497	schizophrenia	_	
63-4	11498-11502	were	_	
63-5	11503-11508	under	_	
63-6	11509-11519	voxel-wise	_	
63-7	11520-11531	correlation	_	
63-8	11532-11540	analysis	_	
63-9	11541-11543	to	_	
63-10	11544-11551	explore	_	
63-11	11552-11555	the	_	
63-12	11556-11568	correlations	_	
63-13	11569-11576	between	_	
63-14	11577-11580	the	_	
63-15	11581-11585	ReHo	_	
63-16	11586-11590	maps	_	
63-17	11591-11594	and	_	
63-18	11595-11598	the	_	
63-19	11599-11604	PANSS	_	
63-20	11605-11606	(	_	
63-21	11606-11614	positive	_	
63-22	11615-11623	symptoms	_	
63-23	11623-11624	,	_	
63-24	11625-11633	negative	_	
63-25	11634-11642	symptoms	_	
63-26	11642-11643	,	_	
63-27	11644-11651	general	_	
63-28	11651-11652	,	_	
63-29	11653-11656	and	_	
63-30	11657-11660	all	_	
63-31	11661-11667	totals	_	
63-32	11667-11668	)	_	
63-33	11669-11672	and	_	
63-34	11673-11676	the	_	
63-35	11677-11689	correlations	_	
63-36	11690-11697	between	_	
63-37	11698-11701	the	_	
63-38	11702-11706	ReHo	_	
63-39	11707-11711	maps	_	
63-40	11712-11715	and	_	
63-41	11716-11719	the	_	
63-42	11720-11724	MCCB	_	
63-43	11725-11726	(	_	
63-44	11726-11731	speed	_	
63-45	11732-11734	of	_	
63-46	11735-11745	processing	_	
63-47	11745-11746	,	_	
63-48	11747-11753	verbal	_	
63-49	11754-11762	learning	_	
63-50	11762-11763	,	_	
63-51	11764-11771	working	_	
63-52	11772-11778	memory	_	
63-53	11778-11779	,	_	
63-54	11780-11789	reasoning	_	
63-55	11789-11790	/	_	
63-56	11790-11797	problem	_	
63-57	11798-11805	solving	_	
63-58	11805-11806	,	_	
63-59	11807-11813	visual	_	
63-60	11814-11822	learning	_	
63-61	11822-11823	,	_	
63-62	11824-11833	attention	_	
63-63	11833-11834	/	_	
63-64	11834-11843	vigilance	_	
63-65	11843-11844	,	_	
63-66	11845-11851	social	_	
63-67	11852-11861	cognition	_	
63-68	11861-11862	,	_	
63-69	11863-11866	and	_	
63-70	11867-11874	overall	_	
63-71	11875-11884	composite	_	
63-72	11884-11885	)	_	
63-73	11885-11886	.	_	

#Text=In addition, age, gender, education, illness duration and the PANSS total score were placed in the model as covariates.
64-1	11887-11889	In	_	
64-2	11890-11898	addition	_	
64-3	11898-11899	,	_	
64-4	11900-11903	age	_	
64-5	11903-11904	,	_	
64-6	11905-11911	gender	_	
64-7	11911-11912	,	_	
64-8	11913-11922	education	_	
64-9	11922-11923	,	_	
64-10	11924-11931	illness	_	
64-11	11932-11940	duration	_	
64-12	11941-11944	and	_	
64-13	11945-11948	the	_	
64-14	11949-11954	PANSS	_	
64-15	11955-11960	total	_	
64-16	11961-11966	score	_	
64-17	11967-11971	were	_	
64-18	11972-11978	placed	_	
64-19	11979-11981	in	_	
64-20	11982-11985	the	_	
64-21	11986-11991	model	_	
64-22	11992-11994	as	_	
64-23	11995-12005	covariates	_	
64-24	12005-12006	.	_	

#Text=The permutation-based nonparametric inference was undertaken with 5000 permutations, and significance level was thresholded for the correction of multiple comparisons by using a TFCE of 0.05.
65-1	12007-12010	The	_	
65-2	12011-12028	permutation-based	_	
65-3	12029-12042	nonparametric	_	
65-4	12043-12052	inference	_	
65-5	12053-12056	was	_	
65-6	12057-12067	undertaken	_	
65-7	12068-12072	with	_	
65-8	12073-12077	5000	_	
65-9	12078-12090	permutations	_	
65-10	12090-12091	,	_	
65-11	12092-12095	and	_	
65-12	12096-12108	significance	_	
65-13	12109-12114	level	_	
65-14	12115-12118	was	_	
65-15	12119-12130	thresholded	_	
65-16	12131-12134	for	_	
65-17	12135-12138	the	_	
65-18	12139-12149	correction	_	
65-19	12150-12152	of	_	
65-20	12153-12161	multiple	_	
65-21	12162-12173	comparisons	_	
65-22	12174-12176	by	_	
65-23	12177-12182	using	_	
65-24	12183-12184	a	_	
65-25	12185-12189	TFCE	_	
65-26	12190-12192	of	_	
65-27	12193-12197	0.05	_	
65-28	12197-12198	.	_	

#Text=Results
#Text=Demographic data outcome
#Text=Demographic data, IQ, the MCCB scores, and clinical information in patients and health controls
#Text=\tdn-FES (n = 69)\tHC (n = 74)\tStatistics\tp Value\t \tAge (years, mean ± SD)\t24.22 ± 7.08\t26.27 ± 6.97\tT = 1.75\t0.083\t \tSex (male/female)\t50/19\t45/29\tX2 = 1.48\t0.142\t \tEducation (years, mean ± SD)\t13.23 ± 2.81\t14.69 ± 3.10\tT = 2.94\t0.004\t \tDUP (mouths, mean ± SD)\t13.74 ± 11.76\tNA\tNA\tNA\t \tSmokers/Nonsmorkers\t6/63\t0/74\tX2 = 6.72\t0.01\t \tPANSS\t \t Positive symptoms\t24.42 ± 3.88\tNA\tNA\tNA\t \t Negative symptoms\t17.58 ± 4.10\tNA\tNA\tNA\t \t General\t42.19 ± 3.55\tNA\tNA\tNA\t \t All totals\t84.19 ± 8.25\tNA\tNA\tNA\t \tCognitive domains\t \t Speed of processing\t35.42 ± 10.79\t51.22 ± 8.46\tF = 50.48\t< 0.001\t \t Verbal learning\t35.51 ± 11.07\t46.35 ± 9.78\tF = 19.62\t< 0.001\t \t Working memory\t34.22 ± 8.92\t45.12 ± 7.10\tF = 33.56\t< 0.001\t \t Reasoning/problem solving\t42.90 ± 11.56\t53.53 ± 8.17\tF = 20.24\t< 0.001\t \t Visual learning\t39.45 ± 11.91\t50.55 ± 7.87\tF = 23.17\t< 0.001\t \t Attention/vigilance\t35.04 ± 11.49\t48.03 ± 7.22\tF = 36.14\t< 0.001\t \t Social cognition\t32.68 ± 11.28\t37.81 ± 9.34\tF = 4.99\t0.008\t \t overall composite\t28.07 ± 12.27\t45.97 ± 8.13\tF = 55.01\t< 0.001\t \t IQ\t104.28 ± 11.81\t115.55 ± 8.30\tF = 50.48\t< 0.001\t \t
#Text=dn-FES, drug-naive First-Episode Schizophrenia; HC, Healthy Control; DUP, Duration of Untreated Psychosis; NA, Not Applicable. p < 0.05 represents a significant difference.
66-1	12199-12206	Results	_	
66-2	12207-12218	Demographic	_	
66-3	12219-12223	data	_	
66-4	12224-12231	outcome	_	
66-5	12232-12243	Demographic	_	
66-6	12244-12248	data	_	
66-7	12248-12249	,	_	
66-8	12250-12252	IQ	_	
66-9	12252-12253	,	_	
66-10	12254-12257	the	_	
66-11	12258-12262	MCCB	_	
66-12	12263-12269	scores	_	
66-13	12269-12270	,	_	
66-14	12271-12274	and	_	
66-15	12275-12283	clinical	_	
66-16	12284-12295	information	_	
66-17	12296-12298	in	_	
66-18	12299-12307	patients	_	
66-19	12308-12311	and	_	
66-20	12312-12318	health	_	
66-21	12319-12327	controls	_	
66-22	12329-12335	dn-FES	_	
66-23	12336-12337	(	_	
66-24	12337-12338	n	_	
66-25	12339-12340	=	_	
66-26	12341-12343	69	_	
66-27	12343-12344	)	_	
66-28	12345-12347	HC	_	
66-29	12348-12349	(	_	
66-30	12349-12350	n	_	
66-31	12351-12352	=	_	
66-32	12353-12355	74	_	
66-33	12355-12356	)	_	
66-34	12357-12367	Statistics	_	
66-35	12368-12369	p	_	
66-36	12370-12375	Value	_	
66-37	12378-12381	Age	_	
66-38	12382-12383	(	_	
66-39	12383-12388	years	_	
66-40	12388-12389	,	_	
66-41	12390-12394	mean	_	
66-42	12395-12396	±	_	
66-43	12397-12399	SD	_	
66-44	12399-12400	)	_	
66-45	12401-12406	24.22	_	
66-46	12407-12408	±	_	
66-47	12409-12413	7.08	_	
66-48	12414-12419	26.27	_	
66-49	12420-12421	±	_	
66-50	12422-12426	6.97	_	
66-51	12427-12428	T	_	
66-52	12429-12430	=	_	
66-53	12431-12435	1.75	_	
66-54	12436-12441	0.083	_	
66-55	12444-12447	Sex	_	
66-56	12448-12449	(	_	
66-57	12449-12453	male	_	
66-58	12453-12454	/	_	
66-59	12454-12460	female	_	
66-60	12460-12461	)	_	
66-61	12462-12464	50	_	
66-62	12464-12465	/	_	
66-63	12465-12467	19	_	
66-64	12468-12470	45	_	
66-65	12470-12471	/	_	
66-66	12471-12473	29	_	
66-67	12474-12476	X2	_	
66-68	12476-12477	 	_	
66-69	12477-12478	=	_	
66-70	12478-12479	 	_	
66-71	12479-12483	1.48	_	
66-72	12484-12489	0.142	_	
66-73	12492-12501	Education	_	
66-74	12502-12503	(	_	
66-75	12503-12508	years	_	
66-76	12508-12509	,	_	
66-77	12510-12514	mean	_	
66-78	12515-12516	±	_	
66-79	12517-12519	SD	_	
66-80	12519-12520	)	_	
66-81	12521-12526	13.23	_	
66-82	12527-12528	±	_	
66-83	12529-12533	2.81	_	
66-84	12534-12539	14.69	_	
66-85	12540-12541	±	_	
66-86	12542-12546	3.10	_	
66-87	12547-12548	T	_	
66-88	12549-12550	=	_	
66-89	12551-12555	2.94	_	
66-90	12556-12561	0.004	_	
66-91	12564-12567	DUP	_	
66-92	12568-12569	(	_	
66-93	12569-12575	mouths	_	
66-94	12575-12576	,	_	
66-95	12577-12581	mean	_	
66-96	12582-12583	±	_	
66-97	12584-12586	SD	_	
66-98	12586-12587	)	_	
66-99	12588-12593	13.74	_	
66-100	12594-12595	±	_	
66-101	12596-12601	11.76	_	
66-102	12602-12604	NA	_	
66-103	12605-12607	NA	_	
66-104	12608-12610	NA	_	
66-105	12613-12620	Smokers	_	
66-106	12620-12621	/	_	
66-107	12621-12632	Nonsmorkers	_	
66-108	12633-12634	6	_	
66-109	12634-12635	/	_	
66-110	12635-12637	63	_	
66-111	12638-12639	0	_	
66-112	12639-12640	/	_	
66-113	12640-12642	74	_	
66-114	12643-12645	X2	_	
66-115	12646-12647	=	_	
66-116	12648-12652	6.72	_	
66-117	12653-12657	0.01	_	
66-118	12660-12665	PANSS	_	
66-119	12669-12677	Positive	_	
66-120	12678-12686	symptoms	_	
66-121	12687-12692	24.42	_	
66-122	12693-12694	±	_	
66-123	12695-12699	3.88	_	
66-124	12700-12702	NA	_	
66-125	12703-12705	NA	_	
66-126	12706-12708	NA	_	
66-127	12712-12720	Negative	_	
66-128	12721-12729	symptoms	_	
66-129	12730-12735	17.58	_	
66-130	12736-12737	±	_	
66-131	12738-12742	4.10	_	
66-132	12743-12745	NA	_	
66-133	12746-12748	NA	_	
66-134	12749-12751	NA	_	
66-135	12755-12762	General	_	
66-136	12763-12768	42.19	_	
66-137	12769-12770	±	_	
66-138	12771-12775	3.55	_	
66-139	12776-12778	NA	_	
66-140	12779-12781	NA	_	
66-141	12782-12784	NA	_	
66-142	12788-12791	All	_	
66-143	12792-12798	totals	_	
66-144	12799-12804	84.19	_	
66-145	12805-12806	±	_	
66-146	12807-12811	8.25	_	
66-147	12812-12814	NA	_	
66-148	12815-12817	NA	_	
66-149	12818-12820	NA	_	
66-150	12823-12832	Cognitive	_	
66-151	12833-12840	domains	_	
66-152	12844-12849	Speed	_	
66-153	12850-12852	of	_	
66-154	12853-12863	processing	_	
66-155	12864-12869	35.42	_	
66-156	12870-12871	±	_	
66-157	12872-12877	10.79	_	
66-158	12878-12883	51.22	_	
66-159	12884-12885	±	_	
66-160	12886-12890	8.46	_	
66-161	12891-12892	F	_	
66-162	12893-12894	=	_	
66-163	12895-12900	50.48	_	
66-164	12901-12902	<	_	
66-165	12903-12908	0.001	_	
66-166	12912-12918	Verbal	_	
66-167	12919-12927	learning	_	
66-168	12928-12933	35.51	_	
66-169	12934-12935	±	_	
66-170	12936-12941	11.07	_	
66-171	12942-12947	46.35	_	
66-172	12948-12949	±	_	
66-173	12950-12954	9.78	_	
66-174	12955-12956	F	_	
66-175	12957-12958	=	_	
66-176	12959-12964	19.62	_	
66-177	12965-12966	<	_	
66-178	12967-12972	0.001	_	
66-179	12976-12983	Working	_	
66-180	12984-12990	memory	_	
66-181	12991-12996	34.22	_	
66-182	12997-12998	±	_	
66-183	12999-13003	8.92	_	
66-184	13004-13009	45.12	_	
66-185	13010-13011	±	_	
66-186	13012-13016	7.10	_	
66-187	13017-13018	F	_	
66-188	13019-13020	=	_	
66-189	13021-13026	33.56	_	
66-190	13027-13028	<	_	
66-191	13029-13034	0.001	_	
66-192	13038-13047	Reasoning	_	
66-193	13047-13048	/	_	
66-194	13048-13055	problem	_	
66-195	13056-13063	solving	_	
66-196	13064-13069	42.90	_	
66-197	13070-13071	±	_	
66-198	13072-13077	11.56	_	
66-199	13078-13083	53.53	_	
66-200	13084-13085	±	_	
66-201	13086-13090	8.17	_	
66-202	13091-13092	F	_	
66-203	13093-13094	=	_	
66-204	13095-13100	20.24	_	
66-205	13101-13102	<	_	
66-206	13103-13108	0.001	_	
66-207	13112-13118	Visual	_	
66-208	13119-13127	learning	_	
66-209	13128-13133	39.45	_	
66-210	13134-13135	±	_	
66-211	13136-13141	11.91	_	
66-212	13142-13147	50.55	_	
66-213	13148-13149	±	_	
66-214	13150-13154	7.87	_	
66-215	13155-13156	F	_	
66-216	13157-13158	=	_	
66-217	13159-13164	23.17	_	
66-218	13165-13166	<	_	
66-219	13167-13172	0.001	_	
66-220	13176-13185	Attention	_	
66-221	13185-13186	/	_	
66-222	13186-13195	vigilance	_	
66-223	13196-13201	35.04	_	
66-224	13202-13203	±	_	
66-225	13204-13209	11.49	_	
66-226	13210-13215	48.03	_	
66-227	13216-13217	±	_	
66-228	13218-13222	7.22	_	
66-229	13223-13224	F	_	
66-230	13225-13226	=	_	
66-231	13227-13232	36.14	_	
66-232	13233-13234	<	_	
66-233	13235-13240	0.001	_	
66-234	13244-13250	Social	_	
66-235	13251-13260	cognition	_	
66-236	13261-13266	32.68	_	
66-237	13267-13268	±	_	
66-238	13269-13274	11.28	_	
66-239	13275-13280	37.81	_	
66-240	13281-13282	±	_	
66-241	13283-13287	9.34	_	
66-242	13288-13289	F	_	
66-243	13290-13291	=	_	
66-244	13292-13296	4.99	_	
66-245	13297-13302	0.008	_	
66-246	13306-13313	overall	_	
66-247	13314-13323	composite	_	
66-248	13324-13329	28.07	_	
66-249	13330-13331	±	_	
66-250	13332-13337	12.27	_	
66-251	13338-13343	45.97	_	
66-252	13344-13345	±	_	
66-253	13346-13350	8.13	_	
66-254	13351-13352	F	_	
66-255	13353-13354	=	_	
66-256	13355-13360	55.01	_	
66-257	13361-13362	<	_	
66-258	13363-13368	0.001	_	
66-259	13372-13374	IQ	_	
66-260	13375-13381	104.28	_	
66-261	13382-13383	±	_	
66-262	13384-13389	11.81	_	
66-263	13390-13396	115.55	_	
66-264	13397-13398	±	_	
66-265	13399-13403	8.30	_	
66-266	13404-13405	F	_	
66-267	13406-13407	=	_	
66-268	13408-13413	50.48	_	
66-269	13414-13415	<	_	
66-270	13416-13421	0.001	_	
66-271	13425-13431	dn-FES	_	
66-272	13431-13432	,	_	
66-273	13433-13443	drug-naive	_	
66-274	13444-13457	First-Episode	_	
66-275	13458-13471	Schizophrenia	_	
66-276	13471-13472	;	_	
66-277	13473-13475	HC	_	
66-278	13475-13476	,	_	
66-279	13477-13484	Healthy	_	
66-280	13485-13492	Control	_	
66-281	13492-13493	;	_	
66-282	13494-13497	DUP	_	
66-283	13497-13498	,	_	
66-284	13499-13507	Duration	_	
66-285	13508-13510	of	_	
66-286	13511-13520	Untreated	_	
66-287	13521-13530	Psychosis	_	
66-288	13530-13531	;	_	
66-289	13532-13534	NA	_	
66-290	13534-13535	,	_	
66-291	13536-13539	Not	_	
66-292	13540-13550	Applicable	_	
66-293	13550-13551	.	_	
66-294	13552-13553	p	_	
66-295	13553-13554	 	_	
66-296	13554-13555	<	_	
66-297	13556-13560	0.05	_	
66-298	13561-13571	represents	_	
66-299	13572-13573	a	_	
66-300	13574-13585	significant	_	
66-301	13586-13596	difference	_	
66-302	13596-13597	.	_	

#Text=The effect of smoking was controlled as a covariate to the analysis in cognitive domains
#Text=Data from 26 subjects (18 patients and 8 HCs) were excluded because of excessive head movement, and the rest of 143 subjects (69 patients and 74 HCs) were used for analyzing.
67-1	13598-13601	The	_	
67-2	13602-13608	effect	_	
67-3	13609-13611	of	_	
67-4	13612-13619	smoking	_	
67-5	13620-13623	was	_	
67-6	13624-13634	controlled	_	
67-7	13635-13637	as	_	
67-8	13638-13639	a	_	
67-9	13640-13649	covariate	_	
67-10	13650-13652	to	_	
67-11	13653-13656	the	_	
67-12	13657-13665	analysis	_	
67-13	13666-13668	in	_	
67-14	13669-13678	cognitive	_	
67-15	13679-13686	domains	_	
67-16	13687-13691	Data	_	
67-17	13692-13696	from	_	
67-18	13697-13699	26	_	
67-19	13700-13708	subjects	_	
67-20	13709-13710	(	_	
67-21	13710-13712	18	_	
67-22	13713-13721	patients	_	
67-23	13722-13725	and	_	
67-24	13726-13727	8	_	
67-25	13728-13731	HCs	_	
67-26	13731-13732	)	_	
67-27	13733-13737	were	_	
67-28	13738-13746	excluded	_	
67-29	13747-13754	because	_	
67-30	13755-13757	of	_	
67-31	13758-13767	excessive	_	
67-32	13768-13772	head	_	
67-33	13773-13781	movement	_	
67-34	13781-13782	,	_	
67-35	13783-13786	and	_	
67-36	13787-13790	the	_	
67-37	13791-13795	rest	_	
67-38	13796-13798	of	_	
67-39	13799-13802	143	_	
67-40	13803-13811	subjects	_	
67-41	13812-13813	(	_	
67-42	13813-13815	69	_	
67-43	13816-13824	patients	_	
67-44	13825-13828	and	_	
67-45	13829-13831	74	_	
67-46	13832-13835	HCs	_	
67-47	13835-13836	)	_	
67-48	13837-13841	were	_	
67-49	13842-13846	used	_	
67-50	13847-13850	for	_	
67-51	13851-13860	analyzing	_	
67-52	13860-13861	.	_	

#Text=No significant differences were found between dn-FES and HC group in terms of age (p = 0.083) or gender (p = 0.142), whereas significant differences were observed in education (p = 0.004).
68-1	13862-13864	No	_	
68-2	13865-13876	significant	_	
68-3	13877-13888	differences	_	
68-4	13889-13893	were	_	
68-5	13894-13899	found	_	
68-6	13900-13907	between	_	
68-7	13908-13914	dn-FES	_	
68-8	13915-13918	and	_	
68-9	13919-13921	HC	_	
68-10	13922-13927	group	_	
68-11	13928-13930	in	_	
68-12	13931-13936	terms	_	
68-13	13937-13939	of	_	
68-14	13940-13943	age	_	
68-15	13944-13945	(	_	
68-16	13945-13946	p	_	
68-17	13947-13948	=	_	
68-18	13949-13954	0.083	_	
68-19	13954-13955	)	_	
68-20	13956-13958	or	_	
68-21	13959-13965	gender	_	
68-22	13966-13967	(	_	
68-23	13967-13968	p	_	
68-24	13969-13970	=	_	
68-25	13971-13976	0.142	_	
68-26	13976-13977	)	_	
68-27	13977-13978	,	_	
68-28	13979-13986	whereas	_	
68-29	13987-13998	significant	_	
68-30	13999-14010	differences	_	
68-31	14011-14015	were	_	
68-32	14016-14024	observed	_	
68-33	14025-14027	in	_	
68-34	14028-14037	education	_	
68-35	14038-14039	(	_	
68-36	14039-14040	p	_	
68-37	14041-14042	=	_	
68-38	14043-14048	0.004	_	
68-39	14048-14049	)	_	
68-40	14049-14050	.	_	

#Text=The effect of smoking was examined by adding this variable to the analysis model as covariate.
69-1	14051-14054	The	_	
69-2	14055-14061	effect	_	
69-3	14062-14064	of	_	
69-4	14065-14072	smoking	_	
69-5	14073-14076	was	_	
69-6	14077-14085	examined	_	
69-7	14086-14088	by	_	
69-8	14089-14095	adding	_	
69-9	14096-14100	this	_	
69-10	14101-14109	variable	_	
69-11	14110-14112	to	_	
69-12	14113-14116	the	_	
69-13	14117-14125	analysis	_	
69-14	14126-14131	model	_	
69-15	14132-14134	as	_	
69-16	14135-14144	covariate	_	
69-17	14144-14145	.	_	

#Text=The results of demographic data are listed in Table 1.
70-1	14146-14149	The	_	
70-2	14150-14157	results	_	
70-3	14158-14160	of	_	
70-4	14161-14172	demographic	_	
70-5	14173-14177	data	_	
70-6	14178-14181	are	_	
70-7	14182-14188	listed	_	
70-8	14189-14191	in	_	
70-9	14192-14197	Table	_	
70-10	14197-14198	 	_	
70-11	14198-14199	1	_	
70-12	14199-14200	.	_	

#Text=Group differences in ReHo
#Text=Regions with ReHo differences in FES and HC subjects
#Text=\tBrain regions\tBrodmann area\tCluster\tMNI coordinates (mm)\tT Value\t \t\t\t\t(voxel)\tX\tY\tZ\t\t \tFES > HC\tRight middle frontal gyrus\t10\t66\t42\t60\t12\t4.98\t \tRight superior frontal gyrus\t9\t37\t27\t45\t42\t4.44\t \tFES < HC\tRight cuneus\t17\t17\t9\t−84\t39\t−5.26\t \t
#Text=Statistically significant differences in ReHo between two groups were defined at p < 0.05.
71-1	14202-14207	Group	_	
71-2	14208-14219	differences	_	
71-3	14220-14222	in	_	
71-4	14223-14227	ReHo	_	
71-5	14228-14235	Regions	_	
71-6	14236-14240	with	_	
71-7	14241-14245	ReHo	_	
71-8	14246-14257	differences	_	
71-9	14258-14260	in	_	
71-10	14261-14264	FES	_	
71-11	14265-14268	and	_	
71-12	14269-14271	HC	_	
71-13	14272-14280	subjects	_	
71-14	14282-14287	Brain	_	
71-15	14288-14295	regions	_	
71-16	14296-14304	Brodmann	_	
71-17	14305-14309	area	_	
71-18	14310-14317	Cluster	_	
71-19	14318-14321	MNI	_	
71-20	14322-14333	coordinates	_	
71-21	14334-14335	(	_	
71-22	14335-14337	mm	_	
71-23	14337-14338	)	_	
71-24	14339-14340	T	_	
71-25	14341-14346	Value	_	
71-26	14352-14353	(	_	
71-27	14353-14358	voxel	_	
71-28	14358-14359	)	_	
71-29	14360-14361	X	_	
71-30	14362-14363	Y	_	
71-31	14364-14365	Z	_	
71-32	14369-14372	FES	_	
71-33	14373-14374	>	_	
71-34	14375-14377	HC	_	
71-35	14378-14383	Right	_	
71-36	14384-14390	middle	_	
71-37	14391-14398	frontal	_	
71-38	14399-14404	gyrus	_	
71-39	14405-14407	10	_	
71-40	14408-14410	66	_	
71-41	14411-14413	42	_	
71-42	14414-14416	60	_	
71-43	14417-14419	12	_	
71-44	14420-14424	4.98	_	
71-45	14427-14432	Right	_	
71-46	14433-14441	superior	_	
71-47	14442-14449	frontal	_	
71-48	14450-14455	gyrus	_	
71-49	14456-14457	9	_	
71-50	14458-14460	37	_	
71-51	14461-14463	27	_	
71-52	14464-14466	45	_	
71-53	14467-14469	42	_	
71-54	14470-14474	4.44	_	
71-55	14477-14480	FES	_	
71-56	14481-14482	<	_	
71-57	14483-14485	HC	_	
71-58	14486-14491	Right	_	
71-59	14492-14498	cuneus	_	
71-60	14499-14501	17	_	
71-61	14502-14504	17	_	
71-62	14505-14506	9	_	
71-63	14507-14508	−	_	
71-64	14508-14510	84	_	
71-65	14511-14513	39	_	
71-66	14514-14515	−	_	
71-67	14515-14519	5.26	_	
71-68	14523-14536	Statistically	_	
71-69	14537-14548	significant	_	
71-70	14549-14560	differences	_	
71-71	14561-14563	in	_	
71-72	14564-14568	ReHo	_	
71-73	14569-14576	between	_	
71-74	14577-14580	two	_	
71-75	14581-14587	groups	_	
71-76	14588-14592	were	_	
71-77	14593-14600	defined	_	
71-78	14601-14603	at	_	
71-79	14604-14605	p	_	
71-80	14605-14606	 	_	
71-81	14606-14607	<	_	
71-82	14608-14612	0.05	_	
71-83	14612-14613	.	_	

#Text=Data were TFCE and FWE corrected.
72-1	14614-14618	Data	_	
72-2	14619-14623	were	_	
72-3	14624-14628	TFCE	_	
72-4	14629-14632	and	_	
72-5	14633-14636	FWE	_	
72-6	14637-14646	corrected	_	
72-7	14646-14647	.	_	

#Text=Data were TFCE corrected after controlling age, gender, education, illness duration, and probability of gray matter
#Text=Brain regions with significantly altered ReHo between patients with dn-FES and HCs.
73-1	14648-14652	Data	_	
73-2	14653-14657	were	_	
73-3	14658-14662	TFCE	_	
73-4	14663-14672	corrected	_	
73-5	14673-14678	after	_	
73-6	14679-14690	controlling	_	
73-7	14691-14694	age	_	
73-8	14694-14695	,	_	
73-9	14696-14702	gender	_	
73-10	14702-14703	,	_	
73-11	14704-14713	education	_	
73-12	14713-14714	,	_	
73-13	14715-14722	illness	_	
73-14	14723-14731	duration	_	
73-15	14731-14732	,	_	
73-16	14733-14736	and	_	
73-17	14737-14748	probability	_	
73-18	14749-14751	of	_	
73-19	14752-14756	gray	_	
73-20	14757-14763	matter	_	
73-21	14764-14769	Brain	_	
73-22	14770-14777	regions	_	
73-23	14778-14782	with	_	
73-24	14783-14796	significantly	_	
73-25	14797-14804	altered	_	
73-26	14805-14809	ReHo	_	
73-27	14810-14817	between	_	
73-28	14818-14826	patients	_	
73-29	14827-14831	with	_	
73-30	14832-14838	dn-FES	_	
73-31	14839-14842	and	_	
73-32	14843-14846	HCs	_	
73-33	14846-14847	.	_	

#Text=Warm color indicated that ReHo was higher in the dn-FES group than in the HC group, and vice versa.
74-1	14848-14852	Warm	_	
74-2	14853-14858	color	_	
74-3	14859-14868	indicated	_	
74-4	14869-14873	that	_	
74-5	14874-14878	ReHo	_	
74-6	14879-14882	was	_	
74-7	14883-14889	higher	_	
74-8	14890-14892	in	_	
74-9	14893-14896	the	_	
74-10	14897-14903	dn-FES	_	
74-11	14904-14909	group	_	
74-12	14910-14914	than	_	
74-13	14915-14917	in	_	
74-14	14918-14921	the	_	
74-15	14922-14924	HC	_	
74-16	14925-14930	group	_	
74-17	14930-14931	,	_	
74-18	14932-14935	and	_	
74-19	14936-14940	vice	_	
74-20	14941-14946	versa	_	
74-21	14946-14947	.	_	

#Text=The detailed T value was showed in Table 2.
75-1	14948-14951	The	_	
75-2	14952-14960	detailed	_	
75-3	14961-14962	T	_	
75-4	14963-14968	value	_	
75-5	14969-14972	was	_	
75-6	14973-14979	showed	_	
75-7	14980-14982	in	_	
75-8	14983-14988	Table	_	
75-9	14989-14990	2	_	
75-10	14990-14991	.	_	

#Text=Statistically significant differences in gray matter volume were defined at p < 0.05.
76-1	14992-15005	Statistically	_	
76-2	15006-15017	significant	_	
76-3	15018-15029	differences	_	
76-4	15030-15032	in	_	
76-5	15033-15037	gray	_	
76-6	15038-15044	matter	_	
76-7	15045-15051	volume	_	
76-8	15052-15056	were	_	
76-9	15057-15064	defined	_	
76-10	15065-15067	at	_	
76-11	15068-15069	p	_	
76-12	15070-15071	<	_	
76-13	15072-15076	0.05	_	
76-14	15076-15077	.	_	

#Text=TFCE and FWE corrected after controlling age, gender, education, illness duration, and probability of gray matter
#Text=In this study, compared with the control group, the increased ReHo values were found mainly in right Middle Frontal Gyrus (MFG) and right Superior Frontal Gyrus (SFG), whereas the decreased ReHo values were observed in right cuneus (p < 0.05, TFCE, FWE corrected).
77-1	15078-15082	TFCE	_	
77-2	15083-15086	and	_	
77-3	15087-15090	FWE	_	
77-4	15091-15100	corrected	_	
77-5	15101-15106	after	_	
77-6	15107-15118	controlling	_	
77-7	15119-15122	age	_	
77-8	15122-15123	,	_	
77-9	15124-15130	gender	_	
77-10	15130-15131	,	_	
77-11	15132-15141	education	_	
77-12	15141-15142	,	_	
77-13	15143-15150	illness	_	
77-14	15151-15159	duration	_	
77-15	15159-15160	,	_	
77-16	15161-15164	and	_	
77-17	15165-15176	probability	_	
77-18	15177-15179	of	_	
77-19	15180-15184	gray	_	
77-20	15185-15191	matter	_	
77-21	15192-15194	In	_	
77-22	15195-15199	this	_	
77-23	15200-15205	study	_	
77-24	15205-15206	,	_	
77-25	15207-15215	compared	_	
77-26	15216-15220	with	_	
77-27	15221-15224	the	_	
77-28	15225-15232	control	_	
77-29	15233-15238	group	_	
77-30	15238-15239	,	_	
77-31	15240-15243	the	_	
77-32	15244-15253	increased	_	
77-33	15254-15258	ReHo	_	
77-34	15259-15265	values	_	
77-35	15266-15270	were	_	
77-36	15271-15276	found	_	
77-37	15277-15283	mainly	_	
77-38	15284-15286	in	_	
77-39	15287-15292	right	_	
77-40	15293-15299	Middle	_	
77-41	15300-15307	Frontal	_	
77-42	15308-15313	Gyrus	_	
77-43	15314-15315	(	_	
77-44	15315-15318	MFG	_	
77-45	15318-15319	)	_	
77-46	15320-15323	and	_	
77-47	15324-15329	right	_	
77-48	15330-15338	Superior	_	
77-49	15339-15346	Frontal	_	
77-50	15347-15352	Gyrus	_	
77-51	15353-15354	(	_	
77-52	15354-15357	SFG	_	
77-53	15357-15358	)	_	
77-54	15358-15359	,	_	
77-55	15360-15367	whereas	_	
77-56	15368-15371	the	_	
77-57	15372-15381	decreased	_	
77-58	15382-15386	ReHo	_	
77-59	15387-15393	values	_	
77-60	15394-15398	were	_	
77-61	15399-15407	observed	_	
77-62	15408-15410	in	_	
77-63	15411-15416	right	_	
77-64	15417-15423	cuneus	_	
77-65	15424-15425	(	_	
77-66	15425-15426	p	_	
77-67	15427-15428	<	_	
77-68	15429-15433	0.05	_	
77-69	15433-15434	,	_	
77-70	15435-15439	TFCE	_	
77-71	15439-15440	,	_	
77-72	15441-15444	FWE	_	
77-73	15445-15454	corrected	_	
77-74	15454-15455	)	_	
77-75	15455-15456	.	_	

#Text=Age, gender, illness duration, and probability of gray matter were corrected as covariates during calculation (Table 2, Fig. 1).
78-1	15457-15460	Age	_	
78-2	15460-15461	,	_	
78-3	15462-15468	gender	_	
78-4	15468-15469	,	_	
78-5	15470-15477	illness	_	
78-6	15478-15486	duration	_	
78-7	15486-15487	,	_	
78-8	15488-15491	and	_	
78-9	15492-15503	probability	_	
78-10	15504-15506	of	_	
78-11	15507-15511	gray	_	
78-12	15512-15518	matter	_	
78-13	15519-15523	were	_	
78-14	15524-15533	corrected	_	
78-15	15534-15536	as	_	
78-16	15537-15547	covariates	_	
78-17	15548-15554	during	_	
78-18	15555-15566	calculation	_	
78-19	15567-15568	(	_	
78-20	15568-15573	Table	_	
78-21	15573-15574	 	_	
78-22	15574-15575	2	_	
78-23	15575-15576	,	_	
78-24	15577-15580	Fig	_	
78-25	15580-15581	.	_	
78-26	15581-15582	 	_	
78-27	15582-15583	1	_	
78-28	15583-15584	)	_	
78-29	15584-15585	.	_	

#Text=Correlation analysis
#Text=Significant correlations between the PANSS and ReHo in patients with schizophrenia
#Text=Brain regions\tPANSS\tBrodmann area\tCluster (voxel)\tMNI coordinates (mm)\tCorrelation coefficient r\t \tX\tY\tZ\t \tRight middle frontal gyrus\tpositive symptom\t10\t53\t36\t60\t15\t0.41\t \tRight middle frontal gyrus\tnegative symptom\t10\t18\t36\t60\t9\t0.32\t \tRight middle frontal gyrus\ttotal score\t10\t42\t36\t60\t12\t0.45\t \t
#Text=Significant correlations between the PANSS and ReHo were at p < 0.05.
79-1	15587-15598	Correlation	_	
79-2	15599-15607	analysis	_	
79-3	15608-15619	Significant	_	
79-4	15620-15632	correlations	_	
79-5	15633-15640	between	_	
79-6	15641-15644	the	_	
79-7	15645-15650	PANSS	_	
79-8	15651-15654	and	_	
79-9	15655-15659	ReHo	_	
79-10	15660-15662	in	_	
79-11	15663-15671	patients	_	
79-12	15672-15676	with	_	
79-13	15677-15690	schizophrenia	_	
79-14	15691-15696	Brain	_	
79-15	15697-15704	regions	_	
79-16	15705-15710	PANSS	_	
79-17	15711-15719	Brodmann	_	
79-18	15720-15724	area	_	
79-19	15725-15732	Cluster	_	
79-20	15733-15734	(	_	
79-21	15734-15739	voxel	_	
79-22	15739-15740	)	_	
79-23	15741-15744	MNI	_	
79-24	15745-15756	coordinates	_	
79-25	15757-15758	(	_	
79-26	15758-15760	mm	_	
79-27	15760-15761	)	_	
79-28	15762-15773	Correlation	_	
79-29	15774-15785	coefficient	_	
79-30	15786-15787	r	_	
79-31	15790-15791	X	_	
79-32	15792-15793	Y	_	
79-33	15794-15795	Z	_	
79-34	15798-15803	Right	_	
79-35	15804-15810	middle	_	
79-36	15811-15818	frontal	_	
79-37	15819-15824	gyrus	_	
79-38	15825-15833	positive	_	
79-39	15834-15841	symptom	_	
79-40	15842-15844	10	_	
79-41	15845-15847	53	_	
79-42	15848-15850	36	_	
79-43	15851-15853	60	_	
79-44	15854-15856	15	_	
79-45	15857-15861	0.41	_	
79-46	15864-15869	Right	_	
79-47	15870-15876	middle	_	
79-48	15877-15884	frontal	_	
79-49	15885-15890	gyrus	_	
79-50	15891-15899	negative	_	
79-51	15900-15907	symptom	_	
79-52	15908-15910	10	_	
79-53	15911-15913	18	_	
79-54	15914-15916	36	_	
79-55	15917-15919	60	_	
79-56	15920-15921	9	_	
79-57	15922-15926	0.32	_	
79-58	15929-15934	Right	_	
79-59	15935-15941	middle	_	
79-60	15942-15949	frontal	_	
79-61	15950-15955	gyrus	_	
79-62	15956-15961	total	_	
79-63	15962-15967	score	_	
79-64	15968-15970	10	_	
79-65	15971-15973	42	_	
79-66	15974-15976	36	_	
79-67	15977-15979	60	_	
79-68	15980-15982	12	_	
79-69	15983-15987	0.45	_	
79-70	15991-16002	Significant	_	
79-71	16003-16015	correlations	_	
79-72	16016-16023	between	_	
79-73	16024-16027	the	_	
79-74	16028-16033	PANSS	_	
79-75	16034-16037	and	_	
79-76	16038-16042	ReHo	_	
79-77	16043-16047	were	_	
79-78	16048-16050	at	_	
79-79	16051-16052	p	_	
79-80	16052-16053	 	_	
79-81	16053-16054	<	_	
79-82	16055-16059	0.05	_	
79-83	16059-16060	.	_	

#Text=Data were TFCE corrected after controlling age, gender, education, and illness duration as covariates
#Text=Significant correlations between the MCCB subdomains and ReHo in patients with schizophrenia
#Text=Brain regions\tMCCB\tBrodmann area\tCluster (voxel)\tMNI coordinates (mm)\tCorrelation coefficient r\t \tX\tY\tZ\t \tRight middle frontal gyrus\tAttention/vigilance\t10\t10\t36\t57\t12\t−0.30\t \tRight middle frontal gyrus\tSocial cognition\t10\t15\t39\t57\t9\t−0.38\t \tRight middle frontal gyrus\tOverall composite\t10\t9\t39\t57\t9\t−0.34\t \t
#Text=Significant correlations between the MCCB subdomains and ReHo were defined at p < 0.05.
80-1	16061-16065	Data	_	
80-2	16066-16070	were	_	
80-3	16071-16075	TFCE	_	
80-4	16076-16085	corrected	_	
80-5	16086-16091	after	_	
80-6	16092-16103	controlling	_	
80-7	16104-16107	age	_	
80-8	16107-16108	,	_	
80-9	16109-16115	gender	_	
80-10	16115-16116	,	_	
80-11	16117-16126	education	_	
80-12	16126-16127	,	_	
80-13	16128-16131	and	_	
80-14	16132-16139	illness	_	
80-15	16140-16148	duration	_	
80-16	16149-16151	as	_	
80-17	16152-16162	covariates	_	
80-18	16163-16174	Significant	_	
80-19	16175-16187	correlations	_	
80-20	16188-16195	between	_	
80-21	16196-16199	the	_	
80-22	16200-16204	MCCB	_	
80-23	16205-16215	subdomains	_	
80-24	16216-16219	and	_	
80-25	16220-16224	ReHo	_	
80-26	16225-16227	in	_	
80-27	16228-16236	patients	_	
80-28	16237-16241	with	_	
80-29	16242-16255	schizophrenia	_	
80-30	16256-16261	Brain	_	
80-31	16262-16269	regions	_	
80-32	16270-16274	MCCB	_	
80-33	16275-16283	Brodmann	_	
80-34	16284-16288	area	_	
80-35	16289-16296	Cluster	_	
80-36	16297-16298	(	_	
80-37	16298-16303	voxel	_	
80-38	16303-16304	)	_	
80-39	16305-16308	MNI	_	
80-40	16309-16320	coordinates	_	
80-41	16321-16322	(	_	
80-42	16322-16324	mm	_	
80-43	16324-16325	)	_	
80-44	16326-16337	Correlation	_	
80-45	16338-16349	coefficient	_	
80-46	16350-16351	r	_	
80-47	16354-16355	X	_	
80-48	16356-16357	Y	_	
80-49	16358-16359	Z	_	
80-50	16362-16367	Right	_	
80-51	16368-16374	middle	_	
80-52	16375-16382	frontal	_	
80-53	16383-16388	gyrus	_	
80-54	16389-16398	Attention	_	
80-55	16398-16399	/	_	
80-56	16399-16408	vigilance	_	
80-57	16409-16411	10	_	
80-58	16412-16414	10	_	
80-59	16415-16417	36	_	
80-60	16418-16420	57	_	
80-61	16421-16423	12	_	
80-62	16424-16425	−	_	
80-63	16425-16429	0.30	_	
80-64	16432-16437	Right	_	
80-65	16438-16444	middle	_	
80-66	16445-16452	frontal	_	
80-67	16453-16458	gyrus	_	
80-68	16459-16465	Social	_	
80-69	16466-16475	cognition	_	
80-70	16476-16478	10	_	
80-71	16479-16481	15	_	
80-72	16482-16484	39	_	
80-73	16485-16487	57	_	
80-74	16488-16489	9	_	
80-75	16490-16491	−	_	
80-76	16491-16495	0.38	_	
80-77	16498-16503	Right	_	
80-78	16504-16510	middle	_	
80-79	16511-16518	frontal	_	
80-80	16519-16524	gyrus	_	
80-81	16525-16532	Overall	_	
80-82	16533-16542	composite	_	
80-83	16543-16545	10	_	
80-84	16546-16547	9	_	
80-85	16548-16550	39	_	
80-86	16551-16553	57	_	
80-87	16554-16555	9	_	
80-88	16556-16557	−	_	
80-89	16557-16561	0.34	_	
80-90	16565-16576	Significant	_	
80-91	16577-16589	correlations	_	
80-92	16590-16597	between	_	
80-93	16598-16601	the	_	
80-94	16602-16606	MCCB	_	
80-95	16607-16617	subdomains	_	
80-96	16618-16621	and	_	
80-97	16622-16626	ReHo	_	
80-98	16627-16631	were	_	
80-99	16632-16639	defined	_	
80-100	16640-16642	at	_	
80-101	16643-16644	p	_	
80-102	16644-16645	 	_	
80-103	16645-16646	<	_	
80-104	16647-16651	0.05	_	
80-105	16651-16652	.	_	

#Text=Data were TFCE corrected after controlling age, gender, education, illness duration and the PANSS total score as covariates
#Text=Voxel-wise correlation analysis between the ReHo maps and the PANSS scores was performed to explore the relationships between the ReHo values and the PANSS scores in the dn-FES group by setting age, gender, education, and illness duration as covariates.
81-1	16653-16657	Data	_	
81-2	16658-16662	were	_	
81-3	16663-16667	TFCE	_	
81-4	16668-16677	corrected	_	
81-5	16678-16683	after	_	
81-6	16684-16695	controlling	_	
81-7	16696-16699	age	_	
81-8	16699-16700	,	_	
81-9	16701-16707	gender	_	
81-10	16707-16708	,	_	
81-11	16709-16718	education	_	
81-12	16718-16719	,	_	
81-13	16720-16727	illness	_	
81-14	16728-16736	duration	_	
81-15	16737-16740	and	_	
81-16	16741-16744	the	_	
81-17	16745-16750	PANSS	_	
81-18	16751-16756	total	_	
81-19	16757-16762	score	_	
81-20	16763-16765	as	_	
81-21	16766-16776	covariates	_	
81-22	16777-16787	Voxel-wise	_	
81-23	16788-16799	correlation	_	
81-24	16800-16808	analysis	_	
81-25	16809-16816	between	_	
81-26	16817-16820	the	_	
81-27	16821-16825	ReHo	_	
81-28	16826-16830	maps	_	
81-29	16831-16834	and	_	
81-30	16835-16838	the	_	
81-31	16839-16844	PANSS	_	
81-32	16845-16851	scores	_	
81-33	16852-16855	was	_	
81-34	16856-16865	performed	_	
81-35	16866-16868	to	_	
81-36	16869-16876	explore	_	
81-37	16877-16880	the	_	
81-38	16881-16894	relationships	_	
81-39	16895-16902	between	_	
81-40	16903-16906	the	_	
81-41	16907-16911	ReHo	_	
81-42	16912-16918	values	_	
81-43	16919-16922	and	_	
81-44	16923-16926	the	_	
81-45	16927-16932	PANSS	_	
81-46	16933-16939	scores	_	
81-47	16940-16942	in	_	
81-48	16943-16946	the	_	
81-49	16947-16953	dn-FES	_	
81-50	16954-16959	group	_	
81-51	16960-16962	by	_	
81-52	16963-16970	setting	_	
81-53	16971-16974	age	_	
81-54	16974-16975	,	_	
81-55	16976-16982	gender	_	
81-56	16982-16983	,	_	
81-57	16984-16993	education	_	
81-58	16993-16994	,	_	
81-59	16995-16998	and	_	
81-60	16999-17006	illness	_	
81-61	17007-17015	duration	_	
81-62	17016-17018	as	_	
81-63	17019-17029	covariates	_	
81-64	17029-17030	.	_	

#Text=Positive symptoms (r = 0.41, p < 0.05, corrected by TFCE), negative symptoms (r = 0.32, p < 0.05, corrected by TFCE), and the PANSS total scores (r = 0.45, p < 0.05, corrected by TFCE) had positive correlations with the ReHo values in the right MFG.
82-1	17031-17039	Positive	_	
82-2	17040-17048	symptoms	_	
82-3	17049-17050	(	_	
82-4	17050-17051	r	_	
82-5	17052-17053	=	_	
82-6	17054-17058	0.41	_	
82-7	17058-17059	,	_	
82-8	17060-17061	p	_	
82-9	17062-17063	<	_	
82-10	17064-17068	0.05	_	
82-11	17068-17069	,	_	
82-12	17070-17079	corrected	_	
82-13	17080-17082	by	_	
82-14	17083-17087	TFCE	_	
82-15	17087-17088	)	_	
82-16	17088-17089	,	_	
82-17	17090-17098	negative	_	
82-18	17099-17107	symptoms	_	
82-19	17108-17109	(	_	
82-20	17109-17110	r	_	
82-21	17111-17112	=	_	
82-22	17113-17117	0.32	_	
82-23	17117-17118	,	_	
82-24	17119-17120	p	_	
82-25	17121-17122	<	_	
82-26	17123-17127	0.05	_	
82-27	17127-17128	,	_	
82-28	17129-17138	corrected	_	
82-29	17139-17141	by	_	
82-30	17142-17146	TFCE	_	
82-31	17146-17147	)	_	
82-32	17147-17148	,	_	
82-33	17149-17152	and	_	
82-34	17153-17156	the	_	
82-35	17157-17162	PANSS	_	
82-36	17163-17168	total	_	
82-37	17169-17175	scores	_	
82-38	17176-17177	(	_	
82-39	17177-17178	r	_	
82-40	17179-17180	=	_	
82-41	17181-17185	0.45	_	
82-42	17185-17186	,	_	
82-43	17187-17188	p	_	
82-44	17189-17190	<	_	
82-45	17191-17195	0.05	_	
82-46	17195-17196	,	_	
82-47	17197-17206	corrected	_	
82-48	17207-17209	by	_	
82-49	17210-17214	TFCE	_	
82-50	17214-17215	)	_	
82-51	17216-17219	had	_	
82-52	17220-17228	positive	_	
82-53	17229-17241	correlations	_	
82-54	17242-17246	with	_	
82-55	17247-17250	the	_	
82-56	17251-17255	ReHo	_	
82-57	17256-17262	values	_	
82-58	17263-17265	in	_	
82-59	17266-17269	the	_	
82-60	17270-17275	right	_	
82-61	17276-17279	MFG	_	
82-62	17279-17280	.	_	

#Text=The same approach was employed to investigate the relationships between the ReHo values and the MCCB in the dn-FES group.
83-1	17281-17284	The	_	
83-2	17285-17289	same	_	
83-3	17290-17298	approach	_	
83-4	17299-17302	was	_	
83-5	17303-17311	employed	_	
83-6	17312-17314	to	_	
83-7	17315-17326	investigate	_	
83-8	17327-17330	the	_	
83-9	17331-17344	relationships	_	
83-10	17345-17352	between	_	
83-11	17353-17356	the	_	
83-12	17357-17361	ReHo	_	
83-13	17362-17368	values	_	
83-14	17369-17372	and	_	
83-15	17373-17376	the	_	
83-16	17377-17381	MCCB	_	
83-17	17382-17384	in	_	
83-18	17385-17388	the	_	
83-19	17389-17395	dn-FES	_	
83-20	17396-17401	group	_	
83-21	17401-17402	.	_	

#Text=Attention/vigilance (r = − 0.30, p < 0.05, corrected by TFCE), social cognition (r = − 0.38, p < 0.05, corrected by TFCE), and overall composite (r = − 0.34, p < 0.05, corrected by TFCE) had negative correlations with the ReHo values in the right MFG (Tables 3 and 4).
84-1	17403-17412	Attention	_	
84-2	17412-17413	/	_	
84-3	17413-17422	vigilance	_	
84-4	17423-17424	(	_	
84-5	17424-17425	r	_	
84-6	17426-17427	=	_	
84-7	17428-17429	−	_	
84-8	17430-17434	0.30	_	
84-9	17434-17435	,	_	
84-10	17436-17437	p	_	
84-11	17438-17439	<	_	
84-12	17440-17444	0.05	_	
84-13	17444-17445	,	_	
84-14	17446-17455	corrected	_	
84-15	17456-17458	by	_	
84-16	17459-17463	TFCE	_	
84-17	17463-17464	)	_	
84-18	17464-17465	,	_	
84-19	17466-17472	social	_	
84-20	17473-17482	cognition	_	
84-21	17483-17484	(	_	
84-22	17484-17485	r	_	
84-23	17486-17487	=	_	
84-24	17488-17489	−	_	
84-25	17490-17494	0.38	_	
84-26	17494-17495	,	_	
84-27	17496-17497	p	_	
84-28	17498-17499	<	_	
84-29	17500-17504	0.05	_	
84-30	17504-17505	,	_	
84-31	17506-17515	corrected	_	
84-32	17516-17518	by	_	
84-33	17519-17523	TFCE	_	
84-34	17523-17524	)	_	
84-35	17524-17525	,	_	
84-36	17526-17529	and	_	
84-37	17530-17537	overall	_	
84-38	17538-17547	composite	_	
84-39	17548-17549	(	_	
84-40	17549-17550	r	_	
84-41	17551-17552	=	_	
84-42	17553-17554	−	_	
84-43	17555-17559	0.34	_	
84-44	17559-17560	,	_	
84-45	17561-17562	p	_	
84-46	17563-17564	<	_	
84-47	17565-17569	0.05	_	
84-48	17569-17570	,	_	
84-49	17571-17580	corrected	_	
84-50	17581-17583	by	_	
84-51	17584-17588	TFCE	_	
84-52	17588-17589	)	_	
84-53	17590-17593	had	_	
84-54	17594-17602	negative	_	
84-55	17603-17615	correlations	_	
84-56	17616-17620	with	_	
84-57	17621-17624	the	_	
84-58	17625-17629	ReHo	_	
84-59	17630-17636	values	_	
84-60	17637-17639	in	_	
84-61	17640-17643	the	_	
84-62	17644-17649	right	_	
84-63	17650-17653	MFG	_	
84-64	17654-17655	(	_	
84-65	17655-17661	Tables	_	
84-66	17661-17662	 	_	
84-67	17662-17663	3	_	
84-68	17664-17667	and	_	
84-69	17668-17669	4	_	
84-70	17669-17670	)	_	
84-71	17670-17671	.	_	

#Text=Discussion
#Text=In the present study, the dn-FES group showed severe and widespread cognitive deficits in all domains, and this observation was consistent with the previous studies that used the same instrument.
85-1	17673-17683	Discussion	_	
85-2	17684-17686	In	_	
85-3	17687-17690	the	_	
85-4	17691-17698	present	_	
85-5	17699-17704	study	_	
85-6	17704-17705	,	_	
85-7	17706-17709	the	_	
85-8	17710-17716	dn-FES	_	
85-9	17717-17722	group	_	
85-10	17723-17729	showed	_	
85-11	17730-17736	severe	_	
85-12	17737-17740	and	_	
85-13	17741-17751	widespread	_	
85-14	17752-17761	cognitive	_	
85-15	17762-17770	deficits	_	
85-16	17771-17773	in	_	
85-17	17774-17777	all	_	
85-18	17778-17785	domains	_	
85-19	17785-17786	,	_	
85-20	17787-17790	and	_	
85-21	17791-17795	this	_	
85-22	17796-17807	observation	_	
85-23	17808-17811	was	_	
85-24	17812-17822	consistent	_	
85-25	17823-17827	with	_	
85-26	17828-17831	the	_	
85-27	17832-17840	previous	_	
85-28	17841-17848	studies	_	
85-29	17849-17853	that	_	
85-30	17854-17858	used	_	
85-31	17859-17862	the	_	
85-32	17863-17867	same	_	
85-33	17868-17878	instrument	_	
85-34	17878-17879	.	_	

#Text=Schizophrenia has distinct cognitive impairments, including speed of processing, working memory, verbal learning, reasoning/problem solving, visual learning, attention/vigilance, and social cognition.
86-1	17880-17893	Schizophrenia	_	
86-2	17894-17897	has	_	
86-3	17898-17906	distinct	_	
86-4	17907-17916	cognitive	_	
86-5	17917-17928	impairments	_	
86-6	17928-17929	,	_	
86-7	17930-17939	including	_	
86-8	17940-17945	speed	_	
86-9	17946-17948	of	_	
86-10	17949-17959	processing	_	
86-11	17959-17960	,	_	
86-12	17961-17968	working	_	
86-13	17969-17975	memory	_	
86-14	17975-17976	,	_	
86-15	17977-17983	verbal	_	
86-16	17984-17992	learning	_	
86-17	17992-17993	,	_	
86-18	17994-18003	reasoning	_	
86-19	18003-18004	/	_	
86-20	18004-18011	problem	_	
86-21	18012-18019	solving	_	
86-22	18019-18020	,	_	
86-23	18021-18027	visual	_	
86-24	18028-18036	learning	_	
86-25	18036-18037	,	_	
86-26	18038-18047	attention	_	
86-27	18047-18048	/	_	
86-28	18048-18057	vigilance	_	
86-29	18057-18058	,	_	
86-30	18059-18062	and	_	
86-31	18063-18069	social	_	
86-32	18070-18079	cognition	_	
86-33	18079-18080	.	_	

#Text=Our results showed that cognitive deficits were present at the onset of schizophrenia without considering the several factors, such as long-term antipsychotic treatment and prolonged illness course.
87-1	18081-18084	Our	_	
87-2	18085-18092	results	_	
87-3	18093-18099	showed	_	
87-4	18100-18104	that	_	
87-5	18105-18114	cognitive	_	
87-6	18115-18123	deficits	_	
87-7	18124-18128	were	_	
87-8	18129-18136	present	_	
87-9	18137-18139	at	_	
87-10	18140-18143	the	_	
87-11	18144-18149	onset	_	
87-12	18150-18152	of	_	
87-13	18153-18166	schizophrenia	_	
87-14	18167-18174	without	_	
87-15	18175-18186	considering	_	
87-16	18187-18190	the	_	
87-17	18191-18198	several	_	
87-18	18199-18206	factors	_	
87-19	18206-18207	,	_	
87-20	18208-18212	such	_	
87-21	18213-18215	as	_	
87-22	18216-18225	long-term	_	
87-23	18226-18239	antipsychotic	_	
87-24	18240-18249	treatment	_	
87-25	18250-18253	and	_	
87-26	18254-18263	prolonged	_	
87-27	18264-18271	illness	_	
87-28	18272-18278	course	_	
87-29	18278-18279	.	_	

#Text=We observed increased ReHo values in right MFG (Brodmann Area 10, BA10) and SFG (BA9) and decreased ReHo values in right cuneus of patients with dn-FES as compared to HCs.
88-1	18280-18282	We	_	
88-2	18283-18291	observed	_	
88-3	18292-18301	increased	_	
88-4	18302-18306	ReHo	_	
88-5	18307-18313	values	_	
88-6	18314-18316	in	_	
88-7	18317-18322	right	_	
88-8	18323-18326	MFG	_	
88-9	18327-18328	(	_	
88-10	18328-18336	Brodmann	_	
88-11	18337-18341	Area	_	
88-12	18342-18344	10	_	
88-13	18344-18345	,	_	
88-14	18346-18350	BA10	_	
88-15	18350-18351	)	_	
88-16	18352-18355	and	_	
88-17	18356-18359	SFG	_	
88-18	18360-18361	(	_	
88-19	18361-18364	BA9	_	
88-20	18364-18365	)	_	
88-21	18366-18369	and	_	
88-22	18370-18379	decreased	_	
88-23	18380-18384	ReHo	_	
88-24	18385-18391	values	_	
88-25	18392-18394	in	_	
88-26	18395-18400	right	_	
88-27	18401-18407	cuneus	_	
88-28	18408-18410	of	_	
88-29	18411-18419	patients	_	
88-30	18420-18424	with	_	
88-31	18425-18431	dn-FES	_	
88-32	18432-18434	as	_	
88-33	18435-18443	compared	_	
88-34	18444-18446	to	_	
88-35	18447-18450	HCs	_	
88-36	18450-18451	.	_	

#Text=The Prefrontal Cortex (PFC) is involved in the modulation of decision-making and executive control to behave appropriately by integrating sensory and emotional information.
89-1	18452-18455	The	_	
89-2	18456-18466	Prefrontal	_	
89-3	18467-18473	Cortex	_	
89-4	18474-18475	(	_	
89-5	18475-18478	PFC	_	
89-6	18478-18479	)	_	
89-7	18480-18482	is	_	
89-8	18483-18491	involved	_	
89-9	18492-18494	in	_	
89-10	18495-18498	the	_	
89-11	18499-18509	modulation	_	
89-12	18510-18512	of	_	
89-13	18513-18528	decision-making	_	
89-14	18529-18532	and	_	
89-15	18533-18542	executive	_	
89-16	18543-18550	control	_	
89-17	18551-18553	to	_	
89-18	18554-18560	behave	_	
89-19	18561-18574	appropriately	_	
89-20	18575-18577	by	_	
89-21	18578-18589	integrating	_	
89-22	18590-18597	sensory	_	
89-23	18598-18601	and	_	
89-24	18602-18611	emotional	_	
89-25	18612-18623	information	_	
89-26	18623-18624	.	_	

#Text=The frontal cortex lesion is related to behavioral impairments, such as inflexibility, social inappropriateness, isolation, and apathy.
90-1	18625-18628	The	_	
90-2	18629-18636	frontal	_	
90-3	18637-18643	cortex	_	
90-4	18644-18650	lesion	_	
90-5	18651-18653	is	_	
90-6	18654-18661	related	_	
90-7	18662-18664	to	_	
90-8	18665-18675	behavioral	_	
90-9	18676-18687	impairments	_	
90-10	18687-18688	,	_	
90-11	18689-18693	such	_	
90-12	18694-18696	as	_	
90-13	18697-18710	inflexibility	_	
90-14	18710-18711	,	_	
90-15	18712-18718	social	_	
90-16	18719-18736	inappropriateness	_	
90-17	18736-18737	,	_	
90-18	18738-18747	isolation	_	
90-19	18747-18748	,	_	
90-20	18749-18752	and	_	
90-21	18753-18759	apathy	_	
90-22	18759-18760	.	_	

#Text=The right MFG has been well studied and may play a major role in integrating visual, auditory, and somatic information to obtain an extensive and generalized interpretation of the environment.
91-1	18761-18764	The	_	
91-2	18765-18770	right	_	
91-3	18771-18774	MFG	_	
91-4	18775-18778	has	_	
91-5	18779-18783	been	_	
91-6	18784-18788	well	_	
91-7	18789-18796	studied	_	
91-8	18797-18800	and	_	
91-9	18801-18804	may	_	
91-10	18805-18809	play	_	
91-11	18810-18811	a	_	
91-12	18812-18817	major	_	
91-13	18818-18822	role	_	
91-14	18823-18825	in	_	
91-15	18826-18837	integrating	_	
91-16	18838-18844	visual	_	
91-17	18844-18845	,	_	
91-18	18846-18854	auditory	_	
91-19	18854-18855	,	_	
91-20	18856-18859	and	_	
91-21	18860-18867	somatic	_	
91-22	18868-18879	information	_	
91-23	18880-18882	to	_	
91-24	18883-18889	obtain	_	
91-25	18890-18892	an	_	
91-26	18893-18902	extensive	_	
91-27	18903-18906	and	_	
91-28	18907-18918	generalized	_	
91-29	18919-18933	interpretation	_	
91-30	18934-18936	of	_	
91-31	18937-18940	the	_	
91-32	18941-18952	environment	_	
91-33	18952-18953	.	_	

#Text=Nevertheless, many research results are not entirely consistent and are even contradictory.
92-1	18954-18966	Nevertheless	_	
92-2	18966-18967	,	_	
92-3	18968-18972	many	_	
92-4	18973-18981	research	_	
92-5	18982-18989	results	_	
92-6	18990-18993	are	_	
92-7	18994-18997	not	_	
92-8	18998-19006	entirely	_	
92-9	19007-19017	consistent	_	
92-10	19018-19021	and	_	
92-11	19022-19025	are	_	
92-12	19026-19030	even	_	
92-13	19031-19044	contradictory	_	
92-14	19044-19045	.	_	

#Text=For instance, some researchers have reported increased ReHo value in the frontal lobe, but others have failed to receive the same results and have even found decreased ReHo value in the frontal lobe.
93-1	19046-19049	For	_	
93-2	19050-19058	instance	_	
93-3	19058-19059	,	_	
93-4	19060-19064	some	_	
93-5	19065-19076	researchers	_	
93-6	19077-19081	have	_	
93-7	19082-19090	reported	_	
93-8	19091-19100	increased	_	
93-9	19101-19105	ReHo	_	
93-10	19106-19111	value	_	
93-11	19112-19114	in	_	
93-12	19115-19118	the	_	
93-13	19119-19126	frontal	_	
93-14	19127-19131	lobe	_	
93-15	19131-19132	,	_	
93-16	19133-19136	but	_	
93-17	19137-19143	others	_	
93-18	19144-19148	have	_	
93-19	19149-19155	failed	_	
93-20	19156-19158	to	_	
93-21	19159-19166	receive	_	
93-22	19167-19170	the	_	
93-23	19171-19175	same	_	
93-24	19176-19183	results	_	
93-25	19184-19187	and	_	
93-26	19188-19192	have	_	
93-27	19193-19197	even	_	
93-28	19198-19203	found	_	
93-29	19204-19213	decreased	_	
93-30	19214-19218	ReHo	_	
93-31	19219-19224	value	_	
93-32	19225-19227	in	_	
93-33	19228-19231	the	_	
93-34	19232-19239	frontal	_	
93-35	19240-19244	lobe	_	
93-36	19244-19245	.	_	

#Text=Several factors, such as head motion regression model, cultural backgrounds, illness courses, illness heterogeneity, experimental parameters, and statistical methods, may be accountable.
94-1	19246-19253	Several	_	
94-2	19254-19261	factors	_	
94-3	19261-19262	,	_	
94-4	19263-19267	such	_	
94-5	19268-19270	as	_	
94-6	19271-19275	head	_	
94-7	19276-19282	motion	_	
94-8	19283-19293	regression	_	
94-9	19294-19299	model	_	
94-10	19299-19300	,	_	
94-11	19301-19309	cultural	_	
94-12	19310-19321	backgrounds	_	
94-13	19321-19322	,	_	
94-14	19323-19330	illness	_	
94-15	19331-19338	courses	_	
94-16	19338-19339	,	_	
94-17	19340-19347	illness	_	
94-18	19348-19361	heterogeneity	_	
94-19	19361-19362	,	_	
94-20	19363-19375	experimental	_	
94-21	19376-19386	parameters	_	
94-22	19386-19387	,	_	
94-23	19388-19391	and	_	
94-24	19392-19403	statistical	_	
94-25	19404-19411	methods	_	
94-26	19411-19412	,	_	
94-27	19413-19416	may	_	
94-28	19417-19419	be	_	
94-29	19420-19431	accountable	_	
94-30	19431-19432	.	_	

#Text=The cuneus belongs to visual cortex which is involved in visual processing and associated with attention and working memory.
95-1	19433-19436	The	_	
95-2	19437-19443	cuneus	_	
95-3	19444-19451	belongs	_	
95-4	19452-19454	to	_	
95-5	19455-19461	visual	_	
95-6	19462-19468	cortex	_	
95-7	19469-19474	which	_	
95-8	19475-19477	is	_	
95-9	19478-19486	involved	_	
95-10	19487-19489	in	_	
95-11	19490-19496	visual	_	
95-12	19497-19507	processing	_	
95-13	19508-19511	and	_	
95-14	19512-19522	associated	_	
95-15	19523-19527	with	_	
95-16	19528-19537	attention	_	
95-17	19538-19541	and	_	
95-18	19542-19549	working	_	
95-19	19550-19556	memory	_	
95-20	19556-19557	.	_	

#Text=The abnormal regional spontaneous activities in the cuneus in the early stages of schizophrenia may cause higher-level cognitive impairments.
96-1	19558-19561	The	_	
96-2	19562-19570	abnormal	_	
96-3	19571-19579	regional	_	
96-4	19580-19591	spontaneous	_	
96-5	19592-19602	activities	_	
96-6	19603-19605	in	_	
96-7	19606-19609	the	_	
96-8	19610-19616	cuneus	_	
96-9	19617-19619	in	_	
96-10	19620-19623	the	_	
96-11	19624-19629	early	_	
96-12	19630-19636	stages	_	
96-13	19637-19639	of	_	
96-14	19640-19653	schizophrenia	_	
96-15	19654-19657	may	_	
96-16	19658-19663	cause	_	
96-17	19664-19676	higher-level	_	
96-18	19677-19686	cognitive	_	
96-19	19687-19698	impairments	_	
96-20	19698-19699	.	_	

#Text=It was discovered that ReHo values decreased in right cuneus of patients with schizophrenia, which was partially consistent with previous findings.
97-1	19700-19702	It	_	
97-2	19703-19706	was	_	
97-3	19707-19717	discovered	_	
97-4	19718-19722	that	_	
97-5	19723-19727	ReHo	_	
97-6	19728-19734	values	_	
97-7	19735-19744	decreased	_	
97-8	19745-19747	in	_	
97-9	19748-19753	right	_	
97-10	19754-19760	cuneus	_	
97-11	19761-19763	of	_	
97-12	19764-19772	patients	_	
97-13	19773-19777	with	_	
97-14	19778-19791	schizophrenia	_	
97-15	19791-19792	,	_	
97-16	19793-19798	which	_	
97-17	19799-19802	was	_	
97-18	19803-19812	partially	_	
97-19	19813-19823	consistent	_	
97-20	19824-19828	with	_	
97-21	19829-19837	previous	_	
97-22	19838-19846	findings	_	
97-23	19846-19847	.	_	

#Text=We proposed that the disruption of the local synchronization of the spontaneous activities in these brain areas be related to the psychopathology of schizophrenia.
98-1	19848-19850	We	_	
98-2	19851-19859	proposed	_	
98-3	19860-19864	that	_	
98-4	19865-19868	the	_	
98-5	19869-19879	disruption	_	
98-6	19880-19882	of	_	
98-7	19883-19886	the	_	
98-8	19887-19892	local	_	
98-9	19893-19908	synchronization	_	
98-10	19909-19911	of	_	
98-11	19912-19915	the	_	
98-12	19916-19927	spontaneous	_	
98-13	19928-19938	activities	_	
98-14	19939-19941	in	_	
98-15	19942-19947	these	_	
98-16	19948-19953	brain	_	
98-17	19954-19959	areas	_	
98-18	19960-19962	be	_	
98-19	19963-19970	related	_	
98-20	19971-19973	to	_	
98-21	19974-19977	the	_	
98-22	19978-19993	psychopathology	_	
98-23	19994-19996	of	_	
98-24	19997-20010	schizophrenia	_	
98-25	20010-20011	.	_	

#Text=In particular, such common frontal aberrations may be concerned with vulnerability to psychosis.
99-1	20012-20014	In	_	
99-2	20015-20025	particular	_	
99-3	20025-20026	,	_	
99-4	20027-20031	such	_	
99-5	20032-20038	common	_	
99-6	20039-20046	frontal	_	
99-7	20047-20058	aberrations	_	
99-8	20059-20062	may	_	
99-9	20063-20065	be	_	
99-10	20066-20075	concerned	_	
99-11	20076-20080	with	_	
99-12	20081-20094	vulnerability	_	
99-13	20095-20097	to	_	
99-14	20098-20107	psychosis	_	
99-15	20107-20108	.	_	

#Text=The correlation analysis showed that ReHo values in right MFG positively correlated with the severity of clinical manifestations (positive symptoms, negative symptoms, and the PANSS total scores) in patients with dn-FES.
100-1	20109-20112	The	_	
100-2	20113-20124	correlation	_	
100-3	20125-20133	analysis	_	
100-4	20134-20140	showed	_	
100-5	20141-20145	that	_	
100-6	20146-20150	ReHo	_	
100-7	20151-20157	values	_	
100-8	20158-20160	in	_	
100-9	20161-20166	right	_	
100-10	20167-20170	MFG	_	
100-11	20171-20181	positively	_	
100-12	20182-20192	correlated	_	
100-13	20193-20197	with	_	
100-14	20198-20201	the	_	
100-15	20202-20210	severity	_	
100-16	20211-20213	of	_	
100-17	20214-20222	clinical	_	
100-18	20223-20237	manifestations	_	
100-19	20238-20239	(	_	
100-20	20239-20247	positive	_	
100-21	20248-20256	symptoms	_	
100-22	20256-20257	,	_	
100-23	20258-20266	negative	_	
100-24	20267-20275	symptoms	_	
100-25	20275-20276	,	_	
100-26	20277-20280	and	_	
100-27	20281-20284	the	_	
100-28	20285-20290	PANSS	_	
100-29	20291-20296	total	_	
100-30	20297-20303	scores	_	
100-31	20303-20304	)	_	
100-32	20305-20307	in	_	
100-33	20308-20316	patients	_	
100-34	20317-20321	with	_	
100-35	20322-20328	dn-FES	_	
100-36	20328-20329	.	_	

#Text=These results were partially consistent with previous studies.
101-1	20330-20335	These	_	
101-2	20336-20343	results	_	
101-3	20344-20348	were	_	
101-4	20349-20358	partially	_	
101-5	20359-20369	consistent	_	
101-6	20370-20374	with	_	
101-7	20375-20383	previous	_	
101-8	20384-20391	studies	_	
101-9	20391-20392	.	_	

#Text=Decreased gray matter volumes in right MFG and SFG were associated with the total PANSS scores in patients with FES.
102-1	20393-20402	Decreased	_	
102-2	20403-20407	gray	_	
102-3	20408-20414	matter	_	
102-4	20415-20422	volumes	_	
102-5	20423-20425	in	_	
102-6	20426-20431	right	_	
102-7	20432-20435	MFG	_	
102-8	20436-20439	and	_	
102-9	20440-20443	SFG	_	
102-10	20444-20448	were	_	
102-11	20449-20459	associated	_	
102-12	20460-20464	with	_	
102-13	20465-20468	the	_	
102-14	20469-20474	total	_	
102-15	20475-20480	PANSS	_	
102-16	20481-20487	scores	_	
102-17	20488-20490	in	_	
102-18	20491-20499	patients	_	
102-19	20500-20504	with	_	
102-20	20505-20508	FES	_	
102-21	20508-20509	.	_	

#Text=Neuroimaging studies have indicated that right MFG aberrations possibly play a crucial role in the emergence of psychotic symptoms of auditory hallucinations, thought disorder, and positive psychotic symptoms in schizophrenia.
103-1	20510-20522	Neuroimaging	_	
103-2	20523-20530	studies	_	
103-3	20531-20535	have	_	
103-4	20536-20545	indicated	_	
103-5	20546-20550	that	_	
103-6	20551-20556	right	_	
103-7	20557-20560	MFG	_	
103-8	20561-20572	aberrations	_	
103-9	20573-20581	possibly	_	
103-10	20582-20586	play	_	
103-11	20587-20588	a	_	
103-12	20589-20596	crucial	_	
103-13	20597-20601	role	_	
103-14	20602-20604	in	_	
103-15	20605-20608	the	_	
103-16	20609-20618	emergence	_	
103-17	20619-20621	of	_	
103-18	20622-20631	psychotic	_	
103-19	20632-20640	symptoms	_	
103-20	20641-20643	of	_	
103-21	20644-20652	auditory	_	
103-22	20653-20667	hallucinations	_	
103-23	20667-20668	,	_	
103-24	20669-20676	thought	_	
103-25	20677-20685	disorder	_	
103-26	20685-20686	,	_	
103-27	20687-20690	and	_	
103-28	20691-20699	positive	_	
103-29	20700-20709	psychotic	_	
103-30	20710-20718	symptoms	_	
103-31	20719-20721	in	_	
103-32	20722-20735	schizophrenia	_	
103-33	20735-20736	.	_	

#Text=Frontal lobe dysfunction possibly correlates with the occurrence of negative symptoms, especially in right MFG, which is particularly vulnerable to long-term effects of schizophrenia.
104-1	20737-20744	Frontal	_	
104-2	20745-20749	lobe	_	
104-3	20750-20761	dysfunction	_	
104-4	20762-20770	possibly	_	
104-5	20771-20781	correlates	_	
104-6	20782-20786	with	_	
104-7	20787-20790	the	_	
104-8	20791-20801	occurrence	_	
104-9	20802-20804	of	_	
104-10	20805-20813	negative	_	
104-11	20814-20822	symptoms	_	
104-12	20822-20823	,	_	
104-13	20824-20834	especially	_	
104-14	20835-20837	in	_	
104-15	20838-20843	right	_	
104-16	20844-20847	MFG	_	
104-17	20847-20848	,	_	
104-18	20849-20854	which	_	
104-19	20855-20857	is	_	
104-20	20858-20870	particularly	_	
104-21	20871-20881	vulnerable	_	
104-22	20882-20884	to	_	
104-23	20885-20894	long-term	_	
104-24	20895-20902	effects	_	
104-25	20903-20905	of	_	
104-26	20906-20919	schizophrenia	_	
104-27	20919-20920	.	_	

#Text=A partial brain area of right MFG overlapped the medial PFC, and a study on adolescent-onset schizophrenia has also shown that ReHo values in right medial PFC increased.
105-1	20921-20922	A	_	
105-2	20923-20930	partial	_	
105-3	20931-20936	brain	_	
105-4	20937-20941	area	_	
105-5	20942-20944	of	_	
105-6	20945-20950	right	_	
105-7	20951-20954	MFG	_	
105-8	20955-20965	overlapped	_	
105-9	20966-20969	the	_	
105-10	20970-20976	medial	_	
105-11	20977-20980	PFC	_	
105-12	20980-20981	,	_	
105-13	20982-20985	and	_	
105-14	20986-20987	a	_	
105-15	20988-20993	study	_	
105-16	20994-20996	on	_	
105-17	20997-21013	adolescent-onset	_	
105-18	21014-21027	schizophrenia	_	
105-19	21028-21031	has	_	
105-20	21032-21036	also	_	
105-21	21037-21042	shown	_	
105-22	21043-21047	that	_	
105-23	21048-21052	ReHo	_	
105-24	21053-21059	values	_	
105-25	21060-21062	in	_	
105-26	21063-21068	right	_	
105-27	21069-21075	medial	_	
105-28	21076-21079	PFC	_	
105-29	21080-21089	increased	_	
105-30	21089-21090	.	_	

#Text=Another study has found that concomitant structural and causal connectivity deficits in medial PFC correlate with the negative symptoms of schizophrenia.
106-1	21091-21098	Another	_	
106-2	21099-21104	study	_	
106-3	21105-21108	has	_	
106-4	21109-21114	found	_	
106-5	21115-21119	that	_	
106-6	21120-21131	concomitant	_	
106-7	21132-21142	structural	_	
106-8	21143-21146	and	_	
106-9	21147-21153	causal	_	
106-10	21154-21166	connectivity	_	
106-11	21167-21175	deficits	_	
106-12	21176-21178	in	_	
106-13	21179-21185	medial	_	
106-14	21186-21189	PFC	_	
106-15	21190-21199	correlate	_	
106-16	21200-21204	with	_	
106-17	21205-21208	the	_	
106-18	21209-21217	negative	_	
106-19	21218-21226	symptoms	_	
106-20	21227-21229	of	_	
106-21	21230-21243	schizophrenia	_	
106-22	21243-21244	.	_	

#Text=Similarly, our results suggested that negative symptoms positively correlated with ReHo values in right MFG in patients with dn-FES at the early stage.
107-1	21245-21254	Similarly	_	
107-2	21254-21255	,	_	
107-3	21256-21259	our	_	
107-4	21260-21267	results	_	
107-5	21268-21277	suggested	_	
107-6	21278-21282	that	_	
107-7	21283-21291	negative	_	
107-8	21292-21300	symptoms	_	
107-9	21301-21311	positively	_	
107-10	21312-21322	correlated	_	
107-11	21323-21327	with	_	
107-12	21328-21332	ReHo	_	
107-13	21333-21339	values	_	
107-14	21340-21342	in	_	
107-15	21343-21348	right	_	
107-16	21349-21352	MFG	_	
107-17	21353-21355	in	_	
107-18	21356-21364	patients	_	
107-19	21365-21369	with	_	
107-20	21370-21376	dn-FES	_	
107-21	21377-21379	at	_	
107-22	21380-21383	the	_	
107-23	21384-21389	early	_	
107-24	21390-21395	stage	_	
107-25	21395-21396	.	_	

#Text=In summary, we found that ReHo values in right MFG were associated with not only positive symptoms but negative symptoms in dn-FES.
108-1	21397-21399	In	_	
108-2	21400-21407	summary	_	
108-3	21407-21408	,	_	
108-4	21409-21411	we	_	
108-5	21412-21417	found	_	
108-6	21418-21422	that	_	
108-7	21423-21427	ReHo	_	
108-8	21428-21434	values	_	
108-9	21435-21437	in	_	
108-10	21438-21443	right	_	
108-11	21444-21447	MFG	_	
108-12	21448-21452	were	_	
108-13	21453-21463	associated	_	
108-14	21464-21468	with	_	
108-15	21469-21472	not	_	
108-16	21473-21477	only	_	
108-17	21478-21486	positive	_	
108-18	21487-21495	symptoms	_	
108-19	21496-21499	but	_	
108-20	21500-21508	negative	_	
108-21	21509-21517	symptoms	_	
108-22	21518-21520	in	_	
108-23	21521-21527	dn-FES	_	
108-24	21527-21528	.	_	

#Text=The increased ReHo values in frontal regions were thought to underlie the manifestation of the psychotic symptoms in schizophrenia.
109-1	21529-21532	The	_	
109-2	21533-21542	increased	_	
109-3	21543-21547	ReHo	_	
109-4	21548-21554	values	_	
109-5	21555-21557	in	_	
109-6	21558-21565	frontal	_	
109-7	21566-21573	regions	_	
109-8	21574-21578	were	_	
109-9	21579-21586	thought	_	
109-10	21587-21589	to	_	
109-11	21590-21598	underlie	_	
109-12	21599-21602	the	_	
109-13	21603-21616	manifestation	_	
109-14	21617-21619	of	_	
109-15	21620-21623	the	_	
109-16	21624-21633	psychotic	_	
109-17	21634-21642	symptoms	_	
109-18	21643-21645	in	_	
109-19	21646-21659	schizophrenia	_	
109-20	21659-21660	.	_	

#Text=However, considering that the data on the relationships between ReHo values and clinical variables in dn-FES are sparse, these findings may need further validation.
110-1	21661-21668	However	_	
110-2	21668-21669	,	_	
110-3	21670-21681	considering	_	
110-4	21682-21686	that	_	
110-5	21687-21690	the	_	
110-6	21691-21695	data	_	
110-7	21696-21698	on	_	
110-8	21699-21702	the	_	
110-9	21703-21716	relationships	_	
110-10	21717-21724	between	_	
110-11	21725-21729	ReHo	_	
110-12	21730-21736	values	_	
110-13	21737-21740	and	_	
110-14	21741-21749	clinical	_	
110-15	21750-21759	variables	_	
110-16	21760-21762	in	_	
110-17	21763-21769	dn-FES	_	
110-18	21770-21773	are	_	
110-19	21774-21780	sparse	_	
110-20	21780-21781	,	_	
110-21	21782-21787	these	_	
110-22	21788-21796	findings	_	
110-23	21797-21800	may	_	
110-24	21801-21805	need	_	
110-25	21806-21813	further	_	
110-26	21814-21824	validation	_	
110-27	21824-21825	.	_	

#Text=The correlation analysis showed that ReHo values in right MFG negatively correlated with the MCCB overall composite performance, social cognitive presentation, and attention/vigilance.
111-1	21826-21829	The	_	
111-2	21830-21841	correlation	_	
111-3	21842-21850	analysis	_	
111-4	21851-21857	showed	_	
111-5	21858-21862	that	_	
111-6	21863-21867	ReHo	_	
111-7	21868-21874	values	_	
111-8	21875-21877	in	_	
111-9	21878-21883	right	_	
111-10	21884-21887	MFG	_	
111-11	21888-21898	negatively	_	
111-12	21899-21909	correlated	_	
111-13	21910-21914	with	_	
111-14	21915-21918	the	_	
111-15	21919-21923	MCCB	_	
111-16	21924-21931	overall	_	
111-17	21932-21941	composite	_	
111-18	21942-21953	performance	_	
111-19	21953-21954	,	_	
111-20	21955-21961	social	_	
111-21	21962-21971	cognitive	_	
111-22	21972-21984	presentation	_	
111-23	21984-21985	,	_	
111-24	21986-21989	and	_	
111-25	21990-21999	attention	_	
111-26	21999-22000	/	_	
111-27	22000-22009	vigilance	_	
111-28	22009-22010	.	_	

#Text=A structural MRI study has found a thinner MFG cortex in patients with schizophrenia, and the decreased cortical thickness in this region is relevant to cognitive impairments.
112-1	22011-22012	A	_	
112-2	22013-22023	structural	_	
112-3	22024-22027	MRI	_	
112-4	22028-22033	study	_	
112-5	22034-22037	has	_	
112-6	22038-22043	found	_	
112-7	22044-22045	a	_	
112-8	22046-22053	thinner	_	
112-9	22054-22057	MFG	_	
112-10	22058-22064	cortex	_	
112-11	22065-22067	in	_	
112-12	22068-22076	patients	_	
112-13	22077-22081	with	_	
112-14	22082-22095	schizophrenia	_	
112-15	22095-22096	,	_	
112-16	22097-22100	and	_	
112-17	22101-22104	the	_	
112-18	22105-22114	decreased	_	
112-19	22115-22123	cortical	_	
112-20	22124-22133	thickness	_	
112-21	22134-22136	in	_	
112-22	22137-22141	this	_	
112-23	22142-22148	region	_	
112-24	22149-22151	is	_	
112-25	22152-22160	relevant	_	
112-26	22161-22163	to	_	
112-27	22164-22173	cognitive	_	
112-28	22174-22185	impairments	_	
112-29	22185-22186	.	_	

#Text=This brain area has input and output connectivity with the supramodal cortex and functions as a mediator of information processing and information transfer during multiple cognitive operations.
113-1	22187-22191	This	_	
113-2	22192-22197	brain	_	
113-3	22198-22202	area	_	
113-4	22203-22206	has	_	
113-5	22207-22212	input	_	
113-6	22213-22216	and	_	
113-7	22217-22223	output	_	
113-8	22224-22236	connectivity	_	
113-9	22237-22241	with	_	
113-10	22242-22245	the	_	
113-11	22246-22256	supramodal	_	
113-12	22257-22263	cortex	_	
113-13	22264-22267	and	_	
113-14	22268-22277	functions	_	
113-15	22278-22280	as	_	
113-16	22281-22282	a	_	
113-17	22283-22291	mediator	_	
113-18	22292-22294	of	_	
113-19	22295-22306	information	_	
113-20	22307-22317	processing	_	
113-21	22318-22321	and	_	
113-22	22322-22333	information	_	
113-23	22334-22342	transfer	_	
113-24	22343-22349	during	_	
113-25	22350-22358	multiple	_	
113-26	22359-22368	cognitive	_	
113-27	22369-22379	operations	_	
113-28	22379-22380	.	_	

#Text=The right MFG region is involved in higher cognitive functions, such as multitasking, planning of future actions, strategic processes in memory recall, various executive functions, and social cognition.
114-1	22381-22384	The	_	
114-2	22385-22390	right	_	
114-3	22391-22394	MFG	_	
114-4	22395-22401	region	_	
114-5	22402-22404	is	_	
114-6	22405-22413	involved	_	
114-7	22414-22416	in	_	
114-8	22417-22423	higher	_	
114-9	22424-22433	cognitive	_	
114-10	22434-22443	functions	_	
114-11	22443-22444	,	_	
114-12	22445-22449	such	_	
114-13	22450-22452	as	_	
114-14	22453-22465	multitasking	_	
114-15	22465-22466	,	_	
114-16	22467-22475	planning	_	
114-17	22476-22478	of	_	
114-18	22479-22485	future	_	
114-19	22486-22493	actions	_	
114-20	22493-22494	,	_	
114-21	22495-22504	strategic	_	
114-22	22505-22514	processes	_	
114-23	22515-22517	in	_	
114-24	22518-22524	memory	_	
114-25	22525-22531	recall	_	
114-26	22531-22532	,	_	
114-27	22533-22540	various	_	
114-28	22541-22550	executive	_	
114-29	22551-22560	functions	_	
114-30	22560-22561	,	_	
114-31	22562-22565	and	_	
114-32	22566-22572	social	_	
114-33	22573-22582	cognition	_	
114-34	22582-22583	.	_	

#Text=Moreover, ReHo values of right MFG negatively correlated with social cognition in our study.
115-1	22584-22592	Moreover	_	
115-2	22592-22593	,	_	
115-3	22594-22598	ReHo	_	
115-4	22599-22605	values	_	
115-5	22606-22608	of	_	
115-6	22609-22614	right	_	
115-7	22615-22618	MFG	_	
115-8	22619-22629	negatively	_	
115-9	22630-22640	correlated	_	
115-10	22641-22645	with	_	
115-11	22646-22652	social	_	
115-12	22653-22662	cognition	_	
115-13	22663-22665	in	_	
115-14	22666-22669	our	_	
115-15	22670-22675	study	_	
115-16	22675-22676	.	_	

#Text=Social cognitive deficits in schizophrenia are broad, thereby imposing a huge burden on functional recovery.
116-1	22677-22683	Social	_	
116-2	22684-22693	cognitive	_	
116-3	22694-22702	deficits	_	
116-4	22703-22705	in	_	
116-5	22706-22719	schizophrenia	_	
116-6	22720-22723	are	_	
116-7	22724-22729	broad	_	
116-8	22729-22730	,	_	
116-9	22731-22738	thereby	_	
116-10	22739-22747	imposing	_	
116-11	22748-22749	a	_	
116-12	22750-22754	huge	_	
116-13	22755-22761	burden	_	
116-14	22762-22764	on	_	
116-15	22765-22775	functional	_	
116-16	22776-22784	recovery	_	
116-17	22784-22785	.	_	

#Text=Severe social cognitive deficits exist in patients with schizophrenia, and social cognitive deficits are associated with abnormal spontaneous activities of the medial PFC.
117-1	22786-22792	Severe	_	
117-2	22793-22799	social	_	
117-3	22800-22809	cognitive	_	
117-4	22810-22818	deficits	_	
117-5	22819-22824	exist	_	
117-6	22825-22827	in	_	
117-7	22828-22836	patients	_	
117-8	22837-22841	with	_	
117-9	22842-22855	schizophrenia	_	
117-10	22855-22856	,	_	
117-11	22857-22860	and	_	
117-12	22861-22867	social	_	
117-13	22868-22877	cognitive	_	
117-14	22878-22886	deficits	_	
117-15	22887-22890	are	_	
117-16	22891-22901	associated	_	
117-17	22902-22906	with	_	
117-18	22907-22915	abnormal	_	
117-19	22916-22927	spontaneous	_	
117-20	22928-22938	activities	_	
117-21	22939-22941	of	_	
117-22	22942-22945	the	_	
117-23	22946-22952	medial	_	
117-24	22953-22956	PFC	_	
117-25	22956-22957	.	_	

#Text=The PFC is an important regulator in social cognition, and the disruption in prefrontal microcircuitry is thought to play an essential role in pathophysiology of schizophrenia with social deficits.
118-1	22958-22961	The	_	
118-2	22962-22965	PFC	_	
118-3	22966-22968	is	_	
118-4	22969-22971	an	_	
118-5	22972-22981	important	_	
118-6	22982-22991	regulator	_	
118-7	22992-22994	in	_	
118-8	22995-23001	social	_	
118-9	23002-23011	cognition	_	
118-10	23011-23012	,	_	
118-11	23013-23016	and	_	
118-12	23017-23020	the	_	
118-13	23021-23031	disruption	_	
118-14	23032-23034	in	_	
118-15	23035-23045	prefrontal	_	
118-16	23046-23060	microcircuitry	_	
118-17	23061-23063	is	_	
118-18	23064-23071	thought	_	
118-19	23072-23074	to	_	
118-20	23075-23079	play	_	
118-21	23080-23082	an	_	
118-22	23083-23092	essential	_	
118-23	23093-23097	role	_	
118-24	23098-23100	in	_	
118-25	23101-23116	pathophysiology	_	
118-26	23117-23119	of	_	
118-27	23120-23133	schizophrenia	_	
118-28	23134-23138	with	_	
118-29	23139-23145	social	_	
118-30	23146-23154	deficits	_	
118-31	23154-23155	.	_	

#Text=In this study, we found that ReHo values of right MFG negatively correlated with attention impairments.
119-1	23156-23158	In	_	
119-2	23159-23163	this	_	
119-3	23164-23169	study	_	
119-4	23169-23170	,	_	
119-5	23171-23173	we	_	
119-6	23174-23179	found	_	
119-7	23180-23184	that	_	
119-8	23185-23189	ReHo	_	
119-9	23190-23196	values	_	
119-10	23197-23199	of	_	
119-11	23200-23205	right	_	
119-12	23206-23209	MFG	_	
119-13	23210-23220	negatively	_	
119-14	23221-23231	correlated	_	
119-15	23232-23236	with	_	
119-16	23237-23246	attention	_	
119-17	23247-23258	impairments	_	
119-18	23258-23259	.	_	

#Text=Attention deficits are core features of endophenotype of schizophrenia, which have yielded extensive researches.
120-1	23260-23269	Attention	_	
120-2	23270-23278	deficits	_	
120-3	23279-23282	are	_	
120-4	23283-23287	core	_	
120-5	23288-23296	features	_	
120-6	23297-23299	of	_	
120-7	23300-23313	endophenotype	_	
120-8	23314-23316	of	_	
120-9	23317-23330	schizophrenia	_	
120-10	23330-23331	,	_	
120-11	23332-23337	which	_	
120-12	23338-23342	have	_	
120-13	23343-23350	yielded	_	
120-14	23351-23360	extensive	_	
120-15	23361-23371	researches	_	
120-16	23371-23372	.	_	

#Text=The right MFG is considered the connecting area of ventral and dorsal attention networks, which plays a prominent role in attention regulation.
121-1	23373-23376	The	_	
121-2	23377-23382	right	_	
121-3	23383-23386	MFG	_	
121-4	23387-23389	is	_	
121-5	23390-23400	considered	_	
121-6	23401-23404	the	_	
121-7	23405-23415	connecting	_	
121-8	23416-23420	area	_	
121-9	23421-23423	of	_	
121-10	23424-23431	ventral	_	
121-11	23432-23435	and	_	
121-12	23436-23442	dorsal	_	
121-13	23443-23452	attention	_	
121-14	23453-23461	networks	_	
121-15	23461-23462	,	_	
121-16	23463-23468	which	_	
121-17	23469-23474	plays	_	
121-18	23475-23476	a	_	
121-19	23477-23486	prominent	_	
121-20	23487-23491	role	_	
121-21	23492-23494	in	_	
121-22	23495-23504	attention	_	
121-23	23505-23515	regulation	_	
121-24	23515-23516	.	_	

#Text=Our study found increased ReHo values in right SFG.
122-1	23517-23520	Our	_	
122-2	23521-23526	study	_	
122-3	23527-23532	found	_	
122-4	23533-23542	increased	_	
122-5	23543-23547	ReHo	_	
122-6	23548-23554	values	_	
122-7	23555-23557	in	_	
122-8	23558-23563	right	_	
122-9	23564-23567	SFG	_	
122-10	23567-23568	.	_	

#Text=A meta-analysis also showed increased ReHo values in the SFG in both patients with first-episode schizophrenia and with treated schizophrenia.
123-1	23569-23570	A	_	
123-2	23571-23584	meta-analysis	_	
123-3	23585-23589	also	_	
123-4	23590-23596	showed	_	
123-5	23597-23606	increased	_	
123-6	23607-23611	ReHo	_	
123-7	23612-23618	values	_	
123-8	23619-23621	in	_	
123-9	23622-23625	the	_	
123-10	23626-23629	SFG	_	
123-11	23630-23632	in	_	
123-12	23633-23637	both	_	
123-13	23638-23646	patients	_	
123-14	23647-23651	with	_	
123-15	23652-23665	first-episode	_	
123-16	23666-23679	schizophrenia	_	
123-17	23680-23683	and	_	
123-18	23684-23688	with	_	
123-19	23689-23696	treated	_	
123-20	23697-23710	schizophrenia	_	
123-21	23710-23711	.	_	

#Text=The SFG is a significant component of the DLPFC.
124-1	23712-23715	The	_	
124-2	23716-23719	SFG	_	
124-3	23720-23722	is	_	
124-4	23723-23724	a	_	
124-5	23725-23736	significant	_	
124-6	23737-23746	component	_	
124-7	23747-23749	of	_	
124-8	23750-23753	the	_	
124-9	23754-23759	DLPFC	_	
124-10	23759-23760	.	_	

#Text=The DLPFC is well-known for its involvement in executive functions, and in fact, it is also involved in risky and moral decision-making, working memory, and social cognition.
125-1	23761-23764	The	_	
125-2	23765-23770	DLPFC	_	
125-3	23771-23773	is	_	
125-4	23774-23784	well-known	_	
125-5	23785-23788	for	_	
125-6	23789-23792	its	_	
125-7	23793-23804	involvement	_	
125-8	23805-23807	in	_	
125-9	23808-23817	executive	_	
125-10	23818-23827	functions	_	
125-11	23827-23828	,	_	
125-12	23829-23832	and	_	
125-13	23833-23835	in	_	
125-14	23836-23840	fact	_	
125-15	23840-23841	,	_	
125-16	23842-23844	it	_	
125-17	23845-23847	is	_	
125-18	23848-23852	also	_	
125-19	23853-23861	involved	_	
125-20	23862-23864	in	_	
125-21	23865-23870	risky	_	
125-22	23871-23874	and	_	
125-23	23875-23880	moral	_	
125-24	23881-23896	decision-making	_	
125-25	23896-23897	,	_	
125-26	23898-23905	working	_	
125-27	23906-23912	memory	_	
125-28	23912-23913	,	_	
125-29	23914-23917	and	_	
125-30	23918-23924	social	_	
125-31	23925-23934	cognition	_	
125-32	23934-23935	.	_	

#Text=Abnormal neuronal activities in the DLPFC are associated with auditory hallucinations in schizophrenia and other advanced cognitive functions.
126-1	23936-23944	Abnormal	_	
126-2	23945-23953	neuronal	_	
126-3	23954-23964	activities	_	
126-4	23965-23967	in	_	
126-5	23968-23971	the	_	
126-6	23972-23977	DLPFC	_	
126-7	23978-23981	are	_	
126-8	23982-23992	associated	_	
126-9	23993-23997	with	_	
126-10	23998-24006	auditory	_	
126-11	24007-24021	hallucinations	_	
126-12	24022-24024	in	_	
126-13	24025-24038	schizophrenia	_	
126-14	24039-24042	and	_	
126-15	24043-24048	other	_	
126-16	24049-24057	advanced	_	
126-17	24058-24067	cognitive	_	
126-18	24068-24077	functions	_	
126-19	24077-24078	.	_	

#Text=However, in our study, ReHo values in the DLPFC did not significantly correlate with the MCCB and PANSS scores in the dn-FES group, which is affected by many factors, including the size and heterogeneity of samples and different indicators of spontaneous brain activities.
127-1	24079-24086	However	_	
127-2	24086-24087	,	_	
127-3	24088-24090	in	_	
127-4	24091-24094	our	_	
127-5	24095-24100	study	_	
127-6	24100-24101	,	_	
127-7	24102-24106	ReHo	_	
127-8	24107-24113	values	_	
127-9	24114-24116	in	_	
127-10	24117-24120	the	_	
127-11	24121-24126	DLPFC	_	
127-12	24127-24130	did	_	
127-13	24131-24134	not	_	
127-14	24135-24148	significantly	_	
127-15	24149-24158	correlate	_	
127-16	24159-24163	with	_	
127-17	24164-24167	the	_	
127-18	24168-24172	MCCB	_	
127-19	24173-24176	and	_	
127-20	24177-24182	PANSS	_	
127-21	24183-24189	scores	_	
127-22	24190-24192	in	_	
127-23	24193-24196	the	_	
127-24	24197-24203	dn-FES	_	
127-25	24204-24209	group	_	
127-26	24209-24210	,	_	
127-27	24211-24216	which	_	
127-28	24217-24219	is	_	
127-29	24220-24228	affected	_	
127-30	24229-24231	by	_	
127-31	24232-24236	many	_	
127-32	24237-24244	factors	_	
127-33	24244-24245	,	_	
127-34	24246-24255	including	_	
127-35	24256-24259	the	_	
127-36	24260-24264	size	_	
127-37	24265-24268	and	_	
127-38	24269-24282	heterogeneity	_	
127-39	24283-24285	of	_	
127-40	24286-24293	samples	_	
127-41	24294-24297	and	_	
127-42	24298-24307	different	_	
127-43	24308-24318	indicators	_	
127-44	24319-24321	of	_	
127-45	24322-24333	spontaneous	_	
127-46	24334-24339	brain	_	
127-47	24340-24350	activities	_	
127-48	24350-24351	.	_	

#Text=Limitations
#Text=Current research has several limitations that should be improved in future research.
128-1	24352-24363	Limitations	_	
128-2	24364-24371	Current	_	
128-3	24372-24380	research	_	
128-4	24381-24384	has	_	
128-5	24385-24392	several	_	
128-6	24393-24404	limitations	_	
128-7	24405-24409	that	_	
128-8	24410-24416	should	_	
128-9	24417-24419	be	_	
128-10	24420-24428	improved	_	
128-11	24429-24431	in	_	
128-12	24432-24438	future	_	
128-13	24439-24447	research	_	
128-14	24447-24448	.	_	

#Text=First, the sample size is insufficient, although it is already more than that of most fMRI studies on first-episode schizophrenia to date, and our results could accept more stringent multiple comparison corrections.
129-1	24449-24454	First	_	
129-2	24454-24455	,	_	
129-3	24456-24459	the	_	
129-4	24460-24466	sample	_	
129-5	24467-24471	size	_	
129-6	24472-24474	is	_	
129-7	24475-24487	insufficient	_	
129-8	24487-24488	,	_	
129-9	24489-24497	although	_	
129-10	24498-24500	it	_	
129-11	24501-24503	is	_	
129-12	24504-24511	already	_	
129-13	24512-24516	more	_	
129-14	24517-24521	than	_	
129-15	24522-24526	that	_	
129-16	24527-24529	of	_	
129-17	24530-24534	most	_	
129-18	24535-24539	fMRI	_	
129-19	24540-24547	studies	_	
129-20	24548-24550	on	_	
129-21	24551-24564	first-episode	_	
129-22	24565-24578	schizophrenia	_	
129-23	24579-24581	to	_	
129-24	24582-24586	date	_	
129-25	24586-24587	,	_	
129-26	24588-24591	and	_	
129-27	24592-24595	our	_	
129-28	24596-24603	results	_	
129-29	24604-24609	could	_	
129-30	24610-24616	accept	_	
129-31	24617-24621	more	_	
129-32	24622-24631	stringent	_	
129-33	24632-24640	multiple	_	
129-34	24641-24651	comparison	_	
129-35	24652-24663	corrections	_	
129-36	24663-24664	.	_	

#Text=Second, we did not follow up these patients with schizophrenia, and hence, we were unable to determine the exact characteristics of brain changes and cognitive outcomes in schizophrenia and whether abnormal ReHo was a cause or a consequence of schizophrenia.
130-1	24665-24671	Second	_	
130-2	24671-24672	,	_	
130-3	24673-24675	we	_	
130-4	24676-24679	did	_	
130-5	24680-24683	not	_	
130-6	24684-24690	follow	_	
130-7	24691-24693	up	_	
130-8	24694-24699	these	_	
130-9	24700-24708	patients	_	
130-10	24709-24713	with	_	
130-11	24714-24727	schizophrenia	_	
130-12	24727-24728	,	_	
130-13	24729-24732	and	_	
130-14	24733-24738	hence	_	
130-15	24738-24739	,	_	
130-16	24740-24742	we	_	
130-17	24743-24747	were	_	
130-18	24748-24754	unable	_	
130-19	24755-24757	to	_	
130-20	24758-24767	determine	_	
130-21	24768-24771	the	_	
130-22	24772-24777	exact	_	
130-23	24778-24793	characteristics	_	
130-24	24794-24796	of	_	
130-25	24797-24802	brain	_	
130-26	24803-24810	changes	_	
130-27	24811-24814	and	_	
130-28	24815-24824	cognitive	_	
130-29	24825-24833	outcomes	_	
130-30	24834-24836	in	_	
130-31	24837-24850	schizophrenia	_	
130-32	24851-24854	and	_	
130-33	24855-24862	whether	_	
130-34	24863-24871	abnormal	_	
130-35	24872-24876	ReHo	_	
130-36	24877-24880	was	_	
130-37	24881-24882	a	_	
130-38	24883-24888	cause	_	
130-39	24889-24891	or	_	
130-40	24892-24893	a	_	
130-41	24894-24905	consequence	_	
130-42	24906-24908	of	_	
130-43	24909-24922	schizophrenia	_	
130-44	24922-24923	.	_	

#Text=Lastly, patients who could not keep their heads stable or complete all the cognitive tests were excluded from the study, which made the results unrepresentative to some extent.
131-1	24924-24930	Lastly	_	
131-2	24930-24931	,	_	
131-3	24932-24940	patients	_	
131-4	24941-24944	who	_	
131-5	24945-24950	could	_	
131-6	24951-24954	not	_	
131-7	24955-24959	keep	_	
131-8	24960-24965	their	_	
131-9	24966-24971	heads	_	
131-10	24972-24978	stable	_	
131-11	24979-24981	or	_	
131-12	24982-24990	complete	_	
131-13	24991-24994	all	_	
131-14	24995-24998	the	_	
131-15	24999-25008	cognitive	_	
131-16	25009-25014	tests	_	
131-17	25015-25019	were	_	
131-18	25020-25028	excluded	_	
131-19	25029-25033	from	_	
131-20	25034-25037	the	_	
131-21	25038-25043	study	_	
131-22	25043-25044	,	_	
131-23	25045-25050	which	_	
131-24	25051-25055	made	_	
131-25	25056-25059	the	_	
131-26	25060-25067	results	_	
131-27	25068-25084	unrepresentative	_	
131-28	25085-25087	to	_	
131-29	25088-25092	some	_	
131-30	25093-25099	extent	_	
131-31	25099-25100	.	_	

#Text=Conclusions
#Text=In conclusion, these findings indicate that increased ReHo values in right MFG and SFG are present even at the early stages of dn-FES, The frontal aberrations may be concerned with vulnerability to psychosis.
132-1	25101-25112	Conclusions	_	
132-2	25113-25115	In	_	
132-3	25116-25126	conclusion	_	
132-4	25126-25127	,	_	
132-5	25128-25133	these	_	
132-6	25134-25142	findings	_	
132-7	25143-25151	indicate	_	
132-8	25152-25156	that	_	
132-9	25157-25166	increased	_	
132-10	25167-25171	ReHo	_	
132-11	25172-25178	values	_	
132-12	25179-25181	in	_	
132-13	25182-25187	right	_	
132-14	25188-25191	MFG	_	
132-15	25192-25195	and	_	
132-16	25196-25199	SFG	_	
132-17	25200-25203	are	_	
132-18	25204-25211	present	_	
132-19	25212-25216	even	_	
132-20	25217-25219	at	_	
132-21	25220-25223	the	_	
132-22	25224-25229	early	_	
132-23	25230-25236	stages	_	
132-24	25237-25239	of	_	
132-25	25240-25246	dn-FES	_	
132-26	25246-25247	,	_	
132-27	25248-25251	The	_	
132-28	25252-25259	frontal	_	
132-29	25260-25271	aberrations	_	
132-30	25272-25275	may	_	
132-31	25276-25278	be	_	
132-32	25279-25288	concerned	_	
132-33	25289-25293	with	_	
132-34	25294-25307	vulnerability	_	
132-35	25308-25310	to	_	
132-36	25311-25320	psychosis	_	
132-37	25320-25321	.	_	

#Text=The abnormal regional spontaneous neuronal activities revealed by ReHo values in right MFG are related not only to the negative and positive symptoms of schizophrenia, but also to attention and cognition deficits.
133-1	25322-25325	The	_	
133-2	25326-25334	abnormal	_	
133-3	25335-25343	regional	_	
133-4	25344-25355	spontaneous	_	
133-5	25356-25364	neuronal	_	
133-6	25365-25375	activities	_	
133-7	25376-25384	revealed	_	
133-8	25385-25387	by	_	
133-9	25388-25392	ReHo	_	
133-10	25393-25399	values	_	
133-11	25400-25402	in	_	
133-12	25403-25408	right	_	
133-13	25409-25412	MFG	_	
133-14	25413-25416	are	_	
133-15	25417-25424	related	_	
133-16	25425-25428	not	_	
133-17	25429-25433	only	_	
133-18	25434-25436	to	_	
133-19	25437-25440	the	_	
133-20	25441-25449	negative	_	
133-21	25450-25453	and	_	
133-22	25454-25462	positive	_	
133-23	25463-25471	symptoms	_	
133-24	25472-25474	of	_	
133-25	25475-25488	schizophrenia	_	
133-26	25488-25489	,	_	
133-27	25490-25493	but	_	
133-28	25494-25498	also	_	
133-29	25499-25501	to	_	
133-30	25502-25511	attention	_	
133-31	25512-25515	and	_	
133-32	25516-25525	cognition	_	
133-33	25526-25534	deficits	_	
133-34	25534-25535	.	_	

#Text=These functional brain changes may reflect a clinical moderators including illness severity and cognitive deficits.
134-1	25536-25541	These	_	
134-2	25542-25552	functional	_	
134-3	25553-25558	brain	_	
134-4	25559-25566	changes	_	
134-5	25567-25570	may	_	
134-6	25571-25578	reflect	_	
134-7	25579-25580	a	_	
134-8	25581-25589	clinical	_	
134-9	25590-25600	moderators	_	
134-10	25601-25610	including	_	
134-11	25611-25618	illness	_	
134-12	25619-25627	severity	_	
134-13	25628-25631	and	_	
134-14	25632-25641	cognitive	_	
134-15	25642-25650	deficits	_	
134-16	25650-25651	.	_	

#Text=This finding suggests that altered spontaneous brain activities in frontal cortex may reflect neuropathological characteristics of schizophrenia.
135-1	25652-25656	This	_	
135-2	25657-25664	finding	_	
135-3	25665-25673	suggests	_	
135-4	25674-25678	that	_	
135-5	25679-25686	altered	_	
135-6	25687-25698	spontaneous	_	
135-7	25699-25704	brain	_	
135-8	25705-25715	activities	_	
135-9	25716-25718	in	_	
135-10	25719-25726	frontal	_	
135-11	25727-25733	cortex	_	
135-12	25734-25737	may	_	
135-13	25738-25745	reflect	_	
135-14	25746-25763	neuropathological	_	
135-15	25764-25779	characteristics	_	
135-16	25780-25782	of	_	
135-17	25783-25796	schizophrenia	_	
135-18	25796-25797	.	_	

#Text=Meanwhile, it serves as a basis for establishing objective diagnostic markers and clinical intervention target.
136-1	25798-25807	Meanwhile	_	
136-2	25807-25808	,	_	
136-3	25809-25811	it	_	
136-4	25812-25818	serves	_	
136-5	25819-25821	as	_	
136-6	25822-25823	a	_	
136-7	25824-25829	basis	_	
136-8	25830-25833	for	_	
136-9	25834-25846	establishing	_	
136-10	25847-25856	objective	_	
136-11	25857-25867	diagnostic	_	
136-12	25868-25875	markers	_	
136-13	25876-25879	and	_	
136-14	25880-25888	clinical	_	
136-15	25889-25901	intervention	_	
136-16	25902-25908	target	_	
136-17	25908-25909	.	_	

#Text=Abbreviations
#Text=BA
#Text=Brodmann Area
#Text=DLPFC
#Text=Dorsolateral Prefrontal Cortex
#Text=dn-FES
#Text=Drug-naive First-Episode Schizophrenia
#Text=FWE
#Text=Family Wise-Error
#Text=MATRICS
#Text=Measurement and Treatment Research to Improve Cognition in Schizophrenia
#Text=MCCB
#Text=MATRICS Consensus Cognitive Battery
#Text=PFC
#Text=Prefrontal Cortex
#Text=MFG
#Text=Middle Frontal Gyrus
#Text=PANSS
#Text=Positive And Negative Syndrome Scale
#Text=ReHo
#Text=Regional Homogeneity
#Text=rs-fMRI
#Text=Resting state functional Magnetic Resonance Imaging
#Text=SFG
#Text=Superior Frontal Gyrus
#Text=TFCE
#Text=Threshold-Free Cluster Enhancement
#Text=WAIS
#Text=Wechsler Adult Intelligence Scale
#Text=Publisher’s Note
#Text=Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
137-1	25910-25923	Abbreviations	_	
137-2	25924-25926	BA	_	
137-3	25927-25935	Brodmann	_	
137-4	25936-25940	Area	_	
137-5	25941-25946	DLPFC	_	
137-6	25947-25959	Dorsolateral	_	
137-7	25960-25970	Prefrontal	_	
137-8	25971-25977	Cortex	_	
137-9	25978-25984	dn-FES	_	
137-10	25985-25995	Drug-naive	_	
137-11	25996-26009	First-Episode	_	
137-12	26010-26023	Schizophrenia	_	
137-13	26024-26027	FWE	_	
137-14	26028-26034	Family	_	
137-15	26035-26045	Wise-Error	_	
137-16	26046-26053	MATRICS	_	
137-17	26054-26065	Measurement	_	
137-18	26066-26069	and	_	
137-19	26070-26079	Treatment	_	
137-20	26080-26088	Research	_	
137-21	26089-26091	to	_	
137-22	26092-26099	Improve	_	
137-23	26100-26109	Cognition	_	
137-24	26110-26112	in	_	
137-25	26113-26126	Schizophrenia	_	
137-26	26127-26131	MCCB	_	
137-27	26132-26139	MATRICS	_	
137-28	26140-26149	Consensus	_	
137-29	26150-26159	Cognitive	_	
137-30	26160-26167	Battery	_	
137-31	26168-26171	PFC	_	
137-32	26172-26182	Prefrontal	_	
137-33	26183-26189	Cortex	_	
137-34	26190-26193	MFG	_	
137-35	26194-26200	Middle	_	
137-36	26201-26208	Frontal	_	
137-37	26209-26214	Gyrus	_	
137-38	26215-26220	PANSS	_	
137-39	26221-26229	Positive	_	
137-40	26230-26233	And	_	
137-41	26234-26242	Negative	_	
137-42	26243-26251	Syndrome	_	
137-43	26252-26257	Scale	_	
137-44	26258-26262	ReHo	_	
137-45	26263-26271	Regional	_	
137-46	26272-26283	Homogeneity	_	
137-47	26284-26291	rs-fMRI	_	
137-48	26292-26299	Resting	_	
137-49	26300-26305	state	_	
137-50	26306-26316	functional	_	
137-51	26317-26325	Magnetic	_	
137-52	26326-26335	Resonance	_	
137-53	26336-26343	Imaging	_	
137-54	26344-26347	SFG	_	
137-55	26348-26356	Superior	_	
137-56	26357-26364	Frontal	_	
137-57	26365-26370	Gyrus	_	
137-58	26371-26375	TFCE	_	
137-59	26376-26390	Threshold-Free	_	
137-60	26391-26398	Cluster	_	
137-61	26399-26410	Enhancement	_	
137-62	26411-26415	WAIS	_	
137-63	26416-26424	Wechsler	_	
137-64	26425-26430	Adult	_	
137-65	26431-26443	Intelligence	_	
137-66	26444-26449	Scale	_	
137-67	26450-26459	Publisher	_	
137-68	26459-26460	’	_	
137-69	26460-26461	s	_	
137-70	26462-26466	Note	_	
137-71	26467-26475	Springer	_	
137-72	26476-26482	Nature	_	
137-73	26483-26490	remains	_	
137-74	26491-26498	neutral	_	
137-75	26499-26503	with	_	
137-76	26504-26510	regard	_	
137-77	26511-26513	to	_	
137-78	26514-26528	jurisdictional	_	
137-79	26529-26535	claims	_	
137-80	26536-26538	in	_	
137-81	26539-26548	published	_	
137-82	26549-26553	maps	_	
137-83	26554-26557	and	_	
137-84	26558-26571	institutional	_	
137-85	26572-26584	affiliations	_	
137-86	26584-26585	.	_	

#Text=Wei Yan and Rongrong Zhang contributed equally to this work.
138-1	26586-26589	Wei	_	
138-2	26590-26593	Yan	_	
138-3	26594-26597	and	_	
138-4	26598-26606	Rongrong	_	
138-5	26607-26612	Zhang	_	
138-6	26613-26624	contributed	_	
138-7	26625-26632	equally	_	
138-8	26633-26635	to	_	
138-9	26636-26640	this	_	
138-10	26641-26645	work	_	
138-11	26645-26646	.	_	

#Text=Authors’ contributions
#Text=N.Z. and S.X. designed the study.
139-1	26647-26654	Authors	_	
139-2	26654-26655	’	_	
139-3	26656-26669	contributions	_	
139-4	26670-26673	N.Z	_	
139-5	26673-26674	.	_	
139-6	26675-26678	and	_	
139-7	26679-26682	S.X	_	
139-8	26682-26683	.	_	
139-9	26684-26692	designed	_	
139-10	26693-26696	the	_	
139-11	26697-26702	study	_	
139-12	26702-26703	.	_	

#Text=M.Z. and S.L. collected the data.
140-1	26704-26707	M.Z	_	
140-2	26707-26708	.	_	
140-3	26709-26712	and	_	
140-4	26713-26716	S.L	_	
140-5	26716-26717	.	_	
140-6	26718-26727	collected	_	
140-7	26728-26731	the	_	
140-8	26732-26736	data	_	
140-9	26736-26737	.	_	

#Text=W.Y., R.Z. and W.L. analyzed the data and wrote the manuscript.
141-1	26738-26741	W.Y	_	
141-2	26741-26742	.	_	
141-3	26742-26743	,	_	
141-4	26744-26747	R.Z	_	
141-5	26747-26748	.	_	
141-6	26749-26752	and	_	
141-7	26753-26756	W.L	_	
141-8	26756-26757	.	_	
141-9	26758-26766	analyzed	_	
141-10	26767-26770	the	_	
141-11	26771-26775	data	_	
141-12	26776-26779	and	_	
141-13	26780-26785	wrote	_	
141-14	26786-26789	the	_	
141-15	26790-26800	manuscript	_	
141-16	26800-26801	.	_	

#Text=N.Z. and S.X. revised the manuscript.
142-1	26802-26805	N.Z	_	
142-2	26805-26806	.	_	
142-3	26807-26810	and	_	
142-4	26811-26814	S.X	_	
142-5	26814-26815	.	_	
142-6	26816-26823	revised	_	
142-7	26824-26827	the	_	
142-8	26828-26838	manuscript	_	
142-9	26838-26839	.	_	

#Text=All authors reviewed the manuscript.
143-1	26840-26843	All	_	
143-2	26844-26851	authors	_	
143-3	26852-26860	reviewed	_	
143-4	26861-26864	the	_	
143-5	26865-26875	manuscript	_	
143-6	26875-26876	.	_	

#Text=Funding
#Text=This study was partially supported by the Key Project of Nanjing Municipal Bureau of Health Commission (ZKX15033), the General Program of Jiangsu commission of health (H2017051), and the Ministry of Science and Technology of China, National Key R&D Program of China (2016YFC1306805).
144-1	26877-26884	Funding	_	
144-2	26885-26889	This	_	
144-3	26890-26895	study	_	
144-4	26896-26899	was	_	
144-5	26900-26909	partially	_	
144-6	26910-26919	supported	_	
144-7	26920-26922	by	_	
144-8	26923-26926	the	_	
144-9	26927-26930	Key	_	
144-10	26931-26938	Project	_	
144-11	26939-26941	of	_	
144-12	26942-26949	Nanjing	_	
144-13	26950-26959	Municipal	_	
144-14	26960-26966	Bureau	_	
144-15	26967-26969	of	_	
144-16	26970-26976	Health	_	
144-17	26977-26987	Commission	_	
144-18	26988-26989	(	_	
144-19	26989-26997	ZKX15033	_	
144-20	26997-26998	)	_	
144-21	26998-26999	,	_	
144-22	27000-27003	the	_	
144-23	27004-27011	General	_	
144-24	27012-27019	Program	_	
144-25	27020-27022	of	_	
144-26	27023-27030	Jiangsu	_	
144-27	27031-27041	commission	_	
144-28	27042-27044	of	_	
144-29	27045-27051	health	_	
144-30	27052-27053	(	_	
144-31	27053-27061	H2017051	_	
144-32	27061-27062	)	_	
144-33	27062-27063	,	_	
144-34	27064-27067	and	_	
144-35	27068-27071	the	_	
144-36	27072-27080	Ministry	_	
144-37	27081-27083	of	_	
144-38	27084-27091	Science	_	
144-39	27092-27095	and	_	
144-40	27096-27106	Technology	_	
144-41	27107-27109	of	_	
144-42	27110-27115	China	_	
144-43	27115-27116	,	_	
144-44	27117-27125	National	_	
144-45	27126-27129	Key	_	
144-46	27130-27131	R	_	
144-47	27131-27132	&	_	
144-48	27132-27133	D	_	
144-49	27134-27141	Program	_	
144-50	27142-27144	of	_	
144-51	27145-27150	China	_	
144-52	27151-27152	(	_	
144-53	27152-27166	2016YFC1306805	_	
144-54	27166-27167	)	_	
144-55	27167-27168	.	_	

#Text=These institutions had no role in the design of the study and collection, analysis, and interpretation of data and writing of the manuscript.
145-1	27169-27174	These	_	
145-2	27175-27187	institutions	_	
145-3	27188-27191	had	_	
145-4	27192-27194	no	_	
145-5	27195-27199	role	_	
145-6	27200-27202	in	_	
145-7	27203-27206	the	_	
145-8	27207-27213	design	_	
145-9	27214-27216	of	_	
145-10	27217-27220	the	_	
145-11	27221-27226	study	_	
145-12	27227-27230	and	_	
145-13	27231-27241	collection	_	
145-14	27241-27242	,	_	
145-15	27243-27251	analysis	_	
145-16	27251-27252	,	_	
145-17	27253-27256	and	_	
145-18	27257-27271	interpretation	_	
145-19	27272-27274	of	_	
145-20	27275-27279	data	_	
145-21	27280-27283	and	_	
145-22	27284-27291	writing	_	
145-23	27292-27294	of	_	
145-24	27295-27298	the	_	
145-25	27299-27309	manuscript	_	
145-26	27309-27310	.	_	

#Text=Availability of data and materials
#Text=The data sets used and /or analyzed during the present study are available from the corresponding author on reasonable request.
146-1	27311-27323	Availability	_	
146-2	27324-27326	of	_	
146-3	27327-27331	data	_	
146-4	27332-27335	and	_	
146-5	27336-27345	materials	_	
146-6	27346-27349	The	_	
146-7	27350-27354	data	_	
146-8	27355-27359	sets	_	
146-9	27360-27364	used	_	
146-10	27365-27368	and	_	
146-11	27369-27370	/	_	
146-12	27370-27372	or	_	
146-13	27373-27381	analyzed	_	
146-14	27382-27388	during	_	
146-15	27389-27392	the	_	
146-16	27393-27400	present	_	
146-17	27401-27406	study	_	
146-18	27407-27410	are	_	
146-19	27411-27420	available	_	
146-20	27421-27425	from	_	
146-21	27426-27429	the	_	
146-22	27430-27443	corresponding	_	
146-23	27444-27450	author	_	
146-24	27451-27453	on	_	
146-25	27454-27464	reasonable	_	
146-26	27465-27472	request	_	
146-27	27472-27473	.	_	

#Text=Ethics approval and consent to participate
#Text=All research procedures were approved by the Medical Research Ethics Committee of Nanjing Brain Hospital, and were conducted in accordance with the 1964 Helsinki declaration and its later amendments.
147-1	27474-27480	Ethics	_	
147-2	27481-27489	approval	_	
147-3	27490-27493	and	_	
147-4	27494-27501	consent	_	
147-5	27502-27504	to	_	
147-6	27505-27516	participate	_	
147-7	27517-27520	All	_	
147-8	27521-27529	research	_	
147-9	27530-27540	procedures	_	
147-10	27541-27545	were	_	
147-11	27546-27554	approved	_	
147-12	27555-27557	by	_	
147-13	27558-27561	the	_	
147-14	27562-27569	Medical	_	
147-15	27570-27578	Research	_	
147-16	27579-27585	Ethics	_	
147-17	27586-27595	Committee	_	
147-18	27596-27598	of	_	
147-19	27599-27606	Nanjing	_	
147-20	27607-27612	Brain	_	
147-21	27613-27621	Hospital	_	
147-22	27621-27622	,	_	
147-23	27623-27626	and	_	
147-24	27627-27631	were	_	
147-25	27632-27641	conducted	_	
147-26	27642-27644	in	_	
147-27	27645-27655	accordance	_	
147-28	27656-27660	with	_	
147-29	27661-27664	the	_	
147-30	27665-27669	1964	_	
147-31	27670-27678	Helsinki	_	
147-32	27679-27690	declaration	_	
147-33	27691-27694	and	_	
147-34	27695-27698	its	_	
147-35	27699-27704	later	_	
147-36	27705-27715	amendments	_	
147-37	27715-27716	.	_	

#Text=Written informed consent of the schizophrenic patient was obtained from his/her legally authorized representative and the control provided written informed consent himself/herself after totally understanding the purpose of our study.
148-1	27717-27724	Written	_	
148-2	27725-27733	informed	_	
148-3	27734-27741	consent	_	
148-4	27742-27744	of	_	
148-5	27745-27748	the	_	
148-6	27749-27762	schizophrenic	_	
148-7	27763-27770	patient	_	
148-8	27771-27774	was	_	
148-9	27775-27783	obtained	_	
148-10	27784-27788	from	_	
148-11	27789-27792	his	_	
148-12	27792-27793	/	_	
148-13	27793-27796	her	_	
148-14	27797-27804	legally	_	
148-15	27805-27815	authorized	_	
148-16	27816-27830	representative	_	
148-17	27831-27834	and	_	
148-18	27835-27838	the	_	
148-19	27839-27846	control	_	
148-20	27847-27855	provided	_	
148-21	27856-27863	written	_	
148-22	27864-27872	informed	_	
148-23	27873-27880	consent	_	
148-24	27881-27888	himself	_	
148-25	27888-27889	/	_	
148-26	27889-27896	herself	_	
148-27	27897-27902	after	_	
148-28	27903-27910	totally	_	
148-29	27911-27924	understanding	_	
148-30	27925-27928	the	_	
148-31	27929-27936	purpose	_	
148-32	27937-27939	of	_	
148-33	27940-27943	our	_	
148-34	27944-27949	study	_	
148-35	27949-27950	.	_	

#Text=Consent for publication
#Text=Not applicable.
149-1	27951-27958	Consent	_	
149-2	27959-27962	for	_	
149-3	27963-27974	publication	_	
149-4	27975-27978	Not	_	
149-5	27979-27989	applicable	_	
149-6	27989-27990	.	_	

#Text=Competing interests
#Text=The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
150-1	27991-28000	Competing	_	
150-2	28001-28010	interests	_	
150-3	28011-28014	The	_	
150-4	28015-28022	authors	_	
150-5	28023-28030	declare	_	
150-6	28031-28035	that	_	
150-7	28036-28039	the	_	
150-8	28040-28048	research	_	
150-9	28049-28052	was	_	
150-10	28053-28062	conducted	_	
150-11	28063-28065	in	_	
150-12	28066-28069	the	_	
150-13	28070-28077	absence	_	
150-14	28078-28080	of	_	
150-15	28081-28084	any	_	
150-16	28085-28095	commercial	_	
150-17	28096-28098	or	_	
150-18	28099-28108	financial	_	
150-19	28109-28122	relationships	_	
150-20	28123-28127	that	_	
150-21	28128-28133	could	_	
150-22	28134-28136	be	_	
150-23	28137-28146	construed	_	
150-24	28147-28149	as	_	
150-25	28150-28151	a	_	
150-26	28152-28161	potential	_	
150-27	28162-28170	conflict	_	
150-28	28171-28173	of	_	
150-29	28174-28182	interest	_	
150-30	28182-28183	.	_	

#Text=References
#Text=Prevalence of mental disorders in China: a cross-sectional epidemiological study
#Text=Cognitive deficits in schizophrenia: understanding the biological correlates and remediation strategies
#Text=The MATRICS consensus cognitive battery, part 2: co-norming and standardization
#Text=The MATRICS consensus cognitive battery, part 1: test selection, reliability, and validity
#Text=Amplitude of low-frequency fluctuation (ALFF) may be associated with cognitive impairment in schizophrenia: a correlation study
#Text=Cognitive improvement in first-episode schizophrenia and healthy controls: a 6-year multi-assessment follow-up study
#Text=Relationships between dorsolateral prefrontal cortex metabolic change and cognitive impairment in first-episode neuroleptic-naive schizophrenia patients
#Text=Contribution of IL-10 and its −592 a/C polymorphism to cognitive functions in first-episode drug-naive schizophrenia
#Text=Xiu MH, Guan HY, Zhao JM, Wang KQ, Pan YF, Su XR, Wang YH, Guo JM, Jiang L, Liu HY, et al.
151-1	28184-28194	References	_	
151-2	28195-28205	Prevalence	_	
151-3	28206-28208	of	_	
151-4	28209-28215	mental	_	
151-5	28216-28225	disorders	_	
151-6	28226-28228	in	_	
151-7	28229-28234	China	_	
151-8	28234-28235	:	_	
151-9	28236-28237	a	_	
151-10	28238-28253	cross-sectional	_	
151-11	28254-28269	epidemiological	_	
151-12	28270-28275	study	_	
151-13	28276-28285	Cognitive	_	
151-14	28286-28294	deficits	_	
151-15	28295-28297	in	_	
151-16	28298-28311	schizophrenia	_	
151-17	28311-28312	:	_	
151-18	28313-28326	understanding	_	
151-19	28327-28330	the	_	
151-20	28331-28341	biological	_	
151-21	28342-28352	correlates	_	
151-22	28353-28356	and	_	
151-23	28357-28368	remediation	_	
151-24	28369-28379	strategies	_	
151-25	28380-28383	The	_	
151-26	28384-28391	MATRICS	_	
151-27	28392-28401	consensus	_	
151-28	28402-28411	cognitive	_	
151-29	28412-28419	battery	_	
151-30	28419-28420	,	_	
151-31	28421-28425	part	_	
151-32	28426-28427	2	_	
151-33	28427-28428	:	_	
151-34	28429-28439	co-norming	_	
151-35	28440-28443	and	_	
151-36	28444-28459	standardization	_	
151-37	28460-28463	The	_	
151-38	28464-28471	MATRICS	_	
151-39	28472-28481	consensus	_	
151-40	28482-28491	cognitive	_	
151-41	28492-28499	battery	_	
151-42	28499-28500	,	_	
151-43	28501-28505	part	_	
151-44	28506-28507	1	_	
151-45	28507-28508	:	_	
151-46	28509-28513	test	_	
151-47	28514-28523	selection	_	
151-48	28523-28524	,	_	
151-49	28525-28536	reliability	_	
151-50	28536-28537	,	_	
151-51	28538-28541	and	_	
151-52	28542-28550	validity	_	
151-53	28551-28560	Amplitude	_	
151-54	28561-28563	of	_	
151-55	28564-28577	low-frequency	_	
151-56	28578-28589	fluctuation	_	
151-57	28590-28591	(	_	
151-58	28591-28595	ALFF	_	
151-59	28595-28596	)	_	
151-60	28597-28600	may	_	
151-61	28601-28603	be	_	
151-62	28604-28614	associated	_	
151-63	28615-28619	with	_	
151-64	28620-28629	cognitive	_	
151-65	28630-28640	impairment	_	
151-66	28641-28643	in	_	
151-67	28644-28657	schizophrenia	_	
151-68	28657-28658	:	_	
151-69	28659-28660	a	_	
151-70	28661-28672	correlation	_	
151-71	28673-28678	study	_	
151-72	28679-28688	Cognitive	_	
151-73	28689-28700	improvement	_	
151-74	28701-28703	in	_	
151-75	28704-28717	first-episode	_	
151-76	28718-28731	schizophrenia	_	
151-77	28732-28735	and	_	
151-78	28736-28743	healthy	_	
151-79	28744-28752	controls	_	
151-80	28752-28753	:	_	
151-81	28754-28755	a	_	
151-82	28756-28757	6	_	
151-83	28757-28758	-	_	
151-84	28758-28762	year	_	
151-85	28763-28779	multi-assessment	_	
151-86	28780-28789	follow-up	_	
151-87	28790-28795	study	_	
151-88	28796-28809	Relationships	_	
151-89	28810-28817	between	_	
151-90	28818-28830	dorsolateral	_	
151-91	28831-28841	prefrontal	_	
151-92	28842-28848	cortex	_	
151-93	28849-28858	metabolic	_	
151-94	28859-28865	change	_	
151-95	28866-28869	and	_	
151-96	28870-28879	cognitive	_	
151-97	28880-28890	impairment	_	
151-98	28891-28893	in	_	
151-99	28894-28907	first-episode	_	
151-100	28908-28925	neuroleptic-naive	_	
151-101	28926-28939	schizophrenia	_	
151-102	28940-28948	patients	_	
151-103	28949-28961	Contribution	_	
151-104	28962-28964	of	_	
151-105	28965-28967	IL	_	
151-106	28967-28968	-	_	
151-107	28968-28970	10	_	
151-108	28971-28974	and	_	
151-109	28975-28978	its	_	
151-110	28979-28980	−	_	
151-111	28980-28983	592	_	
151-112	28984-28985	a	_	
151-113	28985-28986	/	_	
151-114	28986-28987	C	_	
151-115	28988-29000	polymorphism	_	
151-116	29001-29003	to	_	
151-117	29004-29013	cognitive	_	
151-118	29014-29023	functions	_	
151-119	29024-29026	in	_	
151-120	29027-29040	first-episode	_	
151-121	29041-29051	drug-naive	_	
151-122	29052-29065	schizophrenia	_	
151-123	29066-29069	Xiu	_	
151-124	29070-29072	MH	_	
151-125	29072-29073	,	_	
151-126	29074-29078	Guan	_	
151-127	29079-29081	HY	_	
151-128	29081-29082	,	_	
151-129	29083-29087	Zhao	_	
151-130	29088-29090	JM	_	
151-131	29090-29091	,	_	
151-132	29092-29096	Wang	_	
151-133	29097-29099	KQ	_	
151-134	29099-29100	,	_	
151-135	29101-29104	Pan	_	
151-136	29105-29107	YF	_	
151-137	29107-29108	,	_	
151-138	29109-29111	Su	_	
151-139	29112-29114	XR	_	
151-140	29114-29115	,	_	
151-141	29116-29120	Wang	_	
151-142	29121-29123	YH	_	
151-143	29123-29124	,	_	
151-144	29125-29128	Guo	_	
151-145	29129-29131	JM	_	
151-146	29131-29132	,	_	
151-147	29133-29138	Jiang	_	
151-148	29139-29140	L	_	
151-149	29140-29141	,	_	
151-150	29142-29145	Liu	_	
151-151	29146-29148	HY	_	
151-152	29148-29149	,	_	
151-153	29150-29152	et	_	
151-154	29153-29155	al	_	
151-155	29155-29156	.	_	

#Text=Cognitive enhancing effect of high-frequency Neuronavigated rTMS in chronic schizophrenia patients with predominant negative symptoms: a double-blind controlled 32-week follow-up study.
152-1	29157-29166	Cognitive	_	
152-2	29167-29176	enhancing	_	
152-3	29177-29183	effect	_	
152-4	29184-29186	of	_	
152-5	29187-29201	high-frequency	_	
152-6	29202-29216	Neuronavigated	_	
152-7	29217-29221	rTMS	_	
152-8	29222-29224	in	_	
152-9	29225-29232	chronic	_	
152-10	29233-29246	schizophrenia	_	
152-11	29247-29255	patients	_	
152-12	29256-29260	with	_	
152-13	29261-29272	predominant	_	
152-14	29273-29281	negative	_	
152-15	29282-29290	symptoms	_	
152-16	29290-29291	:	_	
152-17	29292-29293	a	_	
152-18	29294-29306	double-blind	_	
152-19	29307-29317	controlled	_	
152-20	29318-29320	32	_	
152-21	29320-29321	-	_	
152-22	29321-29325	week	_	
152-23	29326-29335	follow-up	_	
152-24	29336-29341	study	_	
152-25	29341-29342	.	_	

#Text=Schizophr Bull. 2020; [Epub ahead of print].
153-1	29343-29352	Schizophr	_	
153-2	29353-29357	Bull	_	
153-3	29357-29358	.	_	
153-4	29359-29363	2020	_	
153-5	29363-29364	;	_	
153-6	29365-29366	[	_	
153-7	29366-29370	Epub	_	
153-8	29371-29376	ahead	_	
153-9	29377-29379	of	_	
153-10	29380-29385	print	_	
153-11	29385-29386	]	_	
153-12	29386-29387	.	_	

#Text=Regional homogeneity approach to fMRI data analysis
#Text=Linked 4-way multimodal brain differences in schizophrenia in a large Chinese Han population
#Text=Analysis of first-episode and chronic schizophrenia using multi-modal magnetic resonance imaging
#Text=Abnormalities of localized connectivity in schizophrenia patients and their unaffected relatives: a meta-analysis of resting-state functional magnetic resonance imaging studies
#Text=Abnormal regional homogeneity as a potential imaging biomarker for adolescent-onset schizophrenia: a resting-state fMRI study and support vector machine analysis
#Text=Distinguishing between treatment-resistant and non-treatment-resistant schizophrenia using regional homogeneity
#Text=Abnormal neural activity as a potential biomarker for drug-naive first-episode adolescent-onset schizophrenia with coherence regional homogeneity and support vector machine analyses
#Text=Abnormally increased and incoherent resting-state activity is shared between patients with schizophrenia and their unaffected siblings
#Text=Uncoupled relationship in the brain between regional homogeneity and attention function in first-episode, drug-naive schizophrenia
#Text=Meta-analysis of 41 functional neuroimaging studies of executive function in schizophrenia
#Text=Abnormal functional activation and connectivity in the working memory network in early-onset schizophrenia
#Text=Deficits in prefrontal cortical and Extrastriatal dopamine release in schizophrenia a positron emission tomographic functional magnetic resonance imaging study
#Text=Topological FDR for neuroimaging
#Text=Cluster-extent based thresholding in fMRI analyses: pitfalls and recommendations
#Text=The statistical analysis of fMRI data
#Text=Type I and type II error concerns in fMRI research: re-balancing the scale
#Text=Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC: The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10.
154-1	29388-29396	Regional	_	
154-2	29397-29408	homogeneity	_	
154-3	29409-29417	approach	_	
154-4	29418-29420	to	_	
154-5	29421-29425	fMRI	_	
154-6	29426-29430	data	_	
154-7	29431-29439	analysis	_	
154-8	29440-29446	Linked	_	
154-9	29447-29448	4	_	
154-10	29448-29449	-	_	
154-11	29449-29452	way	_	
154-12	29453-29463	multimodal	_	
154-13	29464-29469	brain	_	
154-14	29470-29481	differences	_	
154-15	29482-29484	in	_	
154-16	29485-29498	schizophrenia	_	
154-17	29499-29501	in	_	
154-18	29502-29503	a	_	
154-19	29504-29509	large	_	
154-20	29510-29517	Chinese	_	
154-21	29518-29521	Han	_	
154-22	29522-29532	population	_	
154-23	29533-29541	Analysis	_	
154-24	29542-29544	of	_	
154-25	29545-29558	first-episode	_	
154-26	29559-29562	and	_	
154-27	29563-29570	chronic	_	
154-28	29571-29584	schizophrenia	_	
154-29	29585-29590	using	_	
154-30	29591-29602	multi-modal	_	
154-31	29603-29611	magnetic	_	
154-32	29612-29621	resonance	_	
154-33	29622-29629	imaging	_	
154-34	29630-29643	Abnormalities	_	
154-35	29644-29646	of	_	
154-36	29647-29656	localized	_	
154-37	29657-29669	connectivity	_	
154-38	29670-29672	in	_	
154-39	29673-29686	schizophrenia	_	
154-40	29687-29695	patients	_	
154-41	29696-29699	and	_	
154-42	29700-29705	their	_	
154-43	29706-29716	unaffected	_	
154-44	29717-29726	relatives	_	
154-45	29726-29727	:	_	
154-46	29728-29729	a	_	
154-47	29730-29743	meta-analysis	_	
154-48	29744-29746	of	_	
154-49	29747-29760	resting-state	_	
154-50	29761-29771	functional	_	
154-51	29772-29780	magnetic	_	
154-52	29781-29790	resonance	_	
154-53	29791-29798	imaging	_	
154-54	29799-29806	studies	_	
154-55	29807-29815	Abnormal	_	
154-56	29816-29824	regional	_	
154-57	29825-29836	homogeneity	_	
154-58	29837-29839	as	_	
154-59	29840-29841	a	_	
154-60	29842-29851	potential	_	
154-61	29852-29859	imaging	_	
154-62	29860-29869	biomarker	_	
154-63	29870-29873	for	_	
154-64	29874-29890	adolescent-onset	_	
154-65	29891-29904	schizophrenia	_	
154-66	29904-29905	:	_	
154-67	29906-29907	a	_	
154-68	29908-29921	resting-state	_	
154-69	29922-29926	fMRI	_	
154-70	29927-29932	study	_	
154-71	29933-29936	and	_	
154-72	29937-29944	support	_	
154-73	29945-29951	vector	_	
154-74	29952-29959	machine	_	
154-75	29960-29968	analysis	_	
154-76	29969-29983	Distinguishing	_	
154-77	29984-29991	between	_	
154-78	29992-30011	treatment-resistant	_	
154-79	30012-30015	and	_	
154-80	30016-30039	non-treatment-resistant	_	
154-81	30040-30053	schizophrenia	_	
154-82	30054-30059	using	_	
154-83	30060-30068	regional	_	
154-84	30069-30080	homogeneity	_	
154-85	30081-30089	Abnormal	_	
154-86	30090-30096	neural	_	
154-87	30097-30105	activity	_	
154-88	30106-30108	as	_	
154-89	30109-30110	a	_	
154-90	30111-30120	potential	_	
154-91	30121-30130	biomarker	_	
154-92	30131-30134	for	_	
154-93	30135-30145	drug-naive	_	
154-94	30146-30159	first-episode	_	
154-95	30160-30176	adolescent-onset	_	
154-96	30177-30190	schizophrenia	_	
154-97	30191-30195	with	_	
154-98	30196-30205	coherence	_	
154-99	30206-30214	regional	_	
154-100	30215-30226	homogeneity	_	
154-101	30227-30230	and	_	
154-102	30231-30238	support	_	
154-103	30239-30245	vector	_	
154-104	30246-30253	machine	_	
154-105	30254-30262	analyses	_	
154-106	30263-30273	Abnormally	_	
154-107	30274-30283	increased	_	
154-108	30284-30287	and	_	
154-109	30288-30298	incoherent	_	
154-110	30299-30312	resting-state	_	
154-111	30313-30321	activity	_	
154-112	30322-30324	is	_	
154-113	30325-30331	shared	_	
154-114	30332-30339	between	_	
154-115	30340-30348	patients	_	
154-116	30349-30353	with	_	
154-117	30354-30367	schizophrenia	_	
154-118	30368-30371	and	_	
154-119	30372-30377	their	_	
154-120	30378-30388	unaffected	_	
154-121	30389-30397	siblings	_	
154-122	30398-30407	Uncoupled	_	
154-123	30408-30420	relationship	_	
154-124	30421-30423	in	_	
154-125	30424-30427	the	_	
154-126	30428-30433	brain	_	
154-127	30434-30441	between	_	
154-128	30442-30450	regional	_	
154-129	30451-30462	homogeneity	_	
154-130	30463-30466	and	_	
154-131	30467-30476	attention	_	
154-132	30477-30485	function	_	
154-133	30486-30488	in	_	
154-134	30489-30502	first-episode	_	
154-135	30502-30503	,	_	
154-136	30504-30514	drug-naive	_	
154-137	30515-30528	schizophrenia	_	
154-138	30529-30542	Meta-analysis	_	
154-139	30543-30545	of	_	
154-140	30546-30548	41	_	
154-141	30549-30559	functional	_	
154-142	30560-30572	neuroimaging	_	
154-143	30573-30580	studies	_	
154-144	30581-30583	of	_	
154-145	30584-30593	executive	_	
154-146	30594-30602	function	_	
154-147	30603-30605	in	_	
154-148	30606-30619	schizophrenia	_	
154-149	30620-30628	Abnormal	_	
154-150	30629-30639	functional	_	
154-151	30640-30650	activation	_	
154-152	30651-30654	and	_	
154-153	30655-30667	connectivity	_	
154-154	30668-30670	in	_	
154-155	30671-30674	the	_	
154-156	30675-30682	working	_	
154-157	30683-30689	memory	_	
154-158	30690-30697	network	_	
154-159	30698-30700	in	_	
154-160	30701-30712	early-onset	_	
154-161	30713-30726	schizophrenia	_	
154-162	30727-30735	Deficits	_	
154-163	30736-30738	in	_	
154-164	30739-30749	prefrontal	_	
154-165	30750-30758	cortical	_	
154-166	30759-30762	and	_	
154-167	30763-30776	Extrastriatal	_	
154-168	30777-30785	dopamine	_	
154-169	30786-30793	release	_	
154-170	30794-30796	in	_	
154-171	30797-30810	schizophrenia	_	
154-172	30811-30812	a	_	
154-173	30813-30821	positron	_	
154-174	30822-30830	emission	_	
154-175	30831-30842	tomographic	_	
154-176	30843-30853	functional	_	
154-177	30854-30862	magnetic	_	
154-178	30863-30872	resonance	_	
154-179	30873-30880	imaging	_	
154-180	30881-30886	study	_	
154-181	30887-30898	Topological	_	
154-182	30899-30902	FDR	_	
154-183	30903-30906	for	_	
154-184	30907-30919	neuroimaging	_	
154-185	30920-30934	Cluster-extent	_	
154-186	30935-30940	based	_	
154-187	30941-30953	thresholding	_	
154-188	30954-30956	in	_	
154-189	30957-30961	fMRI	_	
154-190	30962-30970	analyses	_	
154-191	30970-30971	:	_	
154-192	30972-30980	pitfalls	_	
154-193	30981-30984	and	_	
154-194	30985-31000	recommendations	_	
154-195	31001-31004	The	_	
154-196	31005-31016	statistical	_	
154-197	31017-31025	analysis	_	
154-198	31026-31028	of	_	
154-199	31029-31033	fMRI	_	
154-200	31034-31038	data	_	
154-201	31039-31043	Type	_	
154-202	31044-31045	I	_	
154-203	31046-31049	and	_	
154-204	31050-31054	type	_	
154-205	31055-31057	II	_	
154-206	31058-31063	error	_	
154-207	31064-31072	concerns	_	
154-208	31073-31075	in	_	
154-209	31076-31080	fMRI	_	
154-210	31081-31089	research	_	
154-211	31089-31090	:	_	
154-212	31091-31103	re-balancing	_	
154-213	31104-31107	the	_	
154-214	31108-31113	scale	_	
154-215	31114-31121	Sheehan	_	
154-216	31122-31124	DV	_	
154-217	31124-31125	,	_	
154-218	31126-31135	Lecrubier	_	
154-219	31136-31137	Y	_	
154-220	31137-31138	,	_	
154-221	31139-31146	Sheehan	_	
154-222	31147-31149	KH	_	
154-223	31149-31150	,	_	
154-224	31151-31157	Amorim	_	
154-225	31158-31159	P	_	
154-226	31159-31160	,	_	
154-227	31161-31167	Janavs	_	
154-228	31168-31169	J	_	
154-229	31169-31170	,	_	
154-230	31171-31178	Weiller	_	
154-231	31179-31180	E	_	
154-232	31180-31181	,	_	
154-233	31182-31190	Hergueta	_	
154-234	31191-31192	T	_	
154-235	31192-31193	,	_	
154-236	31194-31199	Baker	_	
154-237	31200-31201	R	_	
154-238	31201-31202	,	_	
154-239	31203-31209	Dunbar	_	
154-240	31210-31212	GC	_	
154-241	31212-31213	:	_	
154-242	31214-31217	The	_	
154-243	31218-31236	Mini-International	_	
154-244	31237-31253	Neuropsychiatric	_	
154-245	31254-31263	Interview	_	
154-246	31264-31265	(	_	
154-247	31265-31272	M.I.N.I	_	
154-248	31272-31273	.	_	
154-249	31273-31274	)	_	
154-250	31274-31275	:	_	
154-251	31276-31279	the	_	
154-252	31280-31291	development	_	
154-253	31292-31295	and	_	
154-254	31296-31306	validation	_	
154-255	31307-31309	of	_	
154-256	31310-31311	a	_	
154-257	31312-31322	structured	_	
154-258	31323-31333	diagnostic	_	
154-259	31334-31345	psychiatric	_	
154-260	31346-31355	interview	_	
154-261	31356-31359	for	_	
154-262	31360-31366	DSM-IV	_	
154-263	31367-31370	and	_	
154-264	31371-31374	ICD	_	
154-265	31374-31375	-	_	
154-266	31375-31377	10	_	
154-267	31377-31378	.	_	

#Text=The Journal of clinical psychiatry 1998, 59 Suppl 20:22–33;quiz 34–57.
155-1	31379-31382	The	_	
155-2	31383-31390	Journal	_	
155-3	31391-31393	of	_	
155-4	31394-31402	clinical	_	
155-5	31403-31413	psychiatry	_	
155-6	31414-31418	1998	_	
155-7	31418-31419	,	_	
155-8	31420-31422	59	_	
155-9	31423-31428	Suppl	_	
155-10	31429-31431	20	_	
155-11	31431-31432	:	_	
155-12	31432-31434	22	_	
155-13	31434-31435	–	_	
155-14	31435-31437	33	_	
155-15	31437-31438	;	_	
155-16	31438-31442	quiz	_	
155-17	31443-31445	34	_	
155-18	31445-31446	–	_	
155-19	31446-31448	57	_	
155-20	31448-31449	.	_	

#Text=H., Green M, F., Kern R, S.: the MATRICS consensus cognitive battery, part 1: test selection, reliability, and validity
#Text=S., Nuechterlein K, H., Green M, F., Baade L, E.: the MATRICS consensus cognitive battery, part 2: co-norming and standardization
#Text=Kay S, R., Fiszbein A, Opler L, A .
156-1	31450-31451	H	_	
156-2	31451-31452	.	_	
156-3	31452-31453	,	_	
156-4	31454-31459	Green	_	
156-5	31460-31461	M	_	
156-6	31461-31462	,	_	
156-7	31463-31464	F	_	
156-8	31464-31465	.	_	
156-9	31465-31466	,	_	
156-10	31467-31471	Kern	_	
156-11	31472-31473	R	_	
156-12	31473-31474	,	_	
156-13	31475-31476	S	_	
156-14	31476-31477	.	_	
156-15	31477-31478	:	_	
156-16	31479-31482	the	_	
156-17	31483-31490	MATRICS	_	
156-18	31491-31500	consensus	_	
156-19	31501-31510	cognitive	_	
156-20	31511-31518	battery	_	
156-21	31518-31519	,	_	
156-22	31520-31524	part	_	
156-23	31525-31526	1	_	
156-24	31526-31527	:	_	
156-25	31528-31532	test	_	
156-26	31533-31542	selection	_	
156-27	31542-31543	,	_	
156-28	31544-31555	reliability	_	
156-29	31555-31556	,	_	
156-30	31557-31560	and	_	
156-31	31561-31569	validity	_	
156-32	31570-31571	S	_	
156-33	31571-31572	.	_	
156-34	31572-31573	,	_	
156-35	31574-31586	Nuechterlein	_	
156-36	31587-31588	K	_	
156-37	31588-31589	,	_	
156-38	31590-31591	H	_	
156-39	31591-31592	.	_	
156-40	31592-31593	,	_	
156-41	31594-31599	Green	_	
156-42	31600-31601	M	_	
156-43	31601-31602	,	_	
156-44	31603-31604	F	_	
156-45	31604-31605	.	_	
156-46	31605-31606	,	_	
156-47	31607-31612	Baade	_	
156-48	31613-31614	L	_	
156-49	31614-31615	,	_	
156-50	31616-31617	E	_	
156-51	31617-31618	.	_	
156-52	31618-31619	:	_	
156-53	31620-31623	the	_	
156-54	31624-31631	MATRICS	_	
156-55	31632-31641	consensus	_	
156-56	31642-31651	cognitive	_	
156-57	31652-31659	battery	_	
156-58	31659-31660	,	_	
156-59	31661-31665	part	_	
156-60	31666-31667	2	_	
156-61	31667-31668	:	_	
156-62	31669-31679	co-norming	_	
156-63	31680-31683	and	_	
156-64	31684-31699	standardization	_	
156-65	31700-31703	Kay	_	
156-66	31704-31705	S	_	
156-67	31705-31706	,	_	
156-68	31707-31708	R	_	
156-69	31708-31709	.	_	
156-70	31709-31710	,	_	
156-71	31711-31719	Fiszbein	_	
156-72	31720-31721	A	_	
156-73	31721-31722	,	_	
156-74	31723-31728	Opler	_	
156-75	31729-31730	L	_	
156-76	31730-31731	,	_	
156-77	31732-31733	A	_	
156-78	31734-31735	.	_	

#Text=The positive and negative syndrome scale (PANSS) for schizophrenia.
157-1	31736-31739	The	_	
157-2	31740-31748	positive	_	
157-3	31749-31752	and	_	
157-4	31753-31761	negative	_	
157-5	31762-31770	syndrome	_	
157-6	31771-31776	scale	_	
157-7	31777-31778	(	_	
157-8	31778-31783	PANSS	_	
157-9	31783-31784	)	_	
157-10	31785-31788	for	_	
157-11	31789-31802	schizophrenia	_	
157-12	31802-31803	.	_	

#Text=Schizophr Bull 1987, 13(2):261–276.
158-1	31804-31813	Schizophr	_	
158-2	31814-31818	Bull	_	
158-3	31819-31823	1987	_	
158-4	31823-31824	,	_	
158-5	31825-31827	13	_	
158-6	31827-31828	(	_	
158-7	31828-31829	2	_	
158-8	31829-31830	)	_	
158-9	31830-31831	:	_	
158-10	31831-31834	261	_	
158-11	31834-31835	–	_	
158-12	31835-31838	276	_	
158-13	31838-31839	.	_	

#Text=Functional connectivity in the resting brain: a network analysis of the default mode hypothesis
#Text=DPABI: Data Processing & Analysis for (resting-state) brain imaging
#Text=Improved optimization for the robust and accurate linear registration and motion correction of brain images
#Text=Movement-related effects in fMRI time-series
#Text=Threshold-free cluster enhancement: addressing problems of smoothing, threshold dependence and localisation in cluster inference
#Text=The MCCB impairment profile for schizophrenia outpatients: results from the MATRICS psychometric and standardization study
#Text=Cognitive performance of individuals with schizophrenia across seven decades: AStudy using the MATRICS consensus cognitive battery
#Text=Neurocognitive normality in schizophrenia revisited
#Text=Speed and capacity of working memory and executive function in schizophrenia compared to unipolar depression
#Text=The effect of impaired verbal memory retrieval on autobiographical memory across different life periods in schizophrenia
#Text=Dario.
159-1	31840-31850	Functional	_	
159-2	31851-31863	connectivity	_	
159-3	31864-31866	in	_	
159-4	31867-31870	the	_	
159-5	31871-31878	resting	_	
159-6	31879-31884	brain	_	
159-7	31884-31885	:	_	
159-8	31886-31887	a	_	
159-9	31888-31895	network	_	
159-10	31896-31904	analysis	_	
159-11	31905-31907	of	_	
159-12	31908-31911	the	_	
159-13	31912-31919	default	_	
159-14	31920-31924	mode	_	
159-15	31925-31935	hypothesis	_	
159-16	31936-31941	DPABI	_	
159-17	31941-31942	:	_	
159-18	31943-31947	Data	_	
159-19	31948-31958	Processing	_	
159-20	31959-31960	&	_	
159-21	31961-31969	Analysis	_	
159-22	31970-31973	for	_	
159-23	31974-31975	(	_	
159-24	31975-31988	resting-state	_	
159-25	31988-31989	)	_	
159-26	31990-31995	brain	_	
159-27	31996-32003	imaging	_	
159-28	32004-32012	Improved	_	
159-29	32013-32025	optimization	_	
159-30	32026-32029	for	_	
159-31	32030-32033	the	_	
159-32	32034-32040	robust	_	
159-33	32041-32044	and	_	
159-34	32045-32053	accurate	_	
159-35	32054-32060	linear	_	
159-36	32061-32073	registration	_	
159-37	32074-32077	and	_	
159-38	32078-32084	motion	_	
159-39	32085-32095	correction	_	
159-40	32096-32098	of	_	
159-41	32099-32104	brain	_	
159-42	32105-32111	images	_	
159-43	32112-32128	Movement-related	_	
159-44	32129-32136	effects	_	
159-45	32137-32139	in	_	
159-46	32140-32144	fMRI	_	
159-47	32145-32156	time-series	_	
159-48	32157-32171	Threshold-free	_	
159-49	32172-32179	cluster	_	
159-50	32180-32191	enhancement	_	
159-51	32191-32192	:	_	
159-52	32193-32203	addressing	_	
159-53	32204-32212	problems	_	
159-54	32213-32215	of	_	
159-55	32216-32225	smoothing	_	
159-56	32225-32226	,	_	
159-57	32227-32236	threshold	_	
159-58	32237-32247	dependence	_	
159-59	32248-32251	and	_	
159-60	32252-32264	localisation	_	
159-61	32265-32267	in	_	
159-62	32268-32275	cluster	_	
159-63	32276-32285	inference	_	
159-64	32286-32289	The	_	
159-65	32290-32294	MCCB	_	
159-66	32295-32305	impairment	_	
159-67	32306-32313	profile	_	
159-68	32314-32317	for	_	
159-69	32318-32331	schizophrenia	_	
159-70	32332-32343	outpatients	_	
159-71	32343-32344	:	_	
159-72	32345-32352	results	_	
159-73	32353-32357	from	_	
159-74	32358-32361	the	_	
159-75	32362-32369	MATRICS	_	
159-76	32370-32382	psychometric	_	
159-77	32383-32386	and	_	
159-78	32387-32402	standardization	_	
159-79	32403-32408	study	_	
159-80	32409-32418	Cognitive	_	
159-81	32419-32430	performance	_	
159-82	32431-32433	of	_	
159-83	32434-32445	individuals	_	
159-84	32446-32450	with	_	
159-85	32451-32464	schizophrenia	_	
159-86	32465-32471	across	_	
159-87	32472-32477	seven	_	
159-88	32478-32485	decades	_	
159-89	32485-32486	:	_	
159-90	32487-32493	AStudy	_	
159-91	32494-32499	using	_	
159-92	32500-32503	the	_	
159-93	32504-32511	MATRICS	_	
159-94	32512-32521	consensus	_	
159-95	32522-32531	cognitive	_	
159-96	32532-32539	battery	_	
159-97	32540-32554	Neurocognitive	_	
159-98	32555-32564	normality	_	
159-99	32565-32567	in	_	
159-100	32568-32581	schizophrenia	_	
159-101	32582-32591	revisited	_	
159-102	32592-32597	Speed	_	
159-103	32598-32601	and	_	
159-104	32602-32610	capacity	_	
159-105	32611-32613	of	_	
159-106	32614-32621	working	_	
159-107	32622-32628	memory	_	
159-108	32629-32632	and	_	
159-109	32633-32642	executive	_	
159-110	32643-32651	function	_	
159-111	32652-32654	in	_	
159-112	32655-32668	schizophrenia	_	
159-113	32669-32677	compared	_	
159-114	32678-32680	to	_	
159-115	32681-32689	unipolar	_	
159-116	32690-32700	depression	_	
159-117	32701-32704	The	_	
159-118	32705-32711	effect	_	
159-119	32712-32714	of	_	
159-120	32715-32723	impaired	_	
159-121	32724-32730	verbal	_	
159-122	32731-32737	memory	_	
159-123	32738-32747	retrieval	_	
159-124	32748-32750	on	_	
159-125	32751-32767	autobiographical	_	
159-126	32768-32774	memory	_	
159-127	32775-32781	across	_	
159-128	32782-32791	different	_	
159-129	32792-32796	life	_	
159-130	32797-32804	periods	_	
159-131	32805-32807	in	_	
159-132	32808-32821	schizophrenia	_	
159-133	32822-32827	Dario	_	
159-134	32827-32828	.	_	

#Text=M, Walter.
160-1	32829-32830	M	_	
160-2	32830-32831	,	_	
160-3	32832-32838	Walter	_	
160-4	32838-32839	.	_	

#Text=HR, McDermid.
161-1	32840-32842	HR	_	
161-2	32842-32843	,	_	
161-3	32844-32852	McDermid	_	
161-4	32852-32853	.	_	

#Text=VS: exploring logical reasoning abilities in schizophrenia patients.
162-1	32854-32856	VS	_	
162-2	32856-32857	:	_	
162-3	32858-32867	exploring	_	
162-4	32868-32875	logical	_	
162-5	32876-32885	reasoning	_	
162-6	32886-32895	abilities	_	
162-7	32896-32898	in	_	
162-8	32899-32912	schizophrenia	_	
162-9	32913-32921	patients	_	
162-10	32921-32922	.	_	

#Text=Schizophr Res 2011, 127(1–3):178–180.
163-1	32923-32932	Schizophr	_	
163-2	32933-32936	Res	_	
163-3	32937-32941	2011	_	
163-4	32941-32942	,	_	
163-5	32943-32946	127	_	
163-6	32946-32947	(	_	
163-7	32947-32948	1	_	
163-8	32948-32949	–	_	
163-9	32949-32950	3	_	
163-10	32950-32951	)	_	
163-11	32951-32952	:	_	
163-12	32952-32955	178	_	
163-13	32955-32956	–	_	
163-14	32956-32959	180	_	
163-15	32959-32960	.	_	

#Text=Visual memory uniquely predicts anhedonia in schizophrenia but not bipolar disorder
#Text=Details of attention and learning change in first-episode schizophrenia
#Text=Social cognition and neurocognitive deficits in first-episode schizophrenia
#Text=The development of the ventral prefrontal cortex and social flexibility
#Text=Prefrontal cortex and social cognition in mouse and man
#Text=Acquired personality disturbances associated with bilateral damage to the ventromedial prefrontal region
#Text=Anterior prefrontal cortex: insights into function from anatomy and neuroimaging
#Text=Putamen-related regional and network functional deficits in first-episode schizophrenia with auditory verbal hallucinations
#Text=Comparative study of regional homogeneity in schizophrenia and major depressive disorder
#Text=Structural and functional brain abnormalities in schizophrenia: a cross-sectional study at different stages of the disease
#Text=Altered contextual modulation of primary visual cortex responses in schizophrenia
#Text=Association between a longer duration of illness, age and lower frontal lobe grey matter volume in schizophrenia
#Text=Gray matter volume changes following antipsychotic therapy in first-episode schizophrenia patients: a longitudinal voxel-based morphometric study
#Text=Aberrant prefrontal-thalamic-cerebellar circuit in schizophrenia and depression: evidence from a possible causal connectivity
#Text=Impaired cognitive control mediates the relationship between cortical thickness of the superior frontal gyrus and role functioning in schizophrenia
#Text=Prefrontal cortex in humans and apes: a comparative study of area 10
#Text=Social brain dysfunctions in schizophrenia: a review of neuroimaging studies
#Text=Identification of separable cognitive factors in schizophrenia
#Text=Taiwan schizophrenia linkage study: lessons learned from endophenotype-based genome-wide linkage scans and perspective
#Text=Is there "one" DLPFC in cognitive action control?
164-1	32961-32967	Visual	_	
164-2	32968-32974	memory	_	
164-3	32975-32983	uniquely	_	
164-4	32984-32992	predicts	_	
164-5	32993-33002	anhedonia	_	
164-6	33003-33005	in	_	
164-7	33006-33019	schizophrenia	_	
164-8	33020-33023	but	_	
164-9	33024-33027	not	_	
164-10	33028-33035	bipolar	_	
164-11	33036-33044	disorder	_	
164-12	33045-33052	Details	_	
164-13	33053-33055	of	_	
164-14	33056-33065	attention	_	
164-15	33066-33069	and	_	
164-16	33070-33078	learning	_	
164-17	33079-33085	change	_	
164-18	33086-33088	in	_	
164-19	33089-33102	first-episode	_	
164-20	33103-33116	schizophrenia	_	
164-21	33117-33123	Social	_	
164-22	33124-33133	cognition	_	
164-23	33134-33137	and	_	
164-24	33138-33152	neurocognitive	_	
164-25	33153-33161	deficits	_	
164-26	33162-33164	in	_	
164-27	33165-33178	first-episode	_	
164-28	33179-33192	schizophrenia	_	
164-29	33193-33196	The	_	
164-30	33197-33208	development	_	
164-31	33209-33211	of	_	
164-32	33212-33215	the	_	
164-33	33216-33223	ventral	_	
164-34	33224-33234	prefrontal	_	
164-35	33235-33241	cortex	_	
164-36	33242-33245	and	_	
164-37	33246-33252	social	_	
164-38	33253-33264	flexibility	_	
164-39	33265-33275	Prefrontal	_	
164-40	33276-33282	cortex	_	
164-41	33283-33286	and	_	
164-42	33287-33293	social	_	
164-43	33294-33303	cognition	_	
164-44	33304-33306	in	_	
164-45	33307-33312	mouse	_	
164-46	33313-33316	and	_	
164-47	33317-33320	man	_	
164-48	33321-33329	Acquired	_	
164-49	33330-33341	personality	_	
164-50	33342-33354	disturbances	_	
164-51	33355-33365	associated	_	
164-52	33366-33370	with	_	
164-53	33371-33380	bilateral	_	
164-54	33381-33387	damage	_	
164-55	33388-33390	to	_	
164-56	33391-33394	the	_	
164-57	33395-33407	ventromedial	_	
164-58	33408-33418	prefrontal	_	
164-59	33419-33425	region	_	
164-60	33426-33434	Anterior	_	
164-61	33435-33445	prefrontal	_	
164-62	33446-33452	cortex	_	
164-63	33452-33453	:	_	
164-64	33454-33462	insights	_	
164-65	33463-33467	into	_	
164-66	33468-33476	function	_	
164-67	33477-33481	from	_	
164-68	33482-33489	anatomy	_	
164-69	33490-33493	and	_	
164-70	33494-33506	neuroimaging	_	
164-71	33507-33522	Putamen-related	_	
164-72	33523-33531	regional	_	
164-73	33532-33535	and	_	
164-74	33536-33543	network	_	
164-75	33544-33554	functional	_	
164-76	33555-33563	deficits	_	
164-77	33564-33566	in	_	
164-78	33567-33580	first-episode	_	
164-79	33581-33594	schizophrenia	_	
164-80	33595-33599	with	_	
164-81	33600-33608	auditory	_	
164-82	33609-33615	verbal	_	
164-83	33616-33630	hallucinations	_	
164-84	33631-33642	Comparative	_	
164-85	33643-33648	study	_	
164-86	33649-33651	of	_	
164-87	33652-33660	regional	_	
164-88	33661-33672	homogeneity	_	
164-89	33673-33675	in	_	
164-90	33676-33689	schizophrenia	_	
164-91	33690-33693	and	_	
164-92	33694-33699	major	_	
164-93	33700-33710	depressive	_	
164-94	33711-33719	disorder	_	
164-95	33720-33730	Structural	_	
164-96	33731-33734	and	_	
164-97	33735-33745	functional	_	
164-98	33746-33751	brain	_	
164-99	33752-33765	abnormalities	_	
164-100	33766-33768	in	_	
164-101	33769-33782	schizophrenia	_	
164-102	33782-33783	:	_	
164-103	33784-33785	a	_	
164-104	33786-33801	cross-sectional	_	
164-105	33802-33807	study	_	
164-106	33808-33810	at	_	
164-107	33811-33820	different	_	
164-108	33821-33827	stages	_	
164-109	33828-33830	of	_	
164-110	33831-33834	the	_	
164-111	33835-33842	disease	_	
164-112	33843-33850	Altered	_	
164-113	33851-33861	contextual	_	
164-114	33862-33872	modulation	_	
164-115	33873-33875	of	_	
164-116	33876-33883	primary	_	
164-117	33884-33890	visual	_	
164-118	33891-33897	cortex	_	
164-119	33898-33907	responses	_	
164-120	33908-33910	in	_	
164-121	33911-33924	schizophrenia	_	
164-122	33925-33936	Association	_	
164-123	33937-33944	between	_	
164-124	33945-33946	a	_	
164-125	33947-33953	longer	_	
164-126	33954-33962	duration	_	
164-127	33963-33965	of	_	
164-128	33966-33973	illness	_	
164-129	33973-33974	,	_	
164-130	33975-33978	age	_	
164-131	33979-33982	and	_	
164-132	33983-33988	lower	_	
164-133	33989-33996	frontal	_	
164-134	33997-34001	lobe	_	
164-135	34002-34006	grey	_	
164-136	34007-34013	matter	_	
164-137	34014-34020	volume	_	
164-138	34021-34023	in	_	
164-139	34024-34037	schizophrenia	_	
164-140	34038-34042	Gray	_	
164-141	34043-34049	matter	_	
164-142	34050-34056	volume	_	
164-143	34057-34064	changes	_	
164-144	34065-34074	following	_	
164-145	34075-34088	antipsychotic	_	
164-146	34089-34096	therapy	_	
164-147	34097-34099	in	_	
164-148	34100-34113	first-episode	_	
164-149	34114-34127	schizophrenia	_	
164-150	34128-34136	patients	_	
164-151	34136-34137	:	_	
164-152	34138-34139	a	_	
164-153	34140-34152	longitudinal	_	
164-154	34153-34164	voxel-based	_	
164-155	34165-34177	morphometric	_	
164-156	34178-34183	study	_	
164-157	34184-34192	Aberrant	_	
164-158	34193-34223	prefrontal-thalamic-cerebellar	_	
164-159	34224-34231	circuit	_	
164-160	34232-34234	in	_	
164-161	34235-34248	schizophrenia	_	
164-162	34249-34252	and	_	
164-163	34253-34263	depression	_	
164-164	34263-34264	:	_	
164-165	34265-34273	evidence	_	
164-166	34274-34278	from	_	
164-167	34279-34280	a	_	
164-168	34281-34289	possible	_	
164-169	34290-34296	causal	_	
164-170	34297-34309	connectivity	_	
164-171	34310-34318	Impaired	_	
164-172	34319-34328	cognitive	_	
164-173	34329-34336	control	_	
164-174	34337-34345	mediates	_	
164-175	34346-34349	the	_	
164-176	34350-34362	relationship	_	
164-177	34363-34370	between	_	
164-178	34371-34379	cortical	_	
164-179	34380-34389	thickness	_	
164-180	34390-34392	of	_	
164-181	34393-34396	the	_	
164-182	34397-34405	superior	_	
164-183	34406-34413	frontal	_	
164-184	34414-34419	gyrus	_	
164-185	34420-34423	and	_	
164-186	34424-34428	role	_	
164-187	34429-34440	functioning	_	
164-188	34441-34443	in	_	
164-189	34444-34457	schizophrenia	_	
164-190	34458-34468	Prefrontal	_	
164-191	34469-34475	cortex	_	
164-192	34476-34478	in	_	
164-193	34479-34485	humans	_	
164-194	34486-34489	and	_	
164-195	34490-34494	apes	_	
164-196	34494-34495	:	_	
164-197	34496-34497	a	_	
164-198	34498-34509	comparative	_	
164-199	34510-34515	study	_	
164-200	34516-34518	of	_	
164-201	34519-34523	area	_	
164-202	34524-34526	10	_	
164-203	34527-34533	Social	_	
164-204	34534-34539	brain	_	
164-205	34540-34552	dysfunctions	_	
164-206	34553-34555	in	_	
164-207	34556-34569	schizophrenia	_	
164-208	34569-34570	:	_	
164-209	34571-34572	a	_	
164-210	34573-34579	review	_	
164-211	34580-34582	of	_	
164-212	34583-34595	neuroimaging	_	
164-213	34596-34603	studies	_	
164-214	34604-34618	Identification	_	
164-215	34619-34621	of	_	
164-216	34622-34631	separable	_	
164-217	34632-34641	cognitive	_	
164-218	34642-34649	factors	_	
164-219	34650-34652	in	_	
164-220	34653-34666	schizophrenia	_	
164-221	34667-34673	Taiwan	_	
164-222	34674-34687	schizophrenia	_	
164-223	34688-34695	linkage	_	
164-224	34696-34701	study	_	
164-225	34701-34702	:	_	
164-226	34703-34710	lessons	_	
164-227	34711-34718	learned	_	
164-228	34719-34723	from	_	
164-229	34724-34743	endophenotype-based	_	
164-230	34744-34755	genome-wide	_	
164-231	34756-34763	linkage	_	
164-232	34764-34769	scans	_	
164-233	34770-34773	and	_	
164-234	34774-34785	perspective	_	
164-235	34786-34788	Is	_	
164-236	34789-34794	there	_	
164-237	34795-34796	"	_	
164-238	34796-34799	one	_	
164-239	34799-34800	"	_	
164-240	34801-34806	DLPFC	_	
164-241	34807-34809	in	_	
164-242	34810-34819	cognitive	_	
164-243	34820-34826	action	_	
164-244	34827-34834	control	_	
164-245	34834-34835	?	_	

#Text=Evidence for heterogeneity from co-activation-based parcellation
#Text=An fMRI investigation of emotional engagement in moral judgment
#Text=Dorsolateral prefrontal contributions to human working memory
#Text=Anodal Transcranial direct-current stimulation over the right dorsolateral prefrontal cortex influences emotional face perception
#Text=Reduced frontotemporal functional connectivity in schizophrenia associated with auditory hallucinations
#Text=Elevated functional connectivity along a Corticostriatal loop and the mechanism of auditory/verbal hallucinations in patients with schizophrenia
#Text=Aberrant connectivity of areas for decoding degraded speech in patients with auditory verbal hallucinations
#Text=Information processing flow and neural activations in the dorsolateral prefrontal cortex in the Stroop task in schizophrenic patients.
165-1	34836-34844	Evidence	_	
165-2	34845-34848	for	_	
165-3	34849-34862	heterogeneity	_	
165-4	34863-34867	from	_	
165-5	34868-34887	co-activation-based	_	
165-6	34888-34900	parcellation	_	
165-7	34901-34903	An	_	
165-8	34904-34908	fMRI	_	
165-9	34909-34922	investigation	_	
165-10	34923-34925	of	_	
165-11	34926-34935	emotional	_	
165-12	34936-34946	engagement	_	
165-13	34947-34949	in	_	
165-14	34950-34955	moral	_	
165-15	34956-34964	judgment	_	
165-16	34965-34977	Dorsolateral	_	
165-17	34978-34988	prefrontal	_	
165-18	34989-35002	contributions	_	
165-19	35003-35005	to	_	
165-20	35006-35011	human	_	
165-21	35012-35019	working	_	
165-22	35020-35026	memory	_	
165-23	35027-35033	Anodal	_	
165-24	35034-35046	Transcranial	_	
165-25	35047-35061	direct-current	_	
165-26	35062-35073	stimulation	_	
165-27	35074-35078	over	_	
165-28	35079-35082	the	_	
165-29	35083-35088	right	_	
165-30	35089-35101	dorsolateral	_	
165-31	35102-35112	prefrontal	_	
165-32	35113-35119	cortex	_	
165-33	35120-35130	influences	_	
165-34	35131-35140	emotional	_	
165-35	35141-35145	face	_	
165-36	35146-35156	perception	_	
165-37	35157-35164	Reduced	_	
165-38	35165-35179	frontotemporal	_	
165-39	35180-35190	functional	_	
165-40	35191-35203	connectivity	_	
165-41	35204-35206	in	_	
165-42	35207-35220	schizophrenia	_	
165-43	35221-35231	associated	_	
165-44	35232-35236	with	_	
165-45	35237-35245	auditory	_	
165-46	35246-35260	hallucinations	_	
165-47	35261-35269	Elevated	_	
165-48	35270-35280	functional	_	
165-49	35281-35293	connectivity	_	
165-50	35294-35299	along	_	
165-51	35300-35301	a	_	
165-52	35302-35317	Corticostriatal	_	
165-53	35318-35322	loop	_	
165-54	35323-35326	and	_	
165-55	35327-35330	the	_	
165-56	35331-35340	mechanism	_	
165-57	35341-35343	of	_	
165-58	35344-35352	auditory	_	
165-59	35352-35353	/	_	
165-60	35353-35359	verbal	_	
165-61	35360-35374	hallucinations	_	
165-62	35375-35377	in	_	
165-63	35378-35386	patients	_	
165-64	35387-35391	with	_	
165-65	35392-35405	schizophrenia	_	
165-66	35406-35414	Aberrant	_	
165-67	35415-35427	connectivity	_	
165-68	35428-35430	of	_	
165-69	35431-35436	areas	_	
165-70	35437-35440	for	_	
165-71	35441-35449	decoding	_	
165-72	35450-35458	degraded	_	
165-73	35459-35465	speech	_	
165-74	35466-35468	in	_	
165-75	35469-35477	patients	_	
165-76	35478-35482	with	_	
165-77	35483-35491	auditory	_	
165-78	35492-35498	verbal	_	
165-79	35499-35513	hallucinations	_	
165-80	35514-35525	Information	_	
165-81	35526-35536	processing	_	
165-82	35537-35541	flow	_	
165-83	35542-35545	and	_	
165-84	35546-35552	neural	_	
165-85	35553-35564	activations	_	
165-86	35565-35567	in	_	
165-87	35568-35571	the	_	
165-88	35572-35584	dorsolateral	_	
165-89	35585-35595	prefrontal	_	
165-90	35596-35602	cortex	_	
165-91	35603-35605	in	_	
165-92	35606-35609	the	_	
165-93	35610-35616	Stroop	_	
165-94	35617-35621	task	_	
165-95	35622-35624	in	_	
165-96	35625-35638	schizophrenic	_	
165-97	35639-35647	patients	_	
165-98	35647-35648	.	_	

#Text=A spatially filtered MEG analysis with high temporal and spatial resolution
#Text=Physiological dysfunction of the dorsolateral prefrontal cortex in schizophrenia revisited
166-1	35649-35650	A	_	
166-2	35651-35660	spatially	_	
166-3	35661-35669	filtered	_	
166-4	35670-35673	MEG	_	
166-5	35674-35682	analysis	_	
166-6	35683-35687	with	_	
166-7	35688-35692	high	_	
166-8	35693-35701	temporal	_	
166-9	35702-35705	and	_	
166-10	35706-35713	spatial	_	
166-11	35714-35724	resolution	_	
166-12	35725-35738	Physiological	_	
166-13	35739-35750	dysfunction	_	
166-14	35751-35753	of	_	
166-15	35754-35757	the	_	
166-16	35758-35770	dorsolateral	_	
166-17	35771-35781	prefrontal	_	
166-18	35782-35788	cortex	_	
166-19	35789-35791	in	_	
166-20	35792-35805	schizophrenia	_	
166-21	35806-35815	revisited	_	
